0001144204-12-059795.txt : 20121106 0001144204-12-059795.hdr.sgml : 20121106 20121106172058 ACCESSION NUMBER: 0001144204-12-059795 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121106 DATE AS OF CHANGE: 20121106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMATHENE, INC CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 121184116 BUSINESS ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 BUSINESS PHONE: 410 269 2600 MAIL ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 10-Q 1 v324923_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-32587

PHARMATHENE, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-2726770
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

One Park Place, Suite 450, Annapolis, MD		21401
(Address of principal executive offices)		(Zip Code)

(410) 269-2600

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ¨		Accelerated Filer x

Non-Accelerated Filer ¨		Smaller Reporting Company ¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: The number of shares of the registrant’s Common Stock, par value $0.0001 per share, outstanding as of November 1, 2012 was 48,365,984.

PHARMATHENE, INC.

TABLE OF CONTENTS

		Page

PART I — FINANCIAL INFORMATION		1

Item 1. Financial Statements		1

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3. Quantitative and Qualitative Disclosures about Market Risk		20

Item 4. Controls and Procedures		21

PART II — OTHER INFORMATION		21

Item 1. Legal Proceedings		21

Item 1A. Risk Factors		22

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		23

Item 3. Default Upon Senior Securities		23

Item 4. Mine Safety Disclosures		23

Item 5. Other Information		23

Item 6. Exhibits		23

Certifications

Item 1. Financial Statements

PHARMATHENE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30,			December 31,
	2012			2011
	(unaudited)

ASSETS
Current assets:
Cash and cash equivalents	$	14,726,328		$	11,236,771
Accounts receivable (billed)		1,606,241			4,424,442
Unbilled accounts receivable		3,682,311			3,021,208
Prepaid expenses and other current assets		363,742			830,585
Restricted cash		—			100,000
Total current assets		20,378,622			19,613,006

Property and equipment, net		553,081			788,666
Other long term assets and deferred costs		130,709			53,384
Goodwill		2,348,453			2,348,453
Total assets	$	23,410,865		$	22,803,509

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$	1,846,614		$	1,445,700
Accrued expenses and other liabilities		3,233,804			3,169,642
Current portion of long term debt		681,822			—
Short term debt		1,208,370			—
Total current liabilities		6,970,610			4,615,342

Other long term liabilities		579,707			449,709
Long term debt, less current portion		1,764,264			—
Derivative instruments		1,545,534			1,886,652
Total liabilities		10,860,115			6,951,703

Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,345,984 and 48,236,172 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively		4,835			4,824
Additional paid-in-capital		210,101,716			208,525,917
Accumulated other comprehensive (loss) income		(215,977	)		1,010,522
Accumulated deficit		(197,339,824	)		(193,689,457	)
Total stockholders' equity		12,550,750			15,851,806
Total liabilities and stockholders' equity	$	23,410,865		$	22,803,509

See the accompanying notes to the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three months ended September 30,						Nine months ended September 30,
	2012			2011			2012			2011

Revenue	$	6,696,126		$	5,260,057		$	19,162,176		$	18,026,619

Operating expenses:
Research and development		5,138,622			4,884,231			14,762,634			16,688,703
General and administrative		3,275,428			3,283,246			9,004,008			11,632,272
Depreciation and amortization		72,453			114,494			234,811			348,813
Total operating expenses		8,486,503			8,281,971			24,001,453			28,669,788

Loss from operations		(1,790,377	)		(3,021,914	)		(4,839,277	)		(10,643,169	)
Other income (expense):
Interest income		5,727			3,961			13,534			10,496
Interest expense		(112,529	)		(9,932	)		(226,910	)		(40,540	)
Realization of cumulative translation adjustment		1,227,656			—			1,227,656			—
Change in fair value of derivative instruments		508,971			2,898,869			341,118			6,075,555
Other income (expense)		(31,312	)		95,520			22,122			50,892
Total other income (expense)		1,598,513			2,988,418			1,377,520			6,096,403

Net loss before provision for income taxes		(191,864	)		(33,496	)		(3,461,757	)		(4,546,766	)
Provision for income taxes		(22,072	)		—			(188,610	)		—
Net loss	$	(213,936	)	$	(33,496	)	$	(3,650,367	)	$	(4,546,766	)

Basic and diluted net loss per share	$	(0.00	)	$	(0.00	)	$	(0.08	)	$	(0.10	)

Weighted average shares used in calculation of basic and diluted net loss per share		48,345,984			48,194,035			48,314,058			47,041,027

See the accompanying notes to the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Three months ended September 30,						Nine months ended September 30,
	2012			2011			2012			2011

Net loss	$	(213,936	)	$	(33,496	)	$	(3,650,367	)	$	(4,546,766	)
Other comprehensive loss:
Realization of cumulative translation adjustment included in net loss		(1,227,656	)		—			(1,227,656	)		—
Foreign currency translation adjustment		7,690			(79,585	)		1,157			(88,877	)
Comprehensive loss	$	(1,433,902	)	$	(113,081	)	$	(4,876,866	)	$	(4,635,643	)

See the accompanying notes to the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine months ended September 30,
	2012			2011
Operating activities
Net loss	$	(3,650,367	)	$	(4,546,766	)
Adjustments to reconcile net loss to net cash used in operating activities:
Realization of cumulative translation adjustment		(1,227,656	)		—
Bad debt recovery		—			(8,168	)
Change in fair value of derivative instruments		(341,118	)		(6,075,555	)
Depreciation and amortization expense		234,811			348,813
Gain of the disposal of property and equipment		(66,626	)		—
Share-based compensation expense		1,499,910			1,881,416
Deferred income taxes		188,610			—
Non-cash interest expense		81,252			—
Changes in operating assets and liabilities:
Accounts receivable		2,818,201			1,080,032
Unbilled accounts receivable		(661,103	)		1,357,711
Prepaid expenses and other current assets		557,683			1,439,312
Accounts payable		400,764			(2,684,507	)
Accrued expenses and other liabilities		(12,225	)		204,291
Net cash used in operating activities		(177,864	)		(7,003,421	)
Investing activities
Purchases of property and equipment		—			(71,439	)
Proceeds from the sale of property and equipment		67,400			—
Net cash provided by (used in) investing activities		67,400			(71,439	)
Financing activities
Proceeds from issuance of long term debt and warrants		2,500,000			—
Net proceeds from (repayment of) revolving credit agreement		1,208,370			—
Deferred financing costs		(216,460	)		—
Change in restricted cash requirements		100,000			—
Proceeds from issuance of common stock and warrants		38,984			5,814,639
Other		(32,960	)		(64,362	)
Net cash provided by financing activities		3,597,934			5,750,277
Effects of exchange rates on cash		2,087			(54,668	)
Increase (decrease) in cash and cash equivalents		3,489,557			(1,379,251	)
Cash and cash equivalents, at beginning of period		11,236,771			11,785,327
Cash and cash equivalents, at end of period	$	14,726,328		$	10,406,076

Supplemental disclosure of cash flow information
Cash paid for interest	$	145,658		$	40,540
Noncash financing activity
Value of warrants issued to lender in connection with loan	$	69,876		$	—

See the accompanying notes to the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

September 30, 2012

Note 1 - Organization and Business

We are a biopharmaceutical company focused on developing biodefense countermeasure applications. We are subject to those risks associated with any biopharmaceutical company that has substantial expenditures for research and development. There can be no assurance that our research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, we operate in an environment of rapid technological change and are largely dependent on the services and expertise of our employees, consultants and other third parties.

Historically, we have performed under government contracts and grants and raised equity, equity-linked and debt capital from investors and lenders to sustain our operations.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Our condensed consolidated financial statements include the accounts of PharmAthene, Inc. and our wholly-owned subsidiaries, collectively referred to herein as “PharmAthene”, “we”, “us”, “our” or the “Company.” All significant intercompany transactions and balances have been eliminated in consolidation. Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2011 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission. We currently operate in one business segment. Certain amounts within current assets in the 2011 financial statements have been reclassified to conform to the current year’s presentation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Foreign Currency Translation

The functional currency of our wholly owned foreign subsidiaries is their local currency. Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive income (loss), a component of stockholders’ equity. Transaction gains and losses are included in the determination of net loss.

In July 2012, we substantially completed our liquidation of our Canadian subsidiary, which we had acquired in 2005. Prior to substantially liquidating the Canadian subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As a result of the substantially completed liquidation, we realized approximately $1.2 million of income in our condensed consolidated statement of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our Canadian subsidiary.

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost which approximates market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.

Revolving Line of Credit and Term Loan

As discussed further in Note 6, we entered into a loan agreement with General Electric Capital Corporation (“GE Capital”) in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in-capital, resulting in a debt discount at the date of issuance. The debt discount is being amortized over the term of the loan agreement using the effective interest method. Financing costs incurred in connection with this agreement are being amortized over the term of the agreement using the effective interest method.

Significant Customers and Accounts Receivable

Our primary customers are the Biomedical Advanced Research and Development Authority (“BARDA”), the U.S. Department of Defense (the “DoD”), and the National Institutes of Health (“NIH”). As of September 30, 2012 and December 31, 2011, our trade receivable and unbilled receivable balances were comprised solely of receivables from these customers.

Revenue Recognition

We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts. Costs consist primarily of direct subcontractor and internal labor charges incurred plus an allocation of fringe benefits, overhead and general and administrative expenses as defined in each contract.

Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, pursuant to the terms of the cost-plus fee contract, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.

Under the milestone method of revenue recognition, milestone payments, including milestone payments for fees, contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone. Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

For fixed price contracts without substantive milestones as described above, revenue is recognized on the percentage-of-completion method in accordance with the applicable accounting guidance for long term contracts. The percentage-of-completion method recognizes income as the contract progresses; recognition of revenue and profits generally related to the costs incurred in providing the services required under the contract. The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates. The fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used. Estimating is an integral part of our business activities, and there may be a necessity to revise estimates on contracts continually as the work progresses. As a result, amounts invoiced may differ from revenue recognized. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue, a component of accrued expenses and other liabilities. We recorded approximately $46 thousand and $0.5 million as deferred revenue as of September 30, 2012 and December 31, 2011, which is included in accrued expenses and other liabilities on the condensed consolidated balance sheet.

As revenue is recognized in accordance with the terms of the contracts, related amounts are recorded as unbilled accounts receivable in our consolidated balance sheets. As specific contract invoices are generated and sent to our customers in accordance with a contract, invoiced amounts are transferred out of unbilled accounts receivable and into billed accounts receivable. Invoicing frequency and payment terms for cost-plus-fee contracts with our customers are defined within each contract, but are typically monthly invoicing with 30-60 day payment cycles.

We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred. For each of the three months ended September 30, 2012 and 2011, we recorded approximately $0.1 million of costs reimbursed by the government as an offset to research and development expenses. For the nine months ended September 30, 2012 and 2011, we recorded approximately $1.1 million and $0.4 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans. The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized ratably as expense over the requisite service period. The fair value of stock option grants is determined using the Black-Scholes option pricing model. The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of the Company’s stock price. The value of the award that is ultimately expected to vest is recognized as compensation expense on a straight line basis over the employee’s requisite service period.

Employee share-based compensation expense recognized in the three months ended September 30, 2012 and 2011 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12% for both 2012 and 2011, based on historical experience of forfeitures.

Share-based compensation expense for the three months ended September 30, 2012 and 2011 was:

	2012		2011

Research and development	$	107,199	$	208,488
General and administrative		332,006		417,603
Total share-based compensation expense	$	439,205	$	626,091

During the three months ended September 30, 2012, we granted no options to employees and made no restricted stock grants. During the three months ended September 30, 2011, we granted 256,639 options to employees and made 50,000 restricted stock grants. At September 30, 2012, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.5 million, net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 1.94 years.

Share-based compensation expense for the nine months ended September 30, 2012 and 2011 was:

	2012		2011

Research and development	$	351,342	$	666,919
General and administrative		1,148,568		1,214,497
Total share-based compensation expense	$	1,499,910	$	1,881,416

During the nine months ended September 30, 2012, we granted 200,948 options to employees and non-employee directors and made no restricted stock grants. During the nine months ended September 30, 2011, we granted 560,639 options to employees and non-employee directors and made 50,000 restricted stock grants to employees.

Income Taxes

We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year, adjusted as necessary for discrete items. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.

The provision for income taxes was approximately $22 thousand and $0.2 million for the three and nine months ended September 30, 2012, respectively; no provision (benefit) for income taxes was recorded in 2011. The provision for income taxes in 2012 resulted from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP. This difference resulted in the recording of a deferred tax liability, which cannot offset deferred tax assets, and results in a corresponding provision for income taxes. This deferred tax liability is included in our condensed consolidated balance sheets in other long term liabilities.

Basic and Diluted Net Loss Per Share

Basic loss per share is computed by dividing consolidated net loss by the weighted average number of shares of common stock outstanding during the quarter, excluding unvested restricted stock.

For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.

For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive shares of common stock is anti-dilutive due to the net losses. A total of approximately 11.5 million and approximately10.9 million potential dilutive shares have been excluded in the calculation of diluted net loss per share in the three and nine months ended September 30, 2012 and 2011, respectively, because their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations or financial position.

Note 3 - Fair Value Measurements

We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that are measured at fair value.

The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2012:

Description	Balance as of December 31, 2011		Unrealized (Gains)			Balance as of September 30, 2012

Derivative liabilities related to warrants	$	1,886,652	$	(341,118	)	$	1,545,534

The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2011:

Description	Balance as of December 31, 2010		New Liabilities in 2011		Unrealized (Gains)			Balance as of September 30, 2011

Derivative liabilities related to warrants	$	8,362,995	$	668,640	$	(6,075,555	)	$	2,956,080

At September 30, 2012 and 2011, derivative liabilities are comprised of 2,899,991 warrants to purchase common stock that are classified as liabilities. The warrants are considered to be derivative liabilities due to the presence of net settlement features and are recorded at fair value at each balance sheet date. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option-pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants’ fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Gains and losses on the fair value adjustments for these derivative instruments are classified in other expenses as the change in fair value of derivative instruments in our condensed consolidated statements of operations. The $0.3 million unrealized gains on the change in the market value of derivative instruments during the nine-month period ended September 30, 2012 is due primarily to the change in the closing price of our stock, which was $1.27 per share as of December 30, 2011 and $1.18 per share as of September 30, 2012. The $6.1 million unrealized gains on the change in the market value of derivative instruments during the nine-month period ended September 30, 2011 is due primarily to the change in the closing price of our stock, which was $4.23 per share as of December 31, 2010 and $1.76 per share as of September 30, 2011.

Note 4 - Commitments and Contingencies

SIGA Litigation

In December 2006, we filed a complaint against SIGA Technologies, Inc. (“SIGA”) in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively development and marketing rights for SIGA’s drug candidate, ST-246^®(Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement.

In September 2011, the Court issued an opinion in the case finding that SIGA had breached certain contractual obligations to us and upholding our claims of promissory estoppel. The Court awarded us the right to receive 50% of all net profits related to the sale of ST-246^® and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of ST-246^® and related products. The Court also awarded us one-third of our reasonable attorney's fees and expert witness fees, which amounts to approximately $2.4 million plus interest. In May 2012, the Court issued its final judgment. SIGA has appealed aspects of the decision to the Delaware Supreme Court, which has set oral argument in the case for January 2013. In response, we have cross-appealed other aspects of the decision. Based on the timing of issuance of past Delaware Supreme Court decisions, we expect a ruling from the high court no later than the second quarter 2013.

We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal, and that the Delaware Supreme Court will not overturn the trial court’s decision awarding us a 10 year 50% net profit of the sales of ST-246^® and related products (once SIGA retains the first $40 million in net profit). We have not yet recorded any amount due from SIGA in relation to this case.

Government Contracting

Payments to the Company on cost-plus-fee contracts are provisional and are subject to adjustment upon audit by the Defense Contract Audit Agency and BARDA. In our opinion, adjustments that may result from audits are not expected to have a material effect on our financial position, results of operations, or cash flows.

Registration Rights Agreements

We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the Securities and Exchange Commission to register the shares underlying the convertible notes and related warrants, which registration statements have been declared effective. We are obligated to maintain the registration statements effective until the date when all shares underlying the convertible notes and related warrants (and any other securities issued or issuable with respect to in exchange for such shares) have been sold. The convertible notes were converted or extinguished in 2010, although the related warrants remain outstanding. The warrants will expire on January 28, 2015.

We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or “piggy-back” basis or both.

Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a “Maintenance Failure”), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at September 30, 2012, would be approximately $0.2 million.

Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision would be approximate $0.2 million for each month until the failure, if it occurs, is cured.

Note 5 - Stockholders’ Equity

Long-Term Incentive Plan

In 2007, the Company’s stockholders approved the 2007 Long Term Incentive Plan (the “2007 Plan”) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses (collectively “awards”) to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.

At that time, we reserved 3,500,000 shares of common stock in connection with awards to be granted under the 2007 Plan, including those awards that had originally been made under a prior plan. In 2008, the Company’s shareholders approved amendments to the 2007 Plan, increasing the maximum number of shares authorized for issuance under the plan to 4,600,000 and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan will increase automatically in each year, beginning in 2009 and continuing through 2015, according to certain limits set forth in the 2007 Plan. At September 30, 2012, there were approximately 8.2 million shares approved for issuance under the 2007 Plan, of which approximately 1.6 million shares are available to be issued. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions, and the exercise price. Stock options issued under the 2007 Plan may have a maximum term of ten years.

Warrants Classified as Equity

In connection with the July 2009 private placement, we issued warrants to purchase an aggregate of 2,572,775 shares of the Company’s common stock at an exercise price of $2.50 per share. The warrants will expire on January 28, 2015.

In connection with the March 30, 2012, debt financing (see Note 6), we issued warrants to purchase an aggregate of 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share to GE Capital. The warrants expire on March 30, 2022.

Also outstanding are warrants to purchase an aggregate of 100,778 shares of common stock at $3.97 per share, which will expire on March 30, 2017.

Note 6 – Financing Transactions

On March 30, 2012, we entered into a Loan and Security Agreement (the “Loan Agreement”) with General Electric Capital Corporation (“GE Capital”), as lender and agent for other lenders that may subsequently become party to the agreement. The Loan Agreement provides for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5 million based on our outstanding qualified accounts receivable. On March 30, 2012, the term loan was funded for an aggregate amount of $2.5 million. As of September 30, 2012 approximately $1.2 million was outstanding under the revolving line of credit, which is recorded as short term debt on our condensed consolidated balance sheet. Under the terms of the Loan Agreement, the Company may draw down from the revolving line of credit up to 85% of qualified billed accounts receivable and 80% of qualified unbilled accounts receivable. As of September 30, 2012, approximately $1.3 million was available under the Loan Agreement to borrow against the revolving line of credit.

The fixed interest rate on the term loan is 10.14% per annum. The revolving line of credit has an adjustable interest rate based upon the 3-month London Interbank Offered Rate (LIBOR), with a floor of 1.5%, plus 5%. As of September 30, 2012, this interest rate was 6.5%. Both the term loan and the revolving line of credit mature in September 2015. Payments on the term loan are interest-only for the first 10 months, which may be extended to 12 months if certain conditions described in the Loan Agreement are met. Subsequently, the term loan will fully amortize over its remaining term. Principal payments on the term loan are scheduled as follows:

		Principal
Year		Payments
	2012	$	-
	2013		909,096
	2014		909,096
	2015		681,808
		$	2,500,000

If we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date, we are obligated to pay a prepayment premium equal to 3% of the then outstanding principal amount of the term loan during the first two years of the loan and 2% during the third year and thereafter. In addition we are obligated to pay a final payment fee of 3% of the term loan balance. The final payment fee will be accrued and expensed over the term of the agreement, using the effective interest method.

Our obligations under the Loan Agreement are collateralized by a security interest in substantially all of our assets including cash, receivables and property and equipment. While the security interest does not, except in limited circumstances, cover our intellectual property, it does cover any proceeds received by us from the use or sale of our intellectual property.

The Loan Agreement contains customary representations, warranties and covenants, including limitations on acquisitions, dispositions, incurrence of indebtedness and the granting of security interests. The representations, warranties and covenants contained in the Loan Agreement were made only for purposes of such agreement and as of a specific date or specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Loan Agreement.

The Loan Agreement contains certain financial and non-financial covenants. Upon the occurrence and during the continuance of any event of default, GE Capital may, and at the written request of the requisite lenders shall, terminate the commitments under the facilities and declare any or all of the obligations to be immediately due and payable, without demand or notice to us; however, any event of default relating to timely payment of debts, insolvency, liquidation, bankruptcy or similar events will result in automatic acceleration. Among the remedies available to GE Capital in case of an event of default are the taking possession and disposition of any collateral under the Loan Agreement.

In connection with the Loan Agreement, we issued GE Capital warrants to purchase 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share, subject to customary anti-dilution adjustments. The warrants are classified as equity. The fair value of the warrants at March 30, 2012 of $69,876 was recorded as a discount to the carrying value of the debt and is being amortized through interest expense over the term of the loan.

Also, in connection with us entering into the Loan Agreement, we incurred approximately $216,000 of related expenses. These expenses are deferred and are being amortized to interest expense over the term of the Loan Agreement.

In June 2011, PharmAthene entered into an agreement with certain accredited investors who purchased an aggregate of 1,857,143 shares of common stock for a purchase price of $3.50 per share and warrants to purchase up to an additional 371,423 shares of common stock. The warrants became exercisable immediately at an exercise price of $3.50 per share and are exercisable until the fifth anniversary of the date of issuance, which is June 15, 2016. The warrants are classified as derivative liabilities. The Company received gross proceeds of approximately $6.5 million and net proceeds of approximately $5.8 million.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. This information may involve known and unknown risks, uncertainties and other factors that are difficult to predict and may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, risk associated with the following:

•

the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates,

•

funding delays, reductions in or elimination of U.S. government funding and/or non-renewal of expiring funding for one or more of our development programs,

•

the award of government contracts to our competitors or delays caused by third parties challenging government contract awards to us,

•

unforeseen safety issues,

•

challenges related to the development, technology transfer, scale-up, and/or process validation of manufacturing processes for our product candidates,

•

unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products,

as well as risks detailed under the caption “Risk Factors” in our Report on Form 10-K for the year ended December 31, 2011 and in our other reports filed with the U.S. Securities and Exchange Commission (the “SEC”) from time to time thereafter. In particular, there can be no assurance, that SIGA Technologies, Inc. (“SIGA”) will not prevail in its appeal, or that we will be successful in our appeal of certain aspects of the decision, to the Delaware Supreme Court of the ruling of the Delaware Court of Chancery awarding PharmAthene 50% of all net profits related to the sale of ST-246^® and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of ST-246^® and related products. Further, the timing and amount of any future sales of ST-246^® is uncertain. Significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for all our products candidates, and with FDA’s August 2012 clinical hold of SparVax^™, it is unclear when, if ever, we can re-initiate human clinical trials for that product candidate. Future government funding to support the development of Valortim^® is unlikely in the near term and remains uncertain. It is also uncertain whether any of our product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans. Forward-looking statements describe management’s current expectations regarding our future plans, strategies and objectives and are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “potential” or “plan” or the negative of these words or other variations on these words or comparable terminology. Such statements include, but are not limited to:

•

statements about potential future government contract or grant awards,

•

potential payments under government contracts or grants,

•

potential regulatory approvals,

•

future product advancements, and

•

anticipated financial or operational results.

Forward-looking statements are based on assumptions that may be incorrect, and we cannot assure you that the projections included in the forward-looking statements will come to pass.

We have based the forward-looking statements included in this Quarterly Report on Form 10-Q on information available to us on the date of this Quarterly Report, and we assume no obligation to update any such forward-looking statements, other than as required by law. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements which present our results of operations for the three and nine months ended September 30, 2012 and 2011, as well as our financial positions at September 30, 2012 and December 31, 2011, contained elsewhere in this Quarterly Report on Form 10-Q. The following discussion should also be read in conjunction with the Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 8, 2012, including the audited consolidated financial statements contained therein.

Overview

We are a biodefense company engaged in the development and commercialization of next generation medical countermeasures against biological and chemical threats. Our current biodefense portfolio includes the following product candidates:

•

SparVax™, a next generation recombinant protective antigen (“rPA”) anthrax vaccine,

•

rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides, and

•

Valortim^®, a fully human monoclonal antibody for the prevention and treatment of anthrax infection.

In addition, we were awarded by the Delaware Court of Chancery in September 2011 the right to receive 50% of all net profits related to the sale of SIGA Technologies, Inc. ST-246^® and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from sales of ST-246^® and related products. In May 2012, the Court issued its final judgment. SIGA has appealed aspects of the decision to the Delaware Supreme Court. In response, we have cross-appealed other aspects of the decision.

Recent Events

On October 19, 2012, Arthur Y. Elliott, Ph.D., a vaccine and infectious disease specialist, assumed the role of acting Chief Scientific Officer for the Company. Dr. Elliott had served as a scientific advisor to the Company since June 2011. Dr. Elliott replaced Dr. Thomas Fuerst who resigned as the Company’s Chief Scientific Officer effective that same day.

From 2010 to 2011, Dr. Elliott served as Branch Chief, responsible for the U.S. Government’s Anthrax Vaccine Portfolio within the Chemical, Biological, Radiological and Nuclear (CBRN) division of the Biomedical Advanced Research and Development Authority (BARDA). Between 2006 and 2010, Dr. Elliott led, for the Department of Health and Human Services, the Avian Influenza Pandemic Preparedness Program, a government/industry collaboration between three pharmaceutical companies and four government agencies (the Department of Health and Human Services, National Institutes of Health, Centers for Disease Control, and Food and Drug Administration (FDA)) to accelerate the production and stockpiling of Pandemic Influenza Vaccine for the United States Strategic National Stockpile.

Prior to his government service, from 2000 to 2006, Dr. Elliot served as an on-site consultant to Aventis (Sanofi Pasteur) Pharmaceutical Corporation, advising on the design and implementation of new manufacturing facilities for the production of influenza vaccine. From 1994 to 1999, Dr. Elliott served as Chief Operating Officer and Senior Vice President, and starting in 1998 Acting President, at North American Vaccine, Inc. Dr. Elliott earned his Ph.D. in virology from Purdue University, and an M.S. in microbiology and a B.A. in biology, both from North Texas State University.

Critical Accounting Policies

A “critical accounting policy” is one that is both important to the portrayal of our financial condition and results of operations and that requires management’s most difficult, subjective or complex judgments. Such judgments are often the result of a need to make estimates about the effect of matters that are inherently uncertain. The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the years ended December 31, 2011, filed with the Securities and Exchange Commission.

There were no significant changes in critical accounting policies from those at December 31, 2011.

Results of Operations

Revenue

We recognized revenue of $6.7 million and $5.3 million during the three months ended September 30, 2012 and 2011, respectively. We recognized revenue of $19.2 million and $18.0 million during the nine months ended September 30, 2012 and 2011, respectively.

Our revenue was derived primarily from contracts with the U.S. government for the development of SparVax™, and our rBChE bioscavanger and in the 2011 periods for Valortim^®as well. Our revenue in the three and nine months ended September 30, 2012 changed from the comparable periods of 2011 primarily due to the following:

•

Under our contract for the development of SparVax™, we recognized approximately $5.6 million and $4.3 million of revenue for the three months ended September 30, 2012 and 2011, respectively and approximately $16.9 million and $15.1 million of revenue for the nine months ended September 30, 2012 and 2011, respectively. During the three and nine months ended September 30, 2012 revenue for the Company's SparVax™ program was primarily attributable to completion of Final Drug Product (FDP) manufacture, the initiation of Bulk Drug Substance (BDS) Process Characterization, the first stage of process validation activities, further progression in the development of bioanalytical and analytical assays, the execution of non-clinical activities and limited clinical trial pre-study activities. Milestone revenue received for the achievement of key technical milestones for the three and nine months ended September 30, 2012 was $20 thousand and $1.3 million, respectively. During the three and nine months ended September 30, 2011 revenue was primarily attributable to work related to the manufacturing platform for SparVax™ and additional activities related to the establishment of analytical and stability-indicating assays for characterization of the product, including the receipt of $0.6 million in connection with the achievement of key technical milestones under our SparVax™ development contract for the three months ended September 30, 2011 and $2.8 million for the nine months ended September 30, 2011. In August 2012 we received notification from the FDA that our SparVax™ rPA anthrax vaccine program was placed on clinical hold. The FDA has requested additional stability data and information related to the stability indicating assays. We have provided supporting data and information to the FDA and have commenced discussions with that agency as well as our customer, BARDA, regarding the clinical hold. BARDA and the FDA are working with us to resolve the clinical hold. We intend to submit a full response to the FDA. It is unclear at this point when or if we will be able to commence the planned Phase 2 human clinical trial with SparVax™. Consequently we expect SparVax™ related revenues to be less in the near term than they otherwise would have been had we commenced the clinical trial as planned.

•

We recognized approximately $0.7 million and $1.7 million related to work on our second generation rBChE bioscavanger in the three and nine months ended September 30, 2012 under the August 2011 fixed price contract with the Department of Defense (DoD) for the development of an advanced expression system (AES) for rBChE. We generated revenue of $0.1 million under that contract for both the three months ended and the nine months ended September 30, 2011. Significant technical progress was made in the development of our second generation rBChE bioscavanger in 2012, including the establishment of final clones, genetic stability and fed batch evaluation to establish the bioreactor conditions for manufacturing. On July 31, 2012, the DoD exercised a $2.5 million option to continue to fund work under this contract.

•

Under our contracts for the advanced development of Valortim®, we recognized $0.4 million of revenue in the three month period ended September 30, 2012 and $0.9 million of revenue for the three month period ended September 30, 2011, and $0.5 million and $2.8 million of revenue for the nine months ended September 30, 2012 and 2011, respectively. Revenue in 2012 primarily reflects completion of activities under our 2007 contract with National Institute of Allergy and Infectious Diseases (“NIAID”) for Valortim®, which ended in accordance with its terms in the first quarter 2012, and certain work related to non-clinical and analytical assay development work to support further development of this product candidate. Additional revenues in 2012 reflect negotiation and completion of close-out activities for the NIAID Valortim contract. Additional government funding for Valortim® is unlikely in the near term. There can be no assurance we will be successful in obtaining additional financial support for this program.

Research and Development Expenses

Our research and development expenses were $5.1 million and $4.9 million for the three months ended September 30, 2012 and 2011, respectively and $14.8 million and $16.7 million for the nine months ended September 30, 2012 and 2011. These expenses resulted from research and development activities in both periods related to our SparVax™ program as well as from activities related to Valortim^® primarily in the 2011 period and the rBChE bioscavanger primarily in the 2012 period. Direct expenses included salaries and other costs of personnel, raw materials and supplies, and an allocation of indirect expenses. We also incurred third-party costs, including contract research, consulting and clinical development costs for individual projects. Research and development expenses for both the three months ended September 30, 2012 and 2011 were net of cost reimbursements under certain of our government grants of $0.1 million. Research and development expenses for the nine months ended September 30, 2012 and 2011 were net of cost reimbursements under certain of our government grants of $1.1 million and $0.4 million, respectively. As a result of the FDA clinical hold related to SparVax™, we expect SparVax™ related R&D costs to be less in the near term than they otherwise would have been had we commenced the clinical trial as planned.

Research and development expenses for the three and nine months ended September 30, 2012 and 2011 were attributable to research programs as follows:

	Three Months ended September 30,
($ in millions)	2012		2011
Anthrax therapeutic and vaccines	$	4.7	$	4.5
Chemical nerve agent bioscavenger		0.4		0.1
Internal research and development		—		0.3
Total research and development expenses	$	5.1	$	4.9

	Nine Months ended September 30,
($ in millions)	2012		2011
Anthrax therapeutic and vaccines	$	13.6	$	14.8
Chemical nerve agent bioscavenger		1.1		0.3
Internal research and development		0.1		1.6
Total research and development expenses	$	14.8	$	16.7

For the three months ended September 30, 2012, research and development expenses increased approximately $0.2 million, from the same period in the prior year, primarily due to higher direct SparVax™ program expenses, partially offset by the decrease in direct costs related to our Valortim® program as a result of the completion in the first quarter of 2012 of work under our 2007 contract with NIAID and a reduction in indirect operating expenses including overhead and internal research and development.

For the nine months ended September 30, 2012, research and development expenses decreased approximately $1.9 million, from the same period in the prior year, primarily due to a reduction in (i) indirect operating expenses including overhead and internal research and development, and (ii) direct costs related to our Valortim® program as a result of the completion in the first quarter of 2012 of work under our 2007 contract with NIAID, offset by higher direct SparVax™ program expenses.

General and Administrative Expenses

General and administrative functions include executive management, finance and administration, government affairs and regulations, corporate development, human resources, legal, and compliance. For each function, we may incur expenses such as salaries, supplies and third-party consulting and other external costs and non-cash expenditures such as expense related to stock option and restricted share awards. An allocation of indirect costs such as facilities, utilities and other administrative overhead is also included in general and administrative expenses.

Expenses associated with general and administrative functions were $3.3 million for each of the three month periods ended September 30, 2012 and 2011. Legal fees in the third quarter 2012 were approximately $0.8 million higher than in the same period in 2011 offset by reduced labor costs as a result of planned reductions. We incurred approximately $0.4 million of bad debt expense in 2011.

Expenses associated with general and administrative functions were $9.0 million for the nine months ended September 30, 2012 and $11.6 million for the nine months ended September 30, 2011. Legal and professional fees in the first nine months of 2011 were approximately $1.6 million higher than in the same period in 2012 primarily due to the increased fees incurred during the first half of 2011 for the trial and post trial activities in the litigation with SIGA. In addition, labor costs were lower in 2012 as a result of planned reductions.

Depreciation and Amortization

Depreciation and amortization expenses were approximately $0.1 million for the three months ended September 30, 2012 and 2011, respectively. Depreciation and amortization expenses were approximately $0.2 million and $0.3 million for the nine months ended September 30, 2012 and 2011, respectively.

Other Income (Expense)

Other income (expense) primarily consists of the realization of cumulative translation adjustment on substantially complete liquidation of PharmAthene Canada, Inc., interest income on our cash and cash equivalents, interest expense on our debt and other financial obligations, changes in fair value of our derivative financial instruments, foreign currency transaction gains and losses, the gain on the disposal of property and equipment, and costs associated with the GE Loan Agreement described in Note 6 to our unaudited condensed consolidated financial statements.

We incurred approximately $0.1 million and $10 thousand in interest expense during the three months ended September 30, 2012 and 2011, respectively. We incurred approximately $0.2 million and $41 thousand in interest expense during the nine months ended September 30, 2012 and 2011, respectively. Interest expense in 2012 is the result of the term loan and revolving line of credit we entered into on March 30, 2012. We anticipate that we will incur higher interest expense as a result of the term loan and use of the revolving line of credit in future periods.

The other income related to the change in the fair value of our derivative instruments was approximately $0.5 million and $2.9 million for the three months ended September 30, 2012 and 2011, respectively. The fair value of these derivative instruments is estimated using the Black-Scholes option pricing model. The decrease in fair value for the three months ended September 30, 2012 was primarily the result of the decrease in our stock price from $1.39 per share on June 30, 2012 to $1.18 per share on September 30, 2012. The $2.9 million change in the fair value of derivative instruments during the three month period ended September 30, 2011 is due primarily to the change in the closing price of our stock, which was $2.94 per share as of June 30, 2011 to $1.76 per share as of September 30, 2011.

The other income related to the change in the fair value of our derivative instruments was approximately $0.3 million and $6.1 million for the nine months ended September 30, 2012 and 2011, respectively. The fair value of these derivative instruments is estimated using the Black-Scholes option pricing model. The decrease in fair value for the nine months ended September 30, 2012 was primarily the result of the decrease in our stock price from $1.27 per share on December 31, 2011 to $1.18 per share on September 30, 2012. The $6.1 million change in the fair value of derivative instruments during the nine month period ended September 30, 2011 is due primarily to the change in the closing price of our stock, which was $4.23 per share as of December 31, 2010 and $1.76 per share as of September 30, 2011.

Income Taxes

The provision for income taxes was approximately $22 thousand and $0.2 million for the three and nine months ended September 30, 2012, respectively. No provision for income taxes was recorded in 2011. The provision for income taxes in 2012 resulted from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP. This difference resulted in the recording of a deferred tax liability, which cannot offset deferred tax assets, and results in a corresponding provision for income taxes. This deferred tax liability is included in our condensed consolidated balance sheet in other long term liabilities.

Liquidity and Capital Resources

Overview

Our primary cash requirements for 2012 are to fund our operations (including our research and development programs) and support our general and administrative activities. Our future capital requirements will depend on many factors, including, but not limited to, timing, amount, and profitability of sales of ST-246^®, if any (and our ability to collect our portion of net profits related to ST-246^®); the progress of our research and development programs; the progress of pre-clinical and clinical testing; the time and cost involved in obtaining regulatory approval; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; changes in our existing research relationships; competing technological and marketing developments; our ability to establish collaborative arrangements and to enter into licensing agreements and contractual arrangements with others; and any future change in our business strategy. These cash requirements could change materially as a result of shifts in our business and strategy.

During the first quarter of 2012, we entered into a term loan for $2.5 million and have access to additional debt capital pursuant to a revolving line of credit for up to an additional $5 million dollars based on a percentage of our accounts receivable. As of September 30, 2012 approximately $1.2 million was outstanding under the revolving line of credit, and approximately $1.3 million in additional funding was available under the Loan Agreement to borrow against the revolving line of credit. As a result of the August 2012 FDA clinical hold, it is unclear when or if we will be able to commence the planned Phase 2 human clinical trial with SparVax™. Consequently we expect SparVax™ related revenues and corresponding R&D costs to be less in the near term than they otherwise would have been had we commenced the clinical trial as planned. Nevertheless, we still currently anticipate that our cash on hand, amounts available under the line of credit, and collection of accounts receivables at September 30, 2012, as well as cash to be collected from contract revenue under contracts currently in place, will be sufficient to meet the Company’s ongoing expenses and capital requirements through at least September 30, 2013.

Since our inception, we have not historically generated positive cash flows from operations. To bridge the gap between payments made to us under our government contracts and grants and our operating and capital needs, we have had to rely on a variety of financing sources, including the issuance of equity securities and equity-linked securities and proceeds from loans and other borrowings. For the foreseeable future, we will continue to need these types of financing vehicles and potentially others to help fund our future operating and capital requirements.

Although the Company was successful in securing credit financing in March 2012, the continuing turmoil affecting the global financial system threatens to once again tighten the credit markets. As a result, there can be no assurance that future funding will be available to us on reasonably acceptable terms, or at all. In addition, due to the U.S. government’s continuing substantial efforts to stabilize the economy, the U.S. government may be forced or choose to reduce or delay spending in the biodefense field, which could decrease the likelihood of future government contract awards, the likelihood that the government will exercise its right to extend any of its existing contracts with us and/or the likelihood that the government would procure products from us.

Our unaudited condensed consolidated financial statements have been prepared on a basis which assumes that we will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business and do not include any adjustments that might result if the carrying amount of recorded assets and liabilities are not realized.

Sources and Uses of Cash

Cash and cash equivalents were $14.7 million and $11.2 million at September 30, 2012 and December 31, 2011, respectively. The $3.5 million increase at September 30, 2012 was primarily attributable to the $2.5 million term loan, which we closed in the first quarter 2012, and the $1.2 million borrowed under the revolving line of credit, partially offset by $0.2 million of cash used in operations, while for the corresponding 2011 period, cash and cash equivalents included $5.8 million in net proceeds from the September 2011 issuance of stock and warrants, offset by $7.0 million of cash used in operations.

Operating Activities

Net cash used in operating activities was $0.2 million and $7.0 million for the nine months ended September 30, 2012 and 2011, respectively.

Net cash used in operations during the nine months ended September 30, 2012 reflects our net loss of $3.6 million, adjusted for non-cash share-based compensation expense of $1.5 million, the $1.2 million gain on substantially complete liquidation of PharmAthene Canada, Inc., the decrease in the fair value of derivative instruments of $0.3 million and other noncash expenses of $0.4 million. The decrease in accounts receivable of approximately $2.8 million was partially offset by an increase in unbilled accounts receivable of approximately $0.7 million. The increase in the fair value of the derivative instruments primarily relates to the change in our stock price from $1.27 per share at December 30, 2011 to $1.18 per share at September 30, 2012.

Net cash used in operations during the nine months ended September 30, 2011 reflects our net loss of $4.5 million, adjusted for the change in market value of noncash derivative instruments of $6.1 million. This was offset by non-cash share-based compensation expense of $1.9 million, a decrease in unbilled accounts receivable of $1.4 million, a decrease in accounts receivable and prepaid expenses and other current assets of $1.1 million and $1.4 million, respectively, and a decrease in accounts payable of $2.7 million and an increase in accrued expenses of $0.2 million. The change in market value of the derivative instruments primarily relates to the change in our stock price from $4.23 per share at December 31, 2010 to $1.76 per share at September 30, 2011.

Investing Activities

There were no significant investing activities during the nine months ended September 30, 2012 and September 30, 2011.

Financing Activities

Net cash provided by financing activities was $3.6 million for the nine months ended September 30, 2012 as compared to $5.8 million for the nine months ended September 30, 2011.

The majority of our cash provided by financing for the nine months ended September 30, 2012, was a result of us entering into a senior fully-secured debt facility with GE Capital as described in Note 6 to the unaudited condensed consolidated financial statements. On March 30, 2012, the term loan was funded for an aggregate amount of $2.5 million. Approximately $1.2 million of the revolving line of credit was drawn as of September 30, 2012.

In June 2011, PharmAthene entered into an agreement with certain accredited investors who purchased an aggregate of 1,857,143 shares of common stock for a purchase price of $3.50 per share and warrants to purchase up to an additional 371,423 shares of common stock. The warrants were exercisable immediately at an exercise price of $3.50 per share and expire on June 15, 2016. The Company received gross proceeds of approximately $6.5 million and net proceeds of approximately $5.8 million.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Contractual Obligations

The following are contractual commitments at September 30, 2012 primarily associated with research and development arrangements, leases and the term loan:

Contractual Obligations⁽¹⁾	Total		Less than 1 Year		1-3 Years		3-5 Years		More than 5 years

Operating facility leases	$	3,798,500	$	780,200	$	1,607,300	$	1,411,000	$	—
Research and development agreements		10,017,000		10,017,000		—		—		—
Term loan		2,500,000		681,822		1,818,178		—		—
Total contractual obligations	$	16,315,500	$	11,479,022	$	3,425,478	$	1,411,000	$	—

(1) This table does not include any royalty payments relating to future sales of products subject to license agreements the Company has entered into in relation to its in-licensed technology, as the timing and likelihood of such payments are not known.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We have limited exposure to interest rate and foreign currency exchange rate risk.

Our exposure to interest rate risk is currently confined to our cash and cash equivalents. Because of the short-term maturities of our cash and cash equivalents, we do not believe that an increase in market interest rates would have a material impact on the realized value of our holdings. Our term loan with GE Capital is at a fixed 10.14% rate. Because of the fixed rate, we do not believe that a change in market interest rates would have a material impact on our amounts payable under the loan. Even though the interest rate on the revolving line of credit is variable, we do not believe that a change in market interest rates would have a material impact on our amounts payable under the revolving line of credit.

The Company’s current operations in foreign countries are minimal. We have closed our active operations in Canada and maintain only nominal operations in the United Kingdom. A 10% change in exchange rates (against the U.S. dollar) would not have a material impact on earnings or cash flow.

We currently do not hedge interest rate exposure or foreign currency exchange exposure. We have not used derivative financial instruments for speculation or trading purposes.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation was performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Accounting Officer concluded that these disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met, and therefore, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. We do not expect that our disclosure controls and procedures or our internal control over financial reporting are able to prevent with certainty all errors and all fraud.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleges, among other things, that we have the right to license exclusively development and marketing rights for SIGA’s drug candidate, ST-246^®, pursuant to a merger agreement between the parties that was terminated in October 2006. The complaint also alleges that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement.

We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal of certain aspects of the decision, and that the Delaware Supreme Court will not overturn the trial court’s decision awarding us a 10 year 50% net profit interest in sales of ST-246® and related products (once SIGA earns $40 million in net profits). In May 2011 SIGA announced the execution of a 5 year contract with BARDA with a base value of $433 million for the procurement of 1.7 million courses of therapy of ST-246® and related development work and an option for the U.S. government to purchase an additional 12 million courses of therapy, bringing the total potential value of the contract at that time to approximately $2.8 billion. In a June 2011 amendment made in response to a protest filed by a third party, this option was removed from the contract, which currently provides for purchases totaling approximately $412.5 million from the U.S. government. SIGA recently re-affirmed its prior guidance to investors that it expects to start delivering product to BARDA under that contract in the first quarter of 2013. We have not recorded any amount due from SIGA in relation to this case.

Item 1A. Risk Factors

Investing in our securities involves risks. In addition to the other information in this quarterly report on Form 10-Q, stockholders and potential investors should carefully consider the risks and uncertainties discussed in the section "Item 1A. Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2011 as supplemented by the risks and uncertainties discussed below. If any of the risks and uncertainties set forth below or in our 2011 annual report on Form 10-K actually materialize, our business, financial condition and/or results of operations could be materially adversely affected, the trading price of our common stock could decline and a stockholder could lose all or part of his or her investment. The risks and uncertainties set forth below and described in our 2011 annual report on Form 10-K are not the only ones that may materialize. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations.

Risks Related to Our Financial Condition

The FDA’s decision to place our SparVax program on clinical hold prevents us from commencing the planned Phase 2 human clinical trial and makes future government funding for SparVax uncertain.

In August 2012 we received notification from the FDA that our SparVax™ rPA anthrax vaccine program was placed on clinical hold. The FDA requested additional stability data and information related to the stability indicating assays. We have provided supporting data and information to the FDA and commenced discussions with that agency as well as our customer, BARDA, regarding the clinical hold. BARDA and the FDA are working with us to resolve the clinical hold. We intend to submit a full response to the FDA. It is unclear at this point when or if we will be able to commence the planned Phase 2 human clinical trial with SparVax™. Consequently we expect SparVax™ related revenues to be less in the near term than they otherwise would have been had we commenced the clinical trial as planned. It is also unclear whether or to what extent the clinical hold will affect future government funding for our SparVax™ program.

Our fully-secured loan agreement with GE Capital is subject to acceleration in specified circumstances, which may result in GE Capital taking possession and disposing of any collateral.

In the first quarter 2012, we closed on a senior fully-secured debt facility with GE Capital providing for a $2.5 million term loan and a revolving line of credit of up to $5 million based on a percentage of our outstanding qualified accounts receivable. The Company’s obligations under the loan and security agreement with GE Capital (“Loan Agreement”) are secured by a security interest in substantially all of the Company’s assets. While the security interest does not, except in limited circumstances, cover the Company’s intellectual property, it does cover any proceeds to the Company from the use of intellectual property. The Loan Agreement contains customary representations, warranties and covenants, including limitations on acquisitions, dispositions, incurrence of indebtedness and the granting of security interests. Upon the occurrence and during the continuance of any event of default, GE Capital may, and at the written request of the requisite lenders shall, terminate the commitments under the facilities and declare any or all of the obligations to be immediately due and payable, without demand or notice to the Company. However, any event of default relating to timely payment of debts, insolvency, liquidation, bankruptcy or similar events will result in automatic acceleration. Among the remedies available to GE Capital in case of an event of default are the taking possession and disposition of any collateral under the Loan Agreement.

Automatic spending cuts by the U.S. Government could have a material adverse effect on our ability to maintain, renew or enter into new contracts.

The U.S. government deficit and budget crisis has created increasing pressure to reduce government spending. In August 2011, President Obama signed into law the Budget Control Act of 2011, which increased the U.S. government’s debt ceiling and enacted 10-year discretionary spending caps expected to generate substantial savings for the U.S. government. The Budget Control Act of 2011 also established a joint bipartisan committee of Congress responsible for identifying at least $1.2 trillion in additional savings by November 2011. The joint committee did not meet the deadline for proposing recommended legislation. Unless the Budget Control Act of 2011 is amended, additional automatic spending cuts (referred to as "sequestration") totaling $1.2 trillion over nine years will be triggered. These discretionary spending cuts, which would begin in January 2013, are expected to be evenly split between defense and non-defense areas.

In early August 2012, the President signed the Sequestration Transparency Act of 2012, under which the President provided to Congress a report on how sequestration would be implemented, including information about specific reductions and any exemptions. This report estimated that sequestration would result in a 9.4% cut in non-exempt defense discretionary spending and a 8.2% cut in non-exempt, non-defense discretionary spending. However, the report also warned that these estimates are preliminary and that the actual results and percentages could differ. We continue to evaluate the potential impact of possible sequestration on our business, and while the ultimate effect on our business is uncertain, the amount and nature of these federal budget spending reductions could severely limit our ability to maintain, renew or enter into new contracts and therefore materially adversely impact our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Default upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

No.		Description
31.1		Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)
31.2		Certification of Principal Financial Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)
32.1		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350
32.2		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350
101		The following financial statements and footnotes from the PharmAthene, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets; (ii) Unaudited Condensed Consolidated Statements of Operations; (iii) Unaudited Condensed Consolidated Statements of Cash Flows; and (vi) Notes to the Unaudited Condensed Consolidated Financial Statements.*

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PHARMATHENE, INC.

Dated: November 6, 2012	By:	/s/ Eric I. Richman
		Eric I. Richman
		President and Chief Executive Officer

Dated: November 6, 2012	By:	/s/ Linda Chang
		Linda Chang
		Senior Vice-President and Chief Financial Officer

EX-31.1 2 v324923_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Eric I. Richman, certify that:

I have reviewed this Form 10-Q of PharmAthene, Inc. for the quarter ended September 30, 2012;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 6, 2012	/s/ Eric I. Richman
	Name: Eric I. Richman
	Title: President and Chief Executive Officer

EX-31.2 3 v324923_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Linda L. Chang, certify that:

I have reviewed this Form 10-Q of PharmAthene, Inc. for the quarter ended September 30, 2012;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 6, 2012	/s/ Linda Chang
	Name: Linda Chang
	Title: Senior Vice-President and Chief Financial Officer

EX-32.1 4 v324923_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report on Form 10-Q of PharmAthene, Inc. (the “Company”) for the quarter ended September 30, 2012, as filed with the Securities and Exchange Commission (the “Report”), I, Eric I. Richman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Eric I. Richman
Eric I. Richman
President and Chief Executive Officer
November 6, 2012

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-32.2 5 v324923_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report on Form 10-Q of PharmAthene, Inc. (the “Company”) for the quarter ended September 30, 2012, as filed with the Securities and Exchange Commission (the “Report”), I, Linda L. Chang, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Linda Chang
Linda Chang
Senior Vice-President and Chief Financial Officer
November 6, 2012

EX-101.INS 6 pip-20120930.xml XBRL INSTANCE DOCUMENT 48365984

46584

1.61

2022-03-30

1200000

5000000

2500000

3500000

1857143

371423

3.50

10406076

2899991

2956080

363742

2348453

69876

210101716

130709

909096

1208370

12550750

0.1014

0.015

2500000

-215977

100000000

1606241

48345984

10860115

1846614

579707

-197339824

23410865

3682311

23410865

2500000

216000

14726328

48345984

46584

909096

6970610

46000

4835

0.0001

681808

20378622

1545534

1.61

553081

681822

1764264

3233804 2022-03-30

2899991

1300000

0.85 0.80

1545534

2572775

2.50

2015-01-28

100778

3.97

2017-03-30

1600000

8200000

0.05

4600000

11785327

8362995

830585

2348453

208525917

53384

15851806

1010522

100000000

4424442

100000

48236172

6951703

1445700

449709

-193689457

22803509

3021208

22803509

11236771

48236172

4615342

500000

4824

0.0001

19613006

1886652

788666

3169642

1886652

-10643169

-2684507

50892

18026619

-4635643

-64362

1881416

-1357711

-0.10

348813

-7003421

-71439

10496

71439

-1379251

11632272

-1439312

-1080032

-88877

-4546766

16688703

5750277

28669788

204291

1881416

40540

47041027

10900000

-4546766

6096403

560639

-54668

400000

6075555

40540

-8168 50000 5814639 1.76

666919

1214497

-6075555

668640 PIP PHARMATHENE, INC false Accelerated Filer Q3 2012 10-Q 2012-09-30 0001326190 --12-31

0.065

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 5 - Stockholders’ Equity   Long-Term Incentive Plan   In 2007, the Company’s stockholders approved the 2007 Long Term Incentive Plan (the “2007 Plan”) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses (collectively “awards”)  to Company officers and employees.  Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.     At that time, we reserved 3,500,000 shares of common stock in connection with awards to be granted under the 2007 Plan, including those awards that had originally been made under a prior plan.  In 2008, the Company’s shareholders approved amendments to the 2007 Plan, increasing the maximum number of shares authorized for issuance under the plan to 4,600,000 and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan will increase automatically in each year, beginning in 2009 and continuing through 2015, according to certain limits set forth in the 2007 Plan.  At September 30, 2012, there were approximately 8.2 million shares approved for issuance under the 2007 Plan, of which approximately 1.6 million shares are available to be issued. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions, and the exercise price.  Stock options issued under the 2007 Plan may have a maximum term of ten years. Warrants Classified as Equity   In connection with the July 2009 private placement, we issued warrants to purchase an aggregate of 2,572,775 shares of the Company’s common stock at an exercise price of $2.50 per share. The warrants will expire on January 28, 2015.      In connection with the March 30, 2012, debt financing (see Note 6), we issued warrants to purchase an aggregate of 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share to GE Capital. The warrants expire on March 30, 2022.      Also outstanding are warrants to purchase an aggregate of 100,778 shares of common stock at $3.97 per share, which will expire on March 30, 2017. </div>

-4839277

216460

<div style="FONT: 10pt Times New Roman, Times, Serif"> Revenue Recognition   We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts.  Costs consist primarily of direct subcontractor and internal labor charges incurred plus an allocation of fringe benefits, overhead and general and administrative expenses as defined in each contract.   Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned.  The estimate of the applicable fee earned is determined by reference to the contract:  if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, pursuant to the terms of the cost-plus fee contract, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.    Under the milestone method of revenue recognition, milestone payments, including milestone payments for fees, contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.  Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.       For fixed price contracts without substantive milestones as described above, revenue is recognized on the percentage-of-completion method in accordance with the applicable accounting guidance for long term contracts.  The percentage-of-completion method recognizes income as the contract progresses; recognition of revenue and profits generally related to the costs incurred in providing the services required under the contract.  The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates.  The fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used. Estimating is an integral part of our business activities, and there may be a necessity to revise estimates on contracts continually as the work progresses. As a result, amounts invoiced may differ from revenue recognized. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue, a component of accrued expenses and other liabilities. We recorded approximately $46 thousand and $0.5 million as deferred revenue as of September 30, 2012 and December 31, 2011, which is included in accrued expenses and other liabilities on the condensed consolidated balance sheet.   As revenue is recognized in accordance with the terms of the contracts, related amounts are recorded as unbilled accounts receivable in our consolidated balance sheets.  As specific contract invoices are generated and sent to our customers in accordance with a contract, invoiced amounts are transferred out of unbilled accounts receivable and into billed accounts receivable.  Invoicing frequency and payment terms for cost-plus-fee contracts with our customers are defined within each contract, but are typically monthly invoicing with 30-60 day payment cycles.   We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred.  For each of the three months ended September 30, 2012 and 2011, we recorded approximately $0.1 million of costs reimbursed by the government as an offset to research and development expenses.  For the nine months ended September 30, 2012 and 2011, we recorded approximately $1.1 million and $0.4 million, respectively, of costs reimbursed by the government as an offset to research and development expenses. </div>

400764

22122

19162176

-4876866

-32960

<div style="FONT: 10pt Times New Roman, Times, Serif"> Cash and Cash Equivalents   Cash and cash equivalents are stated at cost which approximates market value.  We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. </div>

1499910

<div style="FONT: 10pt Times New Roman, Times, Serif"> Basis of Presentation   Our condensed consolidated financial statements include the accounts of PharmAthene, Inc. and our wholly-owned subsidiaries, collectively referred to herein as “PharmAthene”, “we”, “us”, “our” or the “Company.”  All significant intercompany transactions and balances have been eliminated in consolidation.  Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).  In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows.  The condensed consolidated balance sheet at December 31, 2011 has been derived from audited consolidated financial statements at that date.  The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year.   Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission. We currently operate in one business segment. Certain amounts within current assets in the 2011 financial statements have been reclassified to conform to the current year’s presentation. </div>

67400

661103

-0.08

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 3 - Fair Value Measurements   We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date.  We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value.  This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs.  The three levels of inputs used to measure fair value are as follows:     <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 15px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 25px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> •</td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> Level 1 — Quoted prices in active markets for identical assets or liabilities.</td> </tr> </table>   <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 15px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 25px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> •</td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</td> </tr> </table>   <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 15px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 25px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> •</td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.  This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</td> </tr> </table>   An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.  At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value.  All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.    We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.  We have no non-financial assets and liabilities that are measured at fair value.     The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2012:    <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid">Description</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Balance as of December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Unrealized (Gains)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Balance as of September 30,  2012</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="WIDTH: 55%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Derivative liabilities related to warrants</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1,886,652</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">(341,118</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1,545,534</td> <td style="TEXT-ALIGN: left"> </td> </tr> </table>   The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2011:    <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid">Description</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Balance as of December 31, 2010</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">New Liabilities in 2011</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Unrealized (Gains)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Balance as of September 30,  2011</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="WIDTH: 40%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Derivative liabilities related to warrants</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">8,362,995</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">668,640</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">(6,075,555</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2,956,080</td> <td style="TEXT-ALIGN: left"> </td> </tr> </table>     At September 30, 2012 and 2011, derivative liabilities are comprised of 2,899,991 warrants to purchase common stock that are classified as liabilities. The warrants are considered to be derivative liabilities due to the presence of net settlement features and are recorded at fair value at each balance sheet date.  The fair value of our warrants is determined based on the Black-Scholes option pricing model.  Use of the Black-Scholes option-pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends.  Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants’ fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Gains and losses on the fair value adjustments for these derivative instruments are classified in other expenses as the change in fair value of derivative instruments in our condensed consolidated statements of operations.  The $0.3 million unrealized gains on the change in the market value of derivative instruments during the nine-month period ended September 30, 2012 is due primarily to the change in the closing price of our stock, which was $1.27 per share as of December 30, 2011 and $1.18 per share as of September 30, 2012. The $6.1 million unrealized gains on the change in the market value of derivative instruments during the nine-month period ended September 30, 2011 is due primarily to the change in the closing price of our stock, which was $4.23 per share as of December 31, 2010 and $1.76 per share as of September 30, 2011. </div>

234811

-177864

67400

13534

1208370

100000

-1227656

3489557

9004008

<div style="FONT: 10pt Times New Roman, Times, Serif"> Principal payments on the term loan are scheduled as follows:    <table style="WIDTH: 18%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" colspan="2"> </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" colspan="2">Principal</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" colspan="2">Year</td> <td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" colspan="2">Payments</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; WIDTH: 1%; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; WIDTH: 6%; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2012</td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 1%; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 2%; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> $</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 8%; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> -</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2013</td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 909,096</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2014</td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 909,096</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: center; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2015</td> <td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">   </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 681,808</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="BORDER-BOTTOM: black 2.25pt double; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2,500,000</td> </tr> </table> </div>

-557683

-2818201

1157

-3461757

<div style="FONT: 10pt Times New Roman, Times, Serif"> The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2012:    <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid">Description</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Balance as of December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Unrealized (Gains)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Balance as of September 30,  2012</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="WIDTH: 55%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Derivative liabilities related to warrants</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1,886,652</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">(341,118</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1,545,534</td> <td style="TEXT-ALIGN: left"> </td> </tr> </table>   The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2011:    <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid">Description</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Balance as of December 31, 2010</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">New Liabilities in 2011</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Unrealized (Gains)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Balance as of September 30,  2011</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="WIDTH: 40%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Derivative liabilities related to warrants</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">8,362,995</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">668,640</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">(6,075,555</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2,956,080</td> <td style="TEXT-ALIGN: left"> </td> </tr> </table> </div>

14762634

3597934

Payments on the term loan are interest-only for the first 10 months, which may be extended to 12 months if certain conditions described in the Loan Agreement are met. Subsequently, the term loan will fully amortize over its remaining term.

<div style="FONT: 10pt Times New Roman, Times, Serif"> Income Taxes   We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year, adjusted as necessary for discrete items. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.   The provision for income taxes was approximately $22 thousand and $0.2 million for the three and nine months ended September 30, 2012, respectively; no provision (benefit) for income taxes was recorded in 2011. The provision for income taxes in 2012 resulted from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP. This difference resulted in the recording of a deferred tax liability, which cannot offset deferred tax assets, and results in a corresponding provision for income taxes. This deferred tax liability is included in our condensed consolidated balance sheets in other long term liabilities. </div>

24001453

81252

<div style="FONT: 10pt Times New Roman, Times, Serif"> Revolving Line of Credit and Term Loan   As discussed further in Note 6, we entered into a loan agreement with General Electric Capital Corporation (“GE Capital”) in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in-capital, resulting in a debt discount at the date of issuance. The debt discount is being amortized over the term of the loan agreement using the effective interest method. Financing costs incurred in connection with this agreement are being amortized over the term of the agreement using the effective interest method. </div>

-12225

66626

1499910

145658

<div style="FONT: 10pt Times New Roman, Times, Serif"> Share-Based Compensation   We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans.  The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized ratably as expense over the requisite service period.  The fair value of stock option grants is determined using the Black-Scholes option pricing model.  The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of the Company’s stock price.  The value of the award that is ultimately expected to vest is recognized as compensation expense on a straight line basis over the employee’s requisite service period.   Employee share-based compensation expense recognized in the three months ended September 30, 2012 and 2011 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12% for both 2012 and 2011, based on historical experience of forfeitures.    Share-based compensation expense for the three months ended September 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2011</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: right" colspan="3"> </td> <td> </td> <td colspan="3"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Research and development</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">107,199</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">208,488</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 332,006</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 417,603</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Total share-based compensation expense</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 439,205</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 626,091</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> </table>   During the three months ended September 30, 2012, we granted no options to employees and made no restricted stock grants.  During the three months ended September 30, 2011, we granted 256,639 options to employees and made 50,000 restricted stock grants.  At September 30, 2012, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.5 million, net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 1.94 years.     Share-based compensation expense for the nine months ended September 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2011</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: right" colspan="3"> </td> <td> </td> <td colspan="3"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Research and development</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">351,342</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">666,919</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,148,568</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,214,497</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Total share-based compensation expense</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,499,910</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,881,416</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> </table>   During the nine months ended September 30, 2012, we granted 200,948 options to employees and non-employee directors and made no restricted stock grants.  During the nine months ended September 30, 2011, we granted 560,639 options to employees and non-employee directors and made 50,000 restricted stock grants to employees. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 4 - Commitments and Contingencies   SIGA Litigation   In December 2006, we filed a complaint against SIGA Technologies, Inc. (“SIGA”) in the Delaware Court of Chancery.  The complaint alleged, among other things, that we have the right to license exclusively development and marketing rights for SIGA’s drug candidate, ST-246® (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006.  The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement.    In September 2011, the Court issued an opinion in the case finding that SIGA had breached certain contractual obligations to us and upholding our claims of promissory estoppel.  The Court awarded us the right to receive 50% of all net profits related to the sale of ST-246® and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of ST-246® and related products.  The Court also awarded us one-third of our reasonable attorney's fees and expert witness fees, which amounts to approximately $2.4 million plus interest. In May 2012, the Court issued its final judgment. SIGA has appealed aspects of the decision to the Delaware Supreme Court, which has set oral argument in the case for January 2013. In response, we have cross-appealed other aspects of the decision. Based on the timing of issuance of past Delaware Supreme Court decisions, we expect a ruling from the high court no later than the second quarter 2013.      We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal, and that the Delaware Supreme Court will not overturn the trial court’s decision awarding us a 10 year 50% net profit of the sales of ST-246®and related products (once SIGA retains the first $40 million in net profit). We have not yet recorded any amount due from SIGA in relation to this case.    Government Contracting   Payments to the Company on cost-plus-fee contracts are provisional and are subject to adjustment upon audit by the Defense Contract Audit Agency and BARDA. In our opinion, adjustments that may result from audits are not expected to have a material effect on our financial position, results of operations, or cash flows.   Registration Rights Agreements   We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants.  We subsequently filed two registration statements on Form S-3 with the Securities and Exchange Commission to register the shares underlying the convertible notes and related warrants, which registration statements have been declared effective. We are obligated to maintain the registration statements effective until the date when all shares underlying the convertible notes and related warrants (and any other securities issued or issuable with respect to in exchange for such shares) have been sold. The convertible notes were converted or extinguished in 2010, although the related warrants remain outstanding. The warrants will expire on January 28, 2015.   We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or “piggy-back” basis or both.     Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a “Maintenance Failure”), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at September 30, 2012, would be approximately $0.2 million.   Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision would be approximate $0.2 million for each month until the failure, if it occurs, is cured. </div>

48314058

188610

-3650367

1377520

<div style="FONT: 10pt Times New Roman, Times, Serif"> Foreign Currency Translation   The functional currency of our wholly owned foreign subsidiaries is their local currency.  Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period.  Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period.  Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive income (loss), a component of stockholders’ equity.  Transaction gains and losses are included in the determination of net loss.     In July 2012, we substantially completed our liquidation of our Canadian subsidiary, which we had acquired in 2005.  Prior to substantially liquidating the Canadian subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income.  As a result of the substantially completed liquidation, we realized approximately $1.2 million of income in our condensed consolidated statement of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our Canadian subsidiary. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Share-based compensation expense for the three months ended September 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2011</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: right" colspan="3"> </td> <td> </td> <td colspan="3"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Research and development</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">107,199</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">208,488</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 332,006</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 417,603</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Total share-based compensation expense</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 439,205</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 626,091</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> </table>   During the three months ended September 30, 2012, we granted no options to employees and made no restricted stock grants.  During the three months ended September 30, 2011, we granted 256,639 options to employees and made 50,000 restricted stock grants.  At September 30, 2012, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.5 million, net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 1.94 years.     Share-based compensation expense for the nine months ended September 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2011</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: right" colspan="3"> </td> <td> </td> <td colspan="3"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Research and development</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">351,342</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">666,919</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,148,568</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,214,497</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Total share-based compensation expense</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,499,910</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,881,416</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> </table> </div>

200948

188610

2087

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 2 - Summary of Significant Accounting Policies   Basis of Presentation   Our condensed consolidated financial statements include the accounts of PharmAthene, Inc. and our wholly-owned subsidiaries, collectively referred to herein as “PharmAthene”, “we”, “us”, “our” or the “Company.”  All significant intercompany transactions and balances have been eliminated in consolidation.  Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).  In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows.  The condensed consolidated balance sheet at December 31, 2011 has been derived from audited consolidated financial statements at that date.  The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year.   Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission. We currently operate in one business segment. Certain amounts within current assets in the 2011 financial statements have been reclassified to conform to the current year’s presentation.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.    Foreign Currency Translation   The functional currency of our wholly owned foreign subsidiaries is their local currency.  Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period.  Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period.  Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive income (loss), a component of stockholders’ equity.  Transaction gains and losses are included in the determination of net loss.     In July 2012, we substantially completed our liquidation of our Canadian subsidiary, which we had acquired in 2005.  Prior to substantially liquidating the Canadian subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income.  As a result of the substantially completed liquidation, we realized approximately $1.2 million of income in our condensed consolidated statement of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our Canadian subsidiary.  Cash and Cash Equivalents   Cash and cash equivalents are stated at cost which approximates market value.  We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.      Revolving Line of Credit and Term Loan   As discussed further in Note 6, we entered into a loan agreement with General Electric Capital Corporation (“GE Capital”) in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in-capital, resulting in a debt discount at the date of issuance. The debt discount is being amortized over the term of the loan agreement using the effective interest method. Financing costs incurred in connection with this agreement are being amortized over the term of the agreement using the effective interest method.   Significant Customers and Accounts Receivable   Our primary customers are the Biomedical Advanced Research and Development Authority (“BARDA”), the U.S. Department of Defense (the “DoD”), and the National Institutes of Health (“NIH”). As of September 30, 2012 and December 31, 2011, our trade receivable and unbilled receivable balances were comprised solely of receivables from these customers.     Revenue Recognition   We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts.  Costs consist primarily of direct subcontractor and internal labor charges incurred plus an allocation of fringe benefits, overhead and general and administrative expenses as defined in each contract.   Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned.  The estimate of the applicable fee earned is determined by reference to the contract:  if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, pursuant to the terms of the cost-plus fee contract, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.    Under the milestone method of revenue recognition, milestone payments, including milestone payments for fees, contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.  Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.       For fixed price contracts without substantive milestones as described above, revenue is recognized on the percentage-of-completion method in accordance with the applicable accounting guidance for long term contracts.  The percentage-of-completion method recognizes income as the contract progresses; recognition of revenue and profits generally related to the costs incurred in providing the services required under the contract.  The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates.  The fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used. Estimating is an integral part of our business activities, and there may be a necessity to revise estimates on contracts continually as the work progresses. As a result, amounts invoiced may differ from revenue recognized. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue, a component of accrued expenses and other liabilities. We recorded approximately $46 thousand and $0.5 million as deferred revenue as of September 30, 2012 and December 31, 2011, which is included in accrued expenses and other liabilities on the condensed consolidated balance sheet.   As revenue is recognized in accordance with the terms of the contracts, related amounts are recorded as unbilled accounts receivable in our consolidated balance sheets.  As specific contract invoices are generated and sent to our customers in accordance with a contract, invoiced amounts are transferred out of unbilled accounts receivable and into billed accounts receivable.  Invoicing frequency and payment terms for cost-plus-fee contracts with our customers are defined within each contract, but are typically monthly invoicing with 30-60 day payment cycles.   We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred.  For each of the three months ended September 30, 2012 and 2011, we recorded approximately $0.1 million of costs reimbursed by the government as an offset to research and development expenses.  For the nine months ended September 30, 2012 and 2011, we recorded approximately $1.1 million and $0.4 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.     Share-Based Compensation   We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans.  The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized ratably as expense over the requisite service period.  The fair value of stock option grants is determined using the Black-Scholes option pricing model.  The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of the Company’s stock price.  The value of the award that is ultimately expected to vest is recognized as compensation expense on a straight line basis over the employee’s requisite service period.   Employee share-based compensation expense recognized in the three months ended September 30, 2012 and 2011 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12% for both 2012 and 2011, based on historical experience of forfeitures.    Share-based compensation expense for the three months ended September 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2011</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: right" colspan="3"> </td> <td> </td> <td colspan="3"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Research and development</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">107,199</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">208,488</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 332,006</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 417,603</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Total share-based compensation expense</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 439,205</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 626,091</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> </table>   During the three months ended September 30, 2012, we granted no options to employees and made no restricted stock grants.  During the three months ended September 30, 2011, we granted 256,639 options to employees and made 50,000 restricted stock grants.  At September 30, 2012, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.5 million, net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 1.94 years.     Share-based compensation expense for the nine months ended September 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">2011</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: right" colspan="3"> </td> <td> </td> <td colspan="3"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Research and development</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">351,342</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">666,919</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,148,568</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,214,497</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Total share-based compensation expense</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,499,910</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,881,416</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> </table>   During the nine months ended September 30, 2012, we granted 200,948 options to employees and non-employee directors and made no restricted stock grants.  During the nine months ended September 30, 2011, we granted 560,639 options to employees and non-employee directors and made 50,000 restricted stock grants to employees.   Income Taxes   We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year, adjusted as necessary for discrete items. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.   The provision for income taxes was approximately $22 thousand and $0.2 million for the three and nine months ended September 30, 2012, respectively; no provision (benefit) for income taxes was recorded in 2011. The provision for income taxes in 2012 resulted from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP. This difference resulted in the recording of a deferred tax liability, which cannot offset deferred tax assets, and results in a corresponding provision for income taxes. This deferred tax liability is included in our condensed consolidated balance sheets in other long term liabilities.   Basic and Diluted Net Loss Per Share   Basic loss per share is computed by dividing consolidated net loss by the weighted average number of shares of common stock outstanding during the quarter, excluding unvested restricted stock.   For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting  primarily of stock options, unvested restricted stock and stock purchase warrants.  The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.     For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive shares of common stock is anti-dilutive due to the net losses.  A total of approximately 11.5 million and approximately10.9 million potential dilutive shares have been excluded in the calculation of diluted net loss per share in the three and nine months ended September 30, 2012 and 2011, respectively, because their inclusion would be anti-dilutive.     Recent Accounting Pronouncements   We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations or financial position. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 1 - Organization and Business   We are a biopharmaceutical company focused on developing biodefense countermeasure applications.  We are subject to those risks associated with any biopharmaceutical company that has substantial expenditures for research and development.  There can be no assurance that our research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable.  In addition, we operate in an environment of rapid technological change and are largely dependent on the services and expertise of our employees, consultants and other third parties.   Historically, we have performed under government contracts and grants and raised equity, equity-linked and debt capital from investors and lenders to sustain our operations. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Basic and Diluted Net Loss Per Share   Basic loss per share is computed by dividing consolidated net loss by the weighted average number of shares of common stock outstanding during the quarter, excluding unvested restricted stock.   For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting  primarily of stock options, unvested restricted stock and stock purchase warrants.  The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.     For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive shares of common stock is anti-dilutive due to the net losses.  A total of approximately 11.5 million and approximately10.9 million potential dilutive shares have been excluded in the calculation of diluted net loss per share in the three and nine months ended September 30, 2012 and 2011, respectively, because their inclusion would be anti-dilutive. </div>

1100000

341118

226910

69876 0 2015-09 <div style="FONT: 10pt Times New Roman, Times, Serif"> Recent Accounting Pronouncements   We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations or financial position. </div> <div style="FONT: 10pt Times New Roman, Times, Serif"> Note 6 – Financing Transactions   On March 30, 2012, we entered into a Loan and Security Agreement (the “Loan Agreement”) with General Electric Capital Corporation (“GE Capital”), as lender and agent for other lenders that may subsequently become party to the agreement. The Loan Agreement provides for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5 million based on our outstanding qualified accounts receivable.  On March 30, 2012, the term loan was funded for an aggregate amount of $2.5 million. As of September 30, 2012 approximately $1.2 million was outstanding under the revolving line of credit, which is recorded as short term debt on our condensed consolidated balance sheet. Under the terms of the Loan Agreement, the Company may draw down from the revolving line of credit up to 85% of qualified billed accounts receivable and 80% of qualified unbilled accounts receivable. As of September 30, 2012, approximately $1.3 million was available under the Loan Agreement to borrow against the revolving line of credit.     The fixed interest rate on the term loan is 10.14% per annum. The revolving line of credit has an adjustable interest rate based upon the 3-month London Interbank Offered Rate (LIBOR), with a floor of 1.5%, plus 5%. As of September 30, 2012, this interest rate was 6.5%.  Both the term loan and the revolving line of credit mature in September 2015.  Payments on the term loan are interest-only for the first 10 months, which may be extended to 12 months if certain conditions described in the Loan Agreement are met. Subsequently, the term loan will fully amortize over its remaining term. Principal payments on the term loan are scheduled as follows:    <table style="WIDTH: 18%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" colspan="2"> </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" colspan="2">Principal</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" colspan="2">Year</td> <td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" colspan="2">Payments</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; WIDTH: 1%; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; WIDTH: 6%; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2012</td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 1%; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 2%; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> $</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 8%; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> -</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2013</td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 909,096</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2014</td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 909,096</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: center; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2015</td> <td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">   </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 681,808</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">  </td> <td style="BORDER-BOTTOM: black 2.25pt double; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; TEXT-ALIGN: right; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"> 2,500,000</td> </tr> </table>   If we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date, we are obligated to pay a prepayment premium equal to 3% of the then outstanding principal amount of the term loan during the first two years of the loan and 2% during the third year and thereafter.  In addition we are obligated to pay a final payment fee of 3% of the term loan balance. The final payment fee will be accrued and expensed over the term of the agreement, using the effective interest method.   Our obligations under the Loan Agreement are collateralized by a security interest in substantially all of our assets including cash, receivables and property and equipment. While the security interest does not, except in limited circumstances, cover our intellectual property, it does cover any proceeds received by us from the use or sale of our intellectual property.   The Loan Agreement contains customary representations, warranties and covenants, including limitations on acquisitions, dispositions, incurrence of indebtedness and the granting of security interests. The representations, warranties and covenants contained in the Loan Agreement were made only for purposes of such agreement and as of a specific date or specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Loan Agreement.   The Loan Agreement contains certain financial and non-financial covenants. Upon the occurrence and during the continuance of any event of default, GE Capital may, and at the written request of the requisite lenders shall, terminate the commitments under the facilities and declare any or all of the obligations to be immediately due and payable, without demand or notice to us; however, any event of default relating to timely payment of debts, insolvency, liquidation, bankruptcy or similar events will result in automatic acceleration. Among the remedies available to GE Capital in case of an event of default are the taking possession and disposition of any collateral under the Loan Agreement.   In connection with the Loan Agreement, we issued GE Capital warrants to purchase 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share, subject to customary anti-dilution adjustments. The warrants are classified as equity. The fair value of the warrants at March 30, 2012 of $69,876 was recorded as a discount to the carrying value of the debt and is being amortized through interest expense over the term of the loan.     Also, in connection with us entering into the Loan Agreement, we incurred approximately $216,000 of related expenses. These expenses are deferred and are being amortized to interest expense over the term of the Loan Agreement.   In June 2011, PharmAthene entered into an agreement with certain accredited investors who purchased an aggregate of 1,857,143 shares of common stock for a purchase price of $3.50 per share and warrants to purchase up to an additional 371,423 shares of common stock. The warrants became exercisable immediately at an exercise price of $3.50 per share and are exercisable until the fifth anniversary of the date of issuance, which is June 15, 2016. The warrants are classified as derivative liabilities. The Company received gross proceeds of approximately $6.5 million and net proceeds of approximately $5.8 million. </div> <div style="FONT: 10pt Times New Roman, Times, Serif"> Significant Customers and Accounts Receivable   Our primary customers are the Biomedical Advanced Research and Development Authority (“BARDA”), the U.S. Department of Defense (the “DoD”), and the National Institutes of Health (“NIH”). As of September 30, 2012 and December 31, 2011, our trade receivable and unbilled receivable balances were comprised solely of receivables from these customers. </div> 38984 2500000 1227656 1.18

351342

1148568

P3M

-341118

0.03

0.02

0.03

0.02

0.03

5800000 6500000 0.50 40000000 2400000 P10Y 200000 0.010 200000 0.010 1.27 4.23 P10Y

-3021914

95520

5260057

-113081

0.00

114494

3961

3283246

-79585

-33496

4884231

8281971

626091

48194035

-33496

2988418

256639

100000

2898869

9932

50000 0.12

208488

417603

-1790377

-31312

6696126

-1433902

0.00

72453

5727

-1227656

3275428

7690

-191864

5138622

8486503

439205

48345984

11500000

-213936

1598513

22072

100000

508971

112529

0 0.12 1227656

107199

332006

P1Y11M9D

0001326190 us-gaap:MaximumMember 2012-07-01 2012-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2012-07-01 2012-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2012-07-01 2012-09-30 0001326190 2012-07-01 2012-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2011-07-01 2011-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2011-07-01 2011-09-30 0001326190 2011-07-01 2011-09-30 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2008-01-01 2008-12-31 0001326190 pip:PharmAtheneMember 2010-01-01 2010-12-31 0001326190 pip:PharmAtheneMember 2011-01-01 2011-12-30 0001326190 pip:GroupFourMember 2012-09-01 2012-09-30 0001326190 pip:GroupThreeMember 2012-09-01 2012-09-30 0001326190 us-gaap:MaximumMemberpip:PharmAtheneMember 2011-09-01 2011-09-30 0001326190 pip:PharmAtheneMember 2011-09-01 2011-09-30 0001326190 pip:PharmAtheneMember 2011-06-01 2011-06-30 0001326190 pip:YearTwoMember 2012-01-01 2012-09-30 0001326190 pip:YearThreeMember 2012-01-01 2012-09-30 0001326190 pip:YearOneMember 2012-01-01 2012-09-30 0001326190 pip:ThereAfterMember 2012-01-01 2012-09-30 0001326190 pip:TermLoanMember 2012-01-01 2012-09-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2012-01-01 2012-09-30 0001326190 pip:LiquidityArrangementsMemberus-gaap:MaximumMember 2012-01-01 2012-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-09-30 0001326190 pip:PharmAtheneMember 2012-01-01 2012-09-30 0001326190 2012-01-01 2012-09-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2011-01-01 2011-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2011-01-01 2011-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2011-01-01 2011-09-30 0001326190 pip:PharmAtheneMember 2011-01-01 2011-09-30 0001326190 2011-01-01 2011-09-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2011-12-31 0001326190 2011-12-31 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2010-12-31 0001326190 2010-12-31 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2008-12-31 0001326190 pip:PercentageOverLiborMember 2012-09-30 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2012-09-30 0001326190 pip:GroupTwoMember 2012-09-30 0001326190 pip:GroupOneMember 2012-09-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2012-09-30 0001326190 pip:SeniorSecuredCreditFacilityTermLoansMember 2012-09-30 0001326190 pip:DerivativeLiabilitiesMember 2012-09-30 0001326190 2012-09-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2011-09-30 0001326190 pip:DerivativeLiabilitiesMember 2011-09-30 0001326190 2011-09-30 0001326190 pip:PharmAtheneMember 2011-06-30 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2007-08-03 0001326190 pip:CreditFacilitiesMemberpip:TermLoanMember 2012-03-30 0001326190 pip:SeniorSecuredCreditFacilityTermLoansMemberpip:RevolvingLineOfCreditMember 2012-03-30 0001326190 2012-03-30 0001326190 2012-11-01 shares iso4217:USD pip:Right iso4217:USD iso4217:USD shares pure pip:Segment

EX-101.SCH 7 pip-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements Of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Organization and Business link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Financing Transactions link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Financing Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Share-based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Summary of Changes in Fair Value of Our Level 3 Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Financing Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Fully Amortized Term Loan (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 pip-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pip-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pip-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). In addition, includes the amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Accrued Expenses And Other Current Liabilities Accrued expenses and other liabilities Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax Accumulated other comprehensive (loss) income Additional Paid In Capital Common Stock Additional paid-in-capital Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allocated Share Based Compensation Expense Total share-based compensation expense Amendment Flag Amendment Flag Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Anti-dilutive securities excluded from computation of earnings per share Assets Total assets Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] Current assets: Basis Of Presentation And Significant Accounting Policies [Text Block] Basis of Presentation Billed Contract Receivables Accounts receivable (billed) Breach of contractual commitment award period - number of years following initial commercial sale of ST-246. Breach Of Contractual Commitment Award Period SIGA breach of contractual obligation award period following initial commercial sale Business Acquisition Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Cash And Cash Equivalents At Carrying Value Cash and cash equivalents, at end of period Cash and cash equivalents, at beginning of period Cash and cash equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash And Cash Equivalents Period Increase Decrease Increase (decrease) in cash and cash equivalents Cash And Cash Equivalents Policy [Text Block] Cash and Cash Equivalents Cash Equivalents, Maturity Period Cash Equivalents Maturity Period Cash liquidity maturity period Class Of Warrant Or Right [Axis] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Common stock at an exercise price Warrant exercise price Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Warrants issued to purchase shares of common stock Class Of Warrant Or Right Outstanding Warrants to purchase common stock Closing Stock Price Closing Stock Price Closing stock price, per share Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies [Line Items] Common Stock Capital Shares Reserved For Future Issuance Common stock reserved Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Price Issued Per Share Common Stock Price Issued Per Share Common Stock issued price Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common Stock Share issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,345,984 and 48,236,172 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively Comprehensive Income Net Of Tax Comprehensive loss Contracts Revenue Revenue Cost Of Reimbursable Expense Cost reimbursed to offset research and development expenses Court awarded fees. Court Awarded Fees Awarded 1/3 reasonable attorney's fees and expert witness fees, plus interest. Credit Facilities [Member] Credit Facilities [Member] Credit Facilities Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Current Fiscal Year End Date Current Fiscal Year End Date The entire disclosure of costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet. In addition, entire disclosure of gross and net proceeds from the issuance of common stock and the facts surrounding the issuance. Debt And Equity Transaction Disclosure [Text Block] Financing Transactions Debt Instrument Basis Spread On Variable Rate Fixed portion of the variable rate Debt Instrument Carrying Amount Fair value attributable to the warrant Debt Instrument Interest Rate During Period Interest rate on revolving line of credit Debt Instrument Payment Terms Term loan , payment terms Debt Instrument Period [Axis] Debt Instrument Period [Axis] Debt Instrument Period [Axis] Debt Instrument Period [Domain] Debt Instrument Period [Domain] Debt Instrument Period [Domain] Debt Instruments Maturity Date Month and Year Debt Instruments Maturity Date Month And Year Term loan and line of credit, maturity date Debt Policy [Text Block] Revolving Line of Credit and Term Loan Deferred Finance Costs Gross Debt financing costs Deferred Income Tax Expense Benefit Deferred income taxes Deferred Revenue Deferred revenue Depreciation And Amortization Depreciation and amortization Depreciation and amortization expense Derivative Financial Instruments Liabilities Fair Value Disclosure Ending Balance Beginning Balance Derivative Liabilities [Member] Derivative Liabilities [Member] Derivative Liabilities Derivative Liabilities Noncurrent Derivative instruments Disclosure Commitments And Contingencies Additional Information [Abstract] Disclosure Commitments And Contingencies Additional Information [Abstract] Disclosure Commitments And Contingencies Additional Information [Abstract] Disclosure Fair Value Measurements Additional Information [Abstract] Disclosure Fair Value Measurements Additional Information [Abstract] Disclosure Fair Value Measurements Additional Information [Abstract] Disclosure - Financing Transactions - Additional Information [Abstract] Disclosure Financing Transactions Additional Information [Abstract] Disclosure - Financing Transactions - Additional Information [Abstract] Disclosure - Fully Amortized Term Loan [Abstract] Disclosure Fully Amortized Term Loan [Abstract] Disclosure - Fully Amortized Term Loan [Abstract] Disclosure of Significant Customers. Disclosure Of Significant Customers Policy [Text Block] Significant Customers and Accounts Receivable Disclosure Share Based Compensation Expense [Abstract] Disclosure Share Based Compensation Expense [Abstract] Disclosure Share Based Compensation Expense [Abstract] Disclosure Stockholders Equity Additional Information [Abstract] Disclosure Stockholders Equity Additional Information [Abstract] Disclosure Stockholders Equity Additional Information [Abstract] Disclosure - Summary of Changes in Fair Value of Our Level 3 Liabilities [Abstract] Disclosure Summary Of Changes In Fair Value Of Our Level 3 Liabilities [Abstract] Disclosure - Summary of Changes in Fair Value of Our Level 3 Liabilities [Abstract] Disclosure Summary Of Significant Accounting Policies Additional Information [Abstract] Disclosure Summary Of Significant Accounting Policies Additional Information [Abstract] Disclosure Summary Of Significant Accounting Policies Additional Information [Abstract] Document Documentand Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share Basic And Diluted Basic and diluted net loss per share Earnings Per Share Policy [Text Block] Basic and Diluted Net Loss Per Share Effect Of Exchange Rate On Cash And Cash Equivalents Effects of exchange rates on cash Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs Report Line [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Unrecognized share-based compensation expense related to unvested awards Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Extinguishment Of Debt [Line Items] Extinguishment of Debt [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value By Liability Class [Axis] Liability Class [Axis] Fair Value Disclosures [Text Block] Fair Value Measurements Rate at which loans or a loan portfolio are expected to pay on final principal balances, used as an input to measure fair value. Fair Value Inputs Final Payment Rate Percentage of final payment premium Fair Value Inputs Level 3 [Member] Fair Value, Inputs, Level 3 Fair Value Inputs Prepayment Rate Percentage of prepayment premium Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Fair Value by Liability Class [Domain] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Measurements [Line Items] Fair Value Measurements [Line Items] Fair Value Measurements [Line Items] Fair Value Measurements [Table] Fair Value Measurements [Table] Fair Value Measurements [Table] Financial Instrument [Axis] Financial Instrument [Axis] Foreign Currency Transactions And Translations Policy [Text Block] Foreign Currency Translation Gain Loss On Sale Of Property Plant Equipment Gain of the disposal of property and equipment General And Administrative Expense General and administrative General And Administrative Expense [Member] General and Administrative Expense Goodwill Goodwill Gross proceeds from issuance of common stock and warrants. Gross Proceeds From Issuance Of Common Stock And Warrants Gross proceeds from issuance of stock Group Four [Member] Group Four [Member] Every 30 days until failure is cured Group One [Member] Group One [Member] Expiration 2015 Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure. Group Three [Member] Initial Maximum Maintenance Failure Obligation Group Two [Member] Group Two [Member] Expiration 2017 Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Net loss before provision for income taxes Income Statement [Abstract] Income Statement [Abstract] Income Tax Expense Benefit Provision for income taxes Provision for income taxes Income Tax Policy [Text Block] Income Taxes Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Accrued Liabilities And Other Operating Liabilities Accrued expenses and other liabilities Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other current assets Increase Decrease In Unbilled Receivables Unbilled accounts receivable Initial carrying value of derivative instruments issued during the reporting period. Initial Derivative Fair Value New Liabilities in 2011 Interest Expense Interest expense Interest Paid Cash paid for interest Interest Rate Disclosure By Reference Rate [Axis] Interest Rate Disclosure By Reference Rate [Axis] Interest Rate Disclosure By Reference Rate [Axis] Interest Reference Rate [Domain] Interest Reference Rate [Domain] Interest Reference Rate [Domain] Investment Income Interest Interest income Legal Entity [Axis] Legal Entity [Axis] Liabilities Total liabilities Liabilities And Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Line Of Credit Facility Amount Outstanding Line of Credit Facility, Amount Outstanding Line Of Credit Facility [Axis] Lender Name [Axis] Line of Credit Facility Borrowing Base Percentage of Eligible Billed Accounts Receivable Line Of Credit Facility Borrowing Base Percentage Of Eligible Billed Accounts Receivable Percentage of withdrawal from revolving loan qualified billed Line of Credit Facility Borrowing Base Percentage of Eligible Unbilled Accounts Receivable Line Of Credit Facility Borrowing Base Percentage Of Eligible Unbilled Accounts Receivable Percentage of withdrawal from revolving loan qualified unbilled Line Of Credit Facility Lender [Domain] Line of Credit Facility, Lender [Domain] Line Of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line Of Credit Facility Maximum Borrowing Capacity Line of credit facility, maximum borrowing capacity Line Of Credit Facility Remaining Borrowing Capacity Line of credit facility, Remaining borrowing capacity Line Of Credit Facility [Table] Line of Credit Facility [Table] Liquidity Arrangements [Member] Liquidity Arrangements [Member] Liquidity Long Term Debt Senior secured debt facility Senior secured debt facility Long Term Debt By Maturity [Abstract] Principal Payments Long Term Debt Current Current portion of long term debt Long Term Debt Maturities Repayments Of Principal In Year Four 2015 Long Term Debt Maturities Repayments Of Principal In Year Three 2014 Long Term Debt Maturities Repayments Of Principal In Year Two 2013 Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year 2012 Long Term Debt Noncurrent Long term debt, less current portion Long Term Debt Percentage Bearing Fixed Interest Rate Fixed interest rate on term loan Loss Contingencies By Nature Of Contingency [Axis] Loss Contingency Nature [Axis] Loss Contingency Nature [Domain] Loss Contingency, Nature [Domain] Maximum [Member] Maximum Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] Financing activities Net Cash Provided By Used In Investing Activities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities [Abstract] Investing activities Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities [Abstract] Operating activities Net Income Loss Net loss Net loss Net profit retention on sale of ST-246 before distribution for breach of contract. Net Profit Retention From Sales Before Distribution For Breach Of Contract SIGA net profits from sales before distribution for breach of contract Non Cash Financing Activity [Abstract] Non Cash Financing Activity [Abstract] Noncash financing activity Nonoperating Income Expense Total other income (expense) Nonoperating Income Expense [Abstract] Other income (expense): Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure. Notes Payable Aggregate Principal Repayment Amount Aggregate principal amount of obligation Number Of Operating Segments Number of operating segment Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income Loss Loss from operations Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Organization and Business Other Assets Noncurrent Other long term assets and deferred costs Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Foreign currency translation adjustment Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation Before Tax Realization of cumulative translation adjustment Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract] Other comprehensive loss: Income statement impact of the reclassification adjustment for translation gain (loss) realized upon the sale or complete or substantially complete liquidation of an investment in a foreign entity. Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation Net Realized Gains (Losses) Realization of cumulative translation adjustment Realization of cumulative translation adjustment Other Liabilities Noncurrent Other long term liabilities Other Nonoperating Income Expense Other income (expense) Paid In Kind Interest Non-cash interest expense Payments Of Financing Costs Deferred financing costs Payments To Acquire Property Plant And Equipment Purchases of property and equipment Percentage of aggregate principal amount of convertible notes relating to the affected shares. Percentage Of Aggregate Principal Amount Redemption Percentage of aggregate principal amount of convertible Notes Percentage of net profits awarded on the sales of ST-246 and related products. Percentage Of Net Profit Awarded SIGA breach of contractual obligation awarded, percentage of net profits Percentage Over Libor [Member] Percentage Over Libor [Member] Percentage Over Libor PharmAthene [Member] Pharm Athene [Member] PharmAthene Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Proceeds from the issuance of common stock or common stock and warrants. Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants Net proceeds from issuance of common stock and warrants. Proceeds From Issuance Of Common Stock And Warrants Net Net Proceeds from issuance of stock Proceeds from Issuance of Long Term Debt and Warrants Proceeds From Issuance Of Long Term Debt And Warrants Proceeds from issuance of long term debt and warrants Proceeds From Payments For Other Financing Activities Other EX-101.PRE 11 pip-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2012

Fair Value Measurements

Note 3 - Fair Value Measurements

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2012:

Description	Balance as of December 31, 2011		Unrealized (Gains)			Balance as of September 30, 2012

Derivative liabilities related to warrants	$	1,886,652	$	(341,118	)	$	1,545,534

The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2011:

Description	Balance as of December 31, 2010		New Liabilities in 2011		Unrealized (Gains)			Balance as of September 30, 2011

Derivative liabilities related to warrants	$	8,362,995	$	668,640	$	(6,075,555	)	$	2,956,080

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Q-#-A-V8V,E\S,3(W7S0X9&9?83,R-5\X9C1F M.3'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=OF%T:6]N7V%N9%]"=7-I;F5S M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U M;6UA#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O5]O9E]#:&%N9V5S7VEN7T9A:7)?5F%L/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]!9&1I=&EO;F%L/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H M965T4V]U#I%>&-E;%=O#I%>&-E;%=OF5D7U1E#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T M/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^9F%L'0^4V5P(#,P+`T*"0DR,#$R M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^,C`Q,CQS<&%N/CPO'0^43,\2!296=I2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,3,R M-C$Y,#QS<&%N/CPO'0^+2TQ,BTS,3QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q M-#-A-V8V,E\S,3(W7S0X9&9?83,R-5\X9C1F.3'0O:'1M;#L@8VAA'!E;G-E M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$3H\+W-T'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-EF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XW,BPT-3,\F%T:6]N(&]F(&-U;75L871I=F4@=')A;G-L871I;VX@861J=7-T M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,BPP-S(I/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!T'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M+#0Y.2PY,3`\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'1087)T7S$T,V$W9C8R7S,Q,C=?-#AD9E]A,S(U7SAF-&8Y-S@R,68X M-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-#-A-V8V,E\S,3(W M7S0X9&9?83,R-5\X9C1F.3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N(&%N9"!"=7-I;F5S6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF%T:6]N M(&%N9"!"=7-I;F5S2!F;V-U$$P.R8C>$$P.U=E(&%R92!S=6)J96-T('1O('1H;W-E#0IR M:7-K2!D97!E M;F1E;G0@;VX@=&AE('-E'!E6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE2P@97%U:71Y+6QI;FME9"!A M;F0@9&5B="!C87!I=&%L(&9R;VT-"FEN=F5S=&]R7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O M;&EC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]B M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE#(P,4,[=V4F(W@R,#%$.RP-"B8C>#(P,4,[=7,F(W@R,#%$ M.RP@)B-X,C`Q0SMO=7(F(W@R,#%$.R!O#(P,4,[0V]M<&%N M>2XF(W@R,#%$.R8C>$$P.R8C>$$P.T%L;"!S:6=N:69I8V%N="!I;G1E#(P,4,[52Y3+@T*1T%!4"8C>#(P,40[*2XF(WA!,#LF M(WA!,#M);B!T:&4@;W!I;FEO;B!O9B!M86YA9V5M96YT+"!T:&4-"F%C8V]M M<&%N>6EN9R!U;F%U9&ET960@8V]N9&5N65A2!T:&4-"E4N M4RX@4V5C=7)I=&EE65A$$P.S,Q+"`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`H)B-X,C`Q0SM"05)$028C>#(P,40[*2P@=&AE M(%4N4RX@1&5P87)T;65N="!O9@T*1&5F96YS92`H=&AE("8C>#(P,4,[1&]$ M)B-X,C`Q1#LI+"!A;F0@=&AE($YA=&EO;F%L($EN$$P.SPO:3X\+W`^#0H\<"!S M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE2!R969EF5D('=H96X@=&AE#0IR96QA=&5D(&UI;&5S=&]N97,@ M87)E(&5A$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE&ES=#L-"BAI:6DI)B-X03`[8V]L;&5C=&EO;B!I$$P.W-U8G-T86YT:79E(&5F9F]R="!W M87,@;F5C97-S87)Y('1O(&%C:&EE=F4@=&AE#0IM:6QE2!C;VUP;&5T M97,@:71S('!E&5D('!R:6-E(&-O;G1R86-TF5D(&]N('1H92!P97)C96YT86=E+6]F+6-O;7!L M971I;VX@;65T:&]D#0II;B!A8V-O2!A'!E;G-EF5D(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@=&5R;7,@;V8@=&AE#0IC M;VYT6UE;G0@8WEC;&5S+CPO<#X-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE7IE(&5A8V@@8V]S="!R96EM8G5R M$$P.R8C>$$P M.T9O2`D,"XQ(&UI;&QI;VX-"F]F(&-O$$P.T9O2`D,2XQ(&UI;&QI;VX@86YD("0P+C0-"FUI;&QI;VXL M(')E2P@;V8@8V]S=',@2!T:&4@9V]V M97)N;65N="!A$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.SPO<#X-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!A'!E;G-E(&]V97(@=&AE M(')E<75I0T*;V8@ M=&AE($-O;7!A;GDF(W@R,#$Y.W,@$$P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UEF5D(&EN('1H92!T:')E M90T*;6]N=&AS(&5N9&5D(%-E<'1E;6)E2`Q M,B4@9F]R(&)O=&@@,C`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`Q)2<^ M)#PO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=7 M24142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@'!E;G-E/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<^)#PO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P M.R`\9F]N="!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@0T], M3U(Z(&)L86-K)SY$=7)I;F<@=&AE('1H6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!#3TQ/ M4CH@8FQA8VLG/G=E#0IH860@=&]T86P@=6YR96-O9VYI>F5D('-H87)E+6)A M'!E;G-E(')E;&%T960@=&\-"G5N=F5S=&5D M(&%W87)DF4@87,@97AP96YS92!O=F5R(&$-"G=E:6=H=&5D+6%V97)A9V4@ M<&5R:6]D(&]F(#$N.30@>65A6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE'!E;G-E(&9O M$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=724142#H@,3`P)3L@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!C M;VQS<&%N/3-$,SXF(WA!,#L\+W1D/@T*/"]T6QE/3-$)U=)1%1(.B`Q)2<^ M)B-X03`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`\9F]N="!S='EL93TS M1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@0T],3U(Z(&)L86-K)SY$=7)I M;F<@=&AE(&YI;F4@;6]N=&AS#0IE;F1E9"!397!T96UB97(@,S`L(#(P,3$L M('=E(&=R86YT960@-38P+#8S.2!O<'1I;VYS('1O(&5M<&QO>65E6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M&5S/"]I/CPO M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE"!B96YE9FET2!D:69F97)E;F-E65A2!F;W(@9&ES M8W)E=&4@:71E;7,N($$@=F%L=6%T:6]N(&%L;&]W86YC92!I"!A MF5D M+B!792!A;'-O(')E8V]G;FEZ92!A('1A>"!B96YE9FET#0IF2!T:&%N#0IN;W0F(W@R,#%$.R!T:&%T('1H92!P;W-I=&EO;B!I M&5S('=A`T*<'5R<&]S97,@86YD(&9O"!L:6%B:6QI='DL('=H:6-H(&-A M;FYO="!O9F9S970@9&5F97)R960-"G1A>"!A2!I6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE2!D:79I9&EN9R!C;VYS M;VQI9&%T960@;F5T(&QO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE$$P.R8C>$$P.U1H90T* M9&EL=71I=F4@:6UP86-T(&]F(&]U0T*87!P M;'EI;F<@=&AE('1R96%S=7)Y('-T;V-K(&UE=&AO9"XF(WA!,#LF(WA!,#L\ M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE&EM M871E;'D@,3$N-2!M:6QL:6]N(&%N9`T*87!P3$P+CD@;6EL M;&EO;B!P;W1E;G1I86P@9&EL=71I=F4@2P@ M8F5C875S92!T:&5I$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M&ET('!R:6-E*2!I;B!T M:&4-"G!R:6YC:7!A;"!OF5S('1H92!I;G!U=',@=7-E9"!T;R!M96%S=7)E(&9A M:7(-"G9A;'5E+B8C>$$P.R8C>$$P.U1H:7,@:&EE&EM:7IE MF5S M('1H92!U6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=)1%1(.B`Q M,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU2 M24=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X)SX-"B8C>$$P.SPO=&0^#0H\ M=&0@#L@5$585"U)3D1%3E0Z M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%=)1%1(.B`R-7!X.R!0041$24Y' M+5))1TA4.B`P<'@[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U=)1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)U9%4E1)0T%, M+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X M)SX-"B8C>$$P.SPO=&0^#0H\=&0@#L@5$585"U)3D1%3E0Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%=) M1%1(.B`R-7!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D6QE/3-$)U!!1$1)3D0T* M;V)S97)V86)L92!M87)K970@9&%T82X\+W1D/@T*/"]T6QE/3-$)U=)1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U9%4E1) M0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@ M,'!X)SX-"B8C>$$P.SPO=&0^#0H\=&0@#L@5$585"U)3D1%3E0Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[ M(%=)1%1(.B`R-7!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D6QE/3-$)U!!1$1)3D2!L:71T;&4@;W(-"FYO(&UA2!A M;F0@=&AA="!A6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.R8C>$$P M.T%L;"!A2!A;F0@=&AE2!A$$P.SPO<#X-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.SPO<#X-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P M.V%S)B-X03`[;V8\8G(@+SX-"D1E8V5M8F5R)B-X03`[,S$L/&)R("\^#0HR M,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,SY5 M;G)E86QI>F5D)B-X03`[*$=A:6YS*3PO=&0^#0H\=&0@$$P.V%S)B-X03`[;V8\8G(@ M+SX-"E-E<'1E;6)E6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!724142#H@,3(E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S M='EL93TS1"=724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3(E)SXF(WA! M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1( M.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C M>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!724142#H@,3(E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CPO M='(^#0H\='(@$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ M+#4T-2PU,S0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B8C>$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.SPO<#X-"CQP('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$ M)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#%P="!S;VQI9"<^1&5S8W)I<'1I;VX\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@ M$$P.V]F/&)R("\^#0I$96-E;6)E$$P.S,Q+#QB$$P.RA'86EN6QE/3-$)U!!1$1)3D$$P.SPO M=&0^#0H\=&0@$$P.V]F/&)R("\^#0I397!T96UB97(@,S`L)B-X03`[/&)R M("\^#0HR,#$Q/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)U=)1%1(.B`T,"4G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$R)2<^)B-X03`[/"]T M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G M/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q M)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@5TE$5$@Z(#$R)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$R)2<^)B-X03`[ M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@ M,24G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1( M.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@5TE$5$@Z(#$R)2<^)B-X03`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`T*9&EV:61E;F1S+B8C>$$P.R8C>$$P.T-H86YG97,@:6X@86YY(&]F M('1H92!A2!C:&%N9V4@=&AE('-T;V-K M#0IP=7)C:&%S92!W87)R86YT#(P,3D[(&9A:7(@=F%L=64[(&EN8W)E M87-E'!E8W1E9"!T97)M+`T*86YT:6-I<&%T960@=F]L871I;&ET M>2!A;F0@97AP96-T960@9&EV:61E;F1S(&=E;F5R86QL>2!R97-U;'0@:6X- M"FEN8W)E87-E2!R97-U;'0@:6X@ M9&5C'!E M;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q M-#-A-V8V,E\S,3(W7S0X9&9?83,R-5\X9C1F.3'0O:'1M;#L@8VAA6QE/3-$)T9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE#(P,4,[4TE' M028C>#(P,40[*2!I;B!T:&4@1&5L87=A$$P.R8C>$$P.U1H92!C;VUP;&%I;G0@86QL96=E9"P@86UO;F<@;W1H M97(@=&AI;F=S+`T*=&AA="!W92!H879E('1H92!R:6=H="!T;R!L:6-E;G-E M(&5X8VQU#(P,3D[$$P.R8C>$$P.U1H92!C;VUP;&%I M;G0@86QS;R!A;&QE9V5D('1H870@4TE'02!F86EL960@=&\-"FYE9V]T:6%T M92!I;B!G;V]D(&9A:71H('1H92!T97)M$$P.W1H92!R:6=H="!T;R!R96-E:79E M)B-X03`[-3`E(&]F(&%L;"!N970@<')O9FET$%%.SPO$%%.SPO2=S(&9E97,-"F%N M9"!E>'!E&EM871E;'D@)#(N-`T*;6EL;&EO;B!P;'5S(&EN=&5R97-T+B!);B!-87D@ M,C`Q,BP@=&AE($-O=7)T(&ES0T*,C`Q,RX@26X@ M'!E8W0@82!R=6QI;F<@9G)O;2!T:&4@:&EG:"!C;W5R="!N M;R!L871E<@T*=&AA;B!T:&4@3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`Q,"P@86QT M:&]U9V@@=&AE(')E;&%T960-"G=A6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE2UB M86-K)B-X,C`Q1#L@8F%S:7,@;W(@8F]T:"X\+W`^#0H\<"!S='EL93TS1"=- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE0T**&]T:&5R('1H86X@ M9'5R:6YG(&%N(&%L;&]W86)L92!B;&%C:V]U="!P97)I;V0I(&]N('=H:6-H M('-A;&5S(&]F#0IA;&P@;V8@=&AE('-E8W5R:71I97,@2`D,"XR(&UI;&QI;VXN/"]P/@T*/'`@$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE2`S,'1H(&1A>2!A9G1E&EM=6T@;V)L:6=A=&EO;B!U;F1E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE$$P.SPO<#X-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#(P,4,[87=A2!O9F9I8V5R65E&EM=6T@;G5M8F5R(&]F#0IS:&%R97,@875T:&]R M:7IE9"!F;W(@:7-S=6%N8V4@=6YD97(@=&AE('!L86X@=&\@-"PV,#`L,#`P M(&%N9`T*861D:6YG(&%N(&5V97)G$$P.R8C M>$$P.T%T(%-E<'1E;6)E$$P.R8C>$$P.U-T;V-K(&]P=&EO;G,F(WA!,#MI6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE3PO:3X\ M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'!I2`R."P@,C`Q-2XF M(WA!,#LF(WA!,#LF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE28C>#(P,3D[3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Q-#-A-V8V,E\S,3(W7S0X9&9?83,R-5\X9C1F.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#(P,4,[3&]A;B!!9W)E M96UE;G0F(W@R,#%$.RD@=VET:"!'96YE2!B96-O;64@<&%R='D@=&\@=&AE(&%G$$P.R!/;B!-87)C:"`S M,"P@,C`Q,BP@=&AE('1E2`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`P M<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>"<^#0HR,#$R/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!415A4+4E.1$5.5#H@,'!X.R!0 M041$24Y'+4Q%1E0Z(#!P>#L@5TE$5$@Z(#$E.R!0041$24Y'+5))1TA4.B`P M<'@[(%!!1$1)3D#L@5TE$5$@Z(#(E.R!0041$24Y'+5))1TA4.B`P M<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>"<^#0HM/"]T9#X- M"CPO='(^#0H\='(@6QE/3-$)U!!1$1) M3D#L@5$585"U) M3D1%3E0Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>"<^#0HF(WA!,#L\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D#L@4$%$ M1$E.1RU43U`Z(#!P>"<^#0HY,#DL,#DV/"]T9#X-"CPO='(^#0H\='(@#L@4$%$1$E.1RU43U`Z(#!P>"<^#0HF M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E#L@5$585"U)3D1%3E0Z(#!P>#L@4$%$1$E. M1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z M(#!P>"<^#0HR,#$T/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,'!X.R!415A4+4E.1$5.5#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@ M4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X)SX-"B8C>$$P M.SPO=&0^#0H\=&0@#L@5$58 M5"U)3D1%3E0Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>"<^#0H\+W1D/@T*/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,'!X.R!4 M15A4+4E.1$5.5#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU2 M24=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X)SX-"CDP.2PP.38\+W1D/@T* M/"]T#L@4$%$1$E. M1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X)SX-"B8C>$$P.SPO=&0^ M#0H\=&0@#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$ M1$E.1RU43U`Z(#!P>"<^#0HR,#$U/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,7!T.R!415A4+4E.1$5.5#H@,'!X.R!0041$24Y'+4Q% M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X M)SX-"B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G M8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>"<^#0HF(WA!,#L\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D#L@ M4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X)SX-"B0\+W1D M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N,C5P="!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,'!X M.R!415A4+4E.1$5.5#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E. M1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X)SX-"C(L-3`P+#`P,#PO M=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE65A$$P M.TEN(&%D9&ET:6]N('=E(&%R90T*;V)L:6=A=&5D('1O('!A>2!A(&9I;F%L M('!A>6UE;G0@9F5E(&]F(#,E(&]F('1H92!T97)M(&QO86X-"F)A;&%N8V4N M(%1H92!F:6YA;"!P87EM96YT(&9E92!W:6QL(&)E(&%C8W)U960@86YD(&5X M<&5N6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!A#0IS96-U2!I M;G1E0T*:6YT97)E2!U2X\+W`^#0H\<"!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2!R97!R97-E;G1A=&EO;G,L('=A2!B92!S=6)J96-T('1O(&QI;6ET871I;VYS(&%G2!T:&4@8V]N=')A8W1I;F<@<&%R=&EE0T*8V]N9FED96YT:6%L(&1I$$P.SPO<#X-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE0T*979E;G0@;V8@9&5F875L="P@1T4@0V%P:71A;"!M M87DL(&%N9"!A="!T:&4@=W)I='1E;B!R97%U97-T(&]F('1H90T*2!D=64@86YD M('!A>6%B;&4L('=I=&AO=70@9&5M86YD(&]R(&YO=&EC92!T;R!U2!E=F5N="!O9B!D969A=6QT(')E;&%T:6YG('1O('1I;65L M>2!P87EM96YT(&]F(&1E8G1S+`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I M=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E XML 15 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Foreign Currency Translation

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost which approximates market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.

Revolving Line of Credit and Term Loan

Significant Customers and Accounts Receivable

Revenue Recognition

Share-Based Compensation

Share-based compensation expense for the three months ended September 30, 2012 and 2011 was:

	2012		2011

Research and development	$	107,199	$	208,488
General and administrative		332,006		417,603
Total share-based compensation expense	$	439,205	$	626,091

Share-based compensation expense for the nine months ended September 30, 2012 and 2011 was:

	2012		2011

Research and development	$	351,342	$	666,919
General and administrative		1,148,568		1,214,497
Total share-based compensation expense	$	1,499,910	$	1,881,416

Income Taxes

Basic and Diluted Net Loss Per Share

Basic loss per share is computed by dividing consolidated net loss by the weighted average number of shares of common stock outstanding during the quarter, excluding unvested restricted stock.

Recent Accounting Pronouncements

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

XML 16 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 14,726,328	$ 11,236,771
Accounts receivable (billed)	1,606,241	4,424,442
Unbilled accounts receivable	3,682,311	3,021,208
Prepaid expenses and other current assets	363,742	830,585
Restricted cash		100,000
Total current assets	20,378,622	19,613,006
Property and equipment, net	553,081	788,666
Other long term assets and deferred costs	130,709	53,384
Goodwill	2,348,453	2,348,453
Total assets	23,410,865	22,803,509
Current liabilities:
Accounts payable	1,846,614	1,445,700
Accrued expenses and other liabilities	3,233,804	3,169,642
Current portion of long term debt	681,822
Short term debt	1,208,370
Total current liabilities	6,970,610	4,615,342
Other long term liabilities	579,707	449,709
Long term debt, less current portion	1,764,264
Derivative instruments	1,545,534	1,886,652
Total liabilities	10,860,115	6,951,703
Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,345,984 and 48,236,172 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively	4,835	4,824
Additional paid-in-capital	210,101,716	208,525,917
Accumulated other comprehensive (loss) income	(215,977)	1,010,522
Accumulated deficit	(197,339,824)	(193,689,457)
Total stockholders' equity	12,550,750	15,851,806
Total liabilities and stockholders' equity	$ 23,410,865	$ 22,803,509

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
Condensed Consolidated Statements of Cash Flows (USD $)	Sep. 30, 2012	Sep. 30, 2011
Operating activities
Net loss	$ (3,650,367)	$ (4,546,766)
Adjustments to reconcile net loss to net cash used in operating activities:
Realization of cumulative translation adjustment	(1,227,656)
Bad debt recovery		(8,168)
Change in fair value of derivative instruments	(341,118)	(6,075,555)
Depreciation and amortization expense	234,811	348,813
Gain of the disposal of property and equipment	(66,626)
Share-based compensation expense	1,499,910	1,881,416
Deferred income taxes	188,610
Non-cash interest expense	81,252
Changes in operating assets and liabilities:
Accounts receivable	2,818,201	1,080,032
Unbilled accounts receivable	(661,103)	1,357,711
Prepaid expenses and other current assets	557,683	1,439,312
Accounts payable	400,764	(2,684,507)
Accrued expenses and other liabilities	(12,225)	204,291
Net cash used in operating activities	(177,864)	(7,003,421)
Investing activities
Purchases of property and equipment		(71,439)
Proceeds from the sale of property and equipment	67,400
Net cash provided by (used in) investing activities	67,400	(71,439)
Financing activities
Proceeds from issuance of long term debt and warrants	2,500,000
Net proceeds from (repayment of) revolving credit agreement	1,208,370
Deferred financing costs	(216,460)
Change in restricted cash requirements	100,000
Proceeds from issuance of common stock and warrants	38,984	5,814,639
Other	(32,960)	(64,362)
Net cash provided by financing activities	3,597,934	5,750,277
Effects of exchange rates on cash	2,087	(54,668)
Increase (decrease) in cash and cash equivalents	3,489,557	(1,379,251)
Cash and cash equivalents, at beginning of period	11,236,771	11,785,327
Cash and cash equivalents, at end of period	14,726,328	10,406,076
Supplemental disclosure of cash flow information
Cash paid for interest	145,658	40,540
Noncash financing activity
Value of warrants issued to lender in connection with loan	$ 69,876

XML 18 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail)			12 Months Ended
Stockholders' Equity - Additional Information (Detail)	Sep. 30, 2012	Mar. 30, 2012	Dec. 31, 2008 2007 Long Term Incentive Plan	Sep. 30, 2012 2007 Long Term Incentive Plan	Aug. 03, 2007 2007 Long Term Incentive Plan	Sep. 30, 2012 Expiration 2015	Sep. 30, 2012 Expiration 2017
Stockholders Equity [Line Items]
Common stock reserved			4,600,000		3,500,000
Options award term			10 years
Shares approved for issuance				8,200,000
Shares available to be issued				1,600,000
Warrants issued to purchase shares of common stock	46,584	46,584				2,572,775	100,778
Warrant exercise price	1.61	1.61				2.50	3.97
Warrant expiration date	Mar. 30, 2022	Mar. 30, 2022				Jan. 28, 2015	Mar. 30, 2017

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References+ Details

XML 19 R24.htm IDEA: XBRL DOCUMENT

Fully Amortized Term Loan (Detail) (USD $)	Sep. 30, 2012
Principal Payments
2012
2013	909,096
2014	909,096
2015	681,808
Senior secured debt facility	$ 2,500,000

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References+ Details

XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 21 R7.htm IDEA: XBRL DOCUMENT

Organization and Business

9 Months Ended

Sep. 30, 2012

Organization and Business

Note 1 - Organization and Business

Historically, we have performed under government contracts and grants and raised equity, equity-linked and debt capital from investors and lenders to sustain our operations.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

XML 22 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	48,345,984	48,236,172
Common stock, shares outstanding	48,345,984	48,236,172

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References+ Details

XML 23 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 Segment	Sep. 30, 2011	Dec. 31, 2011
Significant Accounting Policies [Line Items]
Number of operating segment			1
Net Realized Gains (Losses)	$ 1,227,656		$ 1,227,656
Deferred revenue	46,000		46,000		500,000
Cost reimbursed to offset research and development expenses	100,000	100,000	1,100,000	400,000
Share-based compensation forfeitures rate	12.00%	12.00%
Stock options granted	0	256,639	200,948	560,639
Restricted stock granted	0	50,000	0	50,000
Unrecognized share-based compensation expense related to unvested awards	2,500,000		2,500,000
Provision for income taxes	$ 22,072		$ 188,610
Anti-dilutive securities excluded from computation of earnings per share	11,500,000			10,900,000
Maximum
Significant Accounting Policies [Line Items]
Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period	1 year 11 months 9 days
Liquidity \| Maximum
Significant Accounting Policies [Line Items]
Cash liquidity maturity period			3 months

XML 24 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012	Nov. 01, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Trading Symbol	PIP
Entity Registrant Name	PHARMATHENE, INC
Entity Central Index Key	0001326190
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		48,365,984

XML 25 R18.htm IDEA: XBRL DOCUMENT

Share-based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
Share-based Compensation Expense (Detail) (USD $)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 439,205	$ 626,091	$ 1,499,910	$ 1,881,416
Research and Development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	107,199	208,488	351,342	666,919
General and Administrative Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 332,006	$ 417,603	$ 1,148,568	$ 1,214,497

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References+ Details

XML 26 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
Condensed Consolidated Statements of Operations (USD $)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue	$ 6,696,126	$ 5,260,057	$ 19,162,176	$ 18,026,619
Operating expenses:
Research and development	5,138,622	4,884,231	14,762,634	16,688,703
General and administrative	3,275,428	3,283,246	9,004,008	11,632,272
Depreciation and amortization	72,453	114,494	234,811	348,813
Total operating expenses	8,486,503	8,281,971	24,001,453	28,669,788
Loss from operations	(1,790,377)	(3,021,914)	(4,839,277)	(10,643,169)
Other income (expense):
Interest income	5,727	3,961	13,534	10,496
Interest expense	(112,529)	(9,932)	(226,910)	(40,540)
Realization of cumulative translation adjustment	1,227,656		1,227,656
Change in fair value of derivative instruments	508,971	2,898,869	341,118	6,075,555
Other income (expense)	(31,312)	95,520	22,122	50,892
Total other income (expense)	1,598,513	2,988,418	1,377,520	6,096,403
Net loss before provision for income taxes	(191,864)	(33,496)	(3,461,757)	(4,546,766)
Provision for income taxes	(22,072)		(188,610)
Net loss	$ (213,936)	$ (33,496)	$ (3,650,367)	$ (4,546,766)
Basic and diluted net loss per share	$ 0.00	$ 0.00	$ (0.08)	$ (0.10)
Weighted average shares used in calculation of basic and diluted net loss per share	48,345,984	48,194,035	48,314,058	47,041,027

XML 27 R12.htm IDEA: XBRL DOCUMENT

Financing Transactions

9 Months Ended

Sep. 30, 2012

Financing Transactions

Note 6 – Financing Transactions

		Principal
Year		Payments
	2012	$	-
	2013		909,096
	2014		909,096
	2015		681,808
		$	2,500,000

XML 28 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2012

Stockholders' Equity

Note 5 - Stockholders’ Equity

Long-Term Incentive Plan

Warrants Classified as Equity

Also outstanding are warrants to purchase an aggregate of 100,778 shares of common stock at $3.97 per share, which will expire on March 30, 2017.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

XML 29 R23.htm IDEA: XBRL DOCUMENT

Financing Transactions - Additional Information (Detail) (USD $)	9 Months Ended			1 Months Ended		9 Months Ended
	Sep. 30, 2012	Mar. 30, 2012	Dec. 31, 2011	Jun. 30, 2011 PharmAthene	Sep. 30, 2012 Percentage Over Libor	Sep. 30, 2012 Year One	Sep. 30, 2012 Year Two	Sep. 30, 2012 Year Three	Sep. 30, 2012 There After	Sep. 30, 2012 Term Loan	Mar. 30, 2012 Credit Facilities Term Loan	Sep. 30, 2012 Senior Secured Credit Facility Term Loans	Mar. 30, 2012 Senior Secured Credit Facility Term Loans Revolving Line Of Credit
Line of Credit Facility [Line Items]
Senior secured debt facility	$ 2,500,000										$ 2,500,000
Line of credit facility, maximum borrowing capacity													5,000,000
Line of Credit Facility, Amount Outstanding													1,200,000
Percentage of withdrawal from revolving loan qualified billed												85.00%
Percentage of withdrawal from revolving loan qualified unbilled												80.00%
Line of credit facility, Remaining borrowing capacity												1,300,000
Fixed interest rate on term loan	10.14%
Variable interest rate	1.50%
Fixed portion of the variable rate					5.00%
Interest rate on revolving line of credit	6.50%
Term loan and line of credit, maturity date	2015-09
Term loan , payment terms	Payments on the term loan are interest-only for the first 10 months, which may be extended to 12 months if certain conditions described in the Loan Agreement are met. Subsequently, the term loan will fully amortize over its remaining term.
Percentage of prepayment premium						3.00%	3.00%	2.00%	2.00%
Percentage of final payment premium										3.00%
Warrants issued to purchase shares of common stock	46,584	46,584		371,423
Common stock at an exercise price	1.61	1.61		3.50
Fair value attributable to the warrant	69,876
Warrant expiration date	Mar. 30, 2022	Mar. 30, 2022
Debt financing costs	216,000
Common Stock Share issued	48,345,984		48,236,172	1,857,143
Common Stock issued price				$ 3.50
Gross proceeds from issuance of stock				6,500,000
Net Proceeds from issuance of stock				$ 5,800,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Changes in Fair Value of Our Level 3 Liabilities (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unrealized (Gains) Losses	$ 508,971	$ 2,898,869	$ 341,118	$ 6,075,555
Fair Value, Inputs, Level 3 \| Warrants
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Beginning Balance			1,886,652	8,362,995
New Liabilities in 2011				668,640
Unrealized (Gains) Losses			(341,118)	(6,075,555)
Ending Balance	$ 1,545,534	$ 2,956,080	$ 1,545,534	$ 2,956,080

- Definition

Derivative instrument obligations meeting the definition of a liability which the Company is a party to as of the balance sheet date.

+ References+ Details

XML 31 R15.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2012

Summary of Changes in Fair Value of Level 3 Liabilities

The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2012:

Description	Balance as of December 31, 2011		Unrealized (Gains)			Balance as of September 30, 2012

Derivative liabilities related to warrants	$	1,886,652	$	(341,118	)	$	1,545,534

The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the nine months ended September 30, 2011:

Description	Balance as of December 31, 2010		New Liabilities in 2011		Unrealized (Gains)			Balance as of September 30, 2011

Derivative liabilities related to warrants	$	8,362,995	$	668,640	$	(6,075,555	)	$	2,956,080

XML 32 R13.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2012

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Foreign Currency Translation

Foreign Currency Translation

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost which approximates market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.

Revolving Line of Credit and Term Loan

Revolving Line of Credit and Term Loan

Significant Customers and Accounts Receivable

Significant Customers and Accounts Receivable

Revenue Recognition

Revenue Recognition

Share-Based Compensation

Share-Based Compensation

Share-based compensation expense for the three months ended September 30, 2012 and 2011 was:

	2012		2011

Research and development	$	107,199	$	208,488
General and administrative		332,006		417,603
Total share-based compensation expense	$	439,205	$	626,091

Share-based compensation expense for the nine months ended September 30, 2012 and 2011 was:

	2012		2011

Research and development	$	351,342	$	666,919
General and administrative		1,148,568		1,214,497
Total share-based compensation expense	$	1,499,910	$	1,881,416

Income Taxes

Income Taxes

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share

Basic loss per share is computed by dividing consolidated net loss by the weighted average number of shares of common stock outstanding during the quarter, excluding unvested restricted stock.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 33 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2012

Share-based Compensation Expense

Share-based compensation expense for the three months ended September 30, 2012 and 2011 was:

	2012		2011

Research and development	$	107,199	$	208,488
General and administrative		332,006		417,603
Total share-based compensation expense	$	439,205	$	626,091

Share-based compensation expense for the nine months ended September 30, 2012 and 2011 was:

	2012		2011

Research and development	$	351,342	$	666,919
General and administrative		1,148,568		1,214,497
Total share-based compensation expense	$	1,499,910	$	1,881,416

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References+ Details

XML 34 R16.htm IDEA: XBRL DOCUMENT

Financing Transactions (Tables)

9 Months Ended

Sep. 30, 2012

Fully Amortized Term Loan

Principal payments on the term loan are scheduled as follows:

		Principal
Year		Payments
	2012	$	-
	2013		909,096
	2014		909,096
	2015		681,808
		$	2,500,000

- Definition

Tabular disclosure of debt extinguished which may include, amount of gain (loss), the income tax effect and the per share amount of the aggregate gain (loss), net of the related income tax.

+ References+ Details

XML 35 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) (USD $) In Millions, unless otherwise specified				1 Months Ended
	Sep. 30, 2012	Mar. 30, 2012	Sep. 30, 2012 Expiration 2015	Sep. 30, 2012 Initial Maximum Maintenance Failure Obligation	Sep. 30, 2012 Every 30 days until failure is cured	Sep. 30, 2011 PharmAthene	Sep. 30, 2011 PharmAthene Maximum
Commitments and Contingencies [Line Items]
SIGA breach of contractual obligation awarded, percentage of net profits						50.00%
SIGA breach of contractual obligation award period following initial commercial sale							10 years
SIGA net profits from sales before distribution for breach of contract						$ 40
Awarded 1/3 reasonable attorney's fees and expert witness fees, plus interest.						2.4
Warrant expiration date	Mar. 30, 2022	Mar. 30, 2022	Jan. 28, 2015
Percentage of aggregate principal amount of convertible Notes				1.00%	1.00%
Aggregate principal amount of obligation				$ 0.2	$ 0.2

XML 36 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net loss	$ (213,936)	$ (33,496)	$ (3,650,367)	$ (4,546,766)
Other comprehensive loss:
Realization of cumulative translation adjustment	(1,227,656)		(1,227,656)
Foreign currency translation adjustment	7,690	(79,585)	1,157	(88,877)
Comprehensive loss	$ (1,433,902)	$ (113,081)	$ (4,876,866)	$ (4,635,643)

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Net of tax and reclassification adjustments of the change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity. Also includes the following: gain (loss) on foreign currency forward exchange contracts; foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; and gain (loss) on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain (loss) that has been designated and qualified as a hedging instrument for hedging of the foreign currency exposure of a net investment in a foreign operation.

+ References+ Details

- Definition

Before tax amount of the income statement impact of the reclassification adjustment for translation gain (loss) realized upon the sale or complete or substantially complete liquidation of an investment in a foreign entity. Also includes reclassification adjustments on foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 52

-Paragraph 14, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 45

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 18, 19

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e689-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 24

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 37 R10.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies

Note 4 - Commitments and Contingencies

SIGA Litigation

In December 2006, we filed a complaint against SIGA Technologies, Inc. (“SIGA”) in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively development and marketing rights for SIGA’s drug candidate, ST-246^® (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement.

We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal, and that the Delaware Supreme Court will not overturn the trial court’s decision awarding us a 10 year 50% net profit of the sales of ST-246^®and related products (once SIGA retains the first $40 million in net profit). We have not yet recorded any amount due from SIGA in relation to this case.

Government Contracting

Registration Rights Agreements

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 53 156 1 false 24 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.pharmathene.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.pharmathene.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.pharmathene.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.pharmathene.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations false false R5.htm 106 - Statement - Condensed Consolidated Statements Of Comprehensive Loss Sheet http://www.pharmathene.com/taxonomy/role/StatementOfOtherComprehensiveIncome Condensed Consolidated Statements Of Comprehensive Loss false false R6.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.pharmathene.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows false false R7.htm 108 - Disclosure - Organization and Business Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Organization and Business false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies false false R9.htm 110 - Disclosure - Fair Value Measurements Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements false false R10.htm 111 - Disclosure - Commitments and Contingencies Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R11.htm 112 - Disclosure - Stockholders' Equity Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity false false R12.htm 113 - Disclosure - Financing Transactions Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsDebtAndEquityTransactionDisclosureTextBlock Financing Transactions false false R13.htm 114 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) false false R14.htm 115 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) false false R15.htm 116 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) false false R16.htm 117 - Disclosure - Financing Transactions (Tables) Sheet http://www.pharmathene.com/taxonomy/role/NotesToFinancialStatementsDebtAndEquityTransactionDisclosureTextBlockTables Financing Transactions (Tables) false false R17.htm 118 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.pharmathene.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) false false R18.htm 119 - Disclosure - Share-based Compensation Expense (Detail) Sheet http://www.pharmathene.com/taxonomy/role/DisclosureSharebasedCompensationExpense Share-based Compensation Expense (Detail) false false R19.htm 120 - Disclosure - Summary of Changes in Fair Value of Our Level 3 Liabilities (Detail) Sheet http://www.pharmathene.com/taxonomy/role/DisclosureSummaryOfChangesInFairValueOfOurLevel3Liabilities Summary of Changes in Fair Value of Our Level 3 Liabilities (Detail) false false R20.htm 121 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.pharmathene.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Detail) false false R21.htm 122 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.pharmathene.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false R22.htm 123 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.pharmathene.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) false false R23.htm 124 - Disclosure - Financing Transactions - Additional Information (Detail) Sheet http://www.pharmathene.com/taxonomy/role/DisclosureFinancingTransactionsAdditionalInformation Financing Transactions - Additional Information (Detail) false false R24.htm 125 - Disclosure - Fully Amortized Term Loan (Detail) Sheet http://www.pharmathene.com/taxonomy/role/DisclosureFullyAmortizedTermLoan Fully Amortized Term Loan (Detail) false false All Reports Book All Reports Element us-gaap_LongTermDebt had a mix of decimals attribute values: -5 0. Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Condensed Consolidated Statements of Operations Process Flow-Through: 106 - Statement - Condensed Consolidated Statements Of Comprehensive Loss Process Flow-Through: 107 - Statement - Condensed Consolidated Statements of Cash Flows pip-20120930.xml pip-20120930.xsd pip-20120930_cal.xml pip-20120930_def.xml pip-20120930_lab.xml pip-20120930_pre.xml true true ZIP 39 0001144204-12-059795-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-12-059795-xbrl.zip M4$L#!!0````(`*6*9D&.EHDF<7<``$YN`P`0`!P`<&EP+3(P,3(P.3,P+GAM M;%54"0`#5HV94%:-F5!U>`L``00E#@``!#D!``#<7>MSVT:2_YZJ_`\\7=76 M754@S0LS`R7V%IY>U\66(RO9['U10>1(PBT(Z`!0EO:OOQZ`#Q`$19`B*/J2 MJC@F'NQ?3[^G>_C+7Y_&\>!197F4)N].\"DZ&:ADF(ZBY.[=R20WPGP812># MO`B341BGB7IW\JSRD[^^__&'7_[-,`:^]\&^'%PD<92HP4?CDRJRZ&GPYU#% M*@L+^"C1CP[5P$N'D[%*BI\&-V&N1H,T&?SI7/XZ(*=X,+@OBH?SL[-OW[Z= MJM%=F!EI^<+383H^&QC&[,O^J.@\'PSX*4'PX.+293I)1N<#7OO(S518P.V# M$1!R/B`($P-C`_$K+,X)/Z?XO^MWIP_/671W7PS^8_B?<#,R#7@"+P'\">`, M3P=V'`\N]:WYX%+E*GM4H]/IFYYNLG@`+$WR=RV/P(66VZ/D4>5%^Q/5M9:'DC1))N-V!HR*[*QX?E!G<),!=ZDL&LZ?V_S0 M\@,/T M^DQYI>VA(EN[_-897*V+X:BQ(-/[^%EU<>G6HO56L[JU.`%U&`Q*A8C/\U)L M+M7MH)3.^TD1%<]N.AZGR=.F9L:>`';@EO^DLF&4JR]@.]3\XOY8-#7HU[]_]:X? M5'9=OK;.,;([O_#)>WS*\09V;4!8\0C4]GQZQ7]ZB++257LZ9-B1`;MB(B?O M"2)@-*E!T2]G:^E:7MI?(1RXN(408Q0503B,8E`C>ZP]W2L,0`4%5!6;@CR9 M`OZ4\#?,I?(K&D[&39EGZ#9YPPP>X4CR_"8OX[BP"#2@M MZ286K3@[^FV?/`)RMQ_**R M4CI[YLNJ9+V",7C&F,VP&@(3YO=V,M)_^/\[B1[#6`&K[,(%ICV#=_HCC"?; M<\):'WG6`:_$9A;'KFD!0C?`$*`YR#6D)P&P=$5`P0%9IJEC,W(-K'V/$4,< M"5X3ARYH.FC,[I':%#M(@12,/IFP:&CK-,6U7.*B`'P,L4P#0-J&1+9IR`!Q MSY%!(`71KI:4KE9"UFIMBKS7AF2>RH!/1?2H@B@!WQ.%L:[,965)+O\U"F]T MU`(&*`BCK.2?%^7#.,TG.VB(-0U,P!%#*(*$I4,TR&T9T7^CG.T@,]37_C:P M#&)[-BB)Y.":"3-8QC6T=BP3J"B8#\#=<@;P:R#+PFQI_39'B<^@A0 M,86$Q5K@;*5[?:KX*2RF\>(EZ/%S:<0N;B$*`,OVH$W;/U287=UG:OMBRJ[8 MJ4\LS'UD,"DA=3()-AP);LTG-I&>$($DN!)LL,\6@G]Y>]K8'=LR?[[>IUFA M7S)/N;2E]S@>MS?=I#-3G.JK;H334\_+1LCQF0@A3STU6Z5Z_?!"< M#V')PCOEP,+`4@?1DP*S5BB(%HO+78J?3

H&'`M^%V#.8%\?1J0[;VA5U,Y@U"MKZ\!_PW_`F5KTR@^[.#*R9 M@;#9HKB=\2SSPQ\_Q.FS4E]5]@CI6YFU.7IK'+R;#LO*PC-X`[VOJ4;VMS`; MY5=IY?WFU]TT+SZGQ3\4`!ZF=TGTKZTK1IWUIJ58B+`G@$D&8104!]3'L%W? M-K#EF*9IV?!I,*^(K!0+>V-`(Q@:#B?C20S\KZ)<_72F[N$%D`Y\3(;I6/V: MYGF09BJZ2ZKH=_A\!5E5'I=?88_^9Y(7VM9^5L7%[57X='26"535(-B$O]=B MI_WCWE"PM"<%Z,1>1+!3`MTUMN2ZB(":5?L7R%_&Z42Z)N<"HBP<:C%3D$N" M:A]=?*&+)1QQPFIE@K7$;UC+U^QB];J8LMS"9M46=A?RFWM3\US_V):/Z/@" MZ3VLNINI$;QBUW3FEW\)G_6"'FGQ`3.]0\`XKX<1[:2WI'(U\,>;SV%(Z""& M$$@T$KI6ZI=17JH"(G8U\L,LT:%_S6A[ZC8:1D>'ED(D!`Y>4&I)4EO3S4@: MXEMFN\>&#N.RGJ35L*:#%:W+]/^>W"R9UGQA6X\-%-,%0$DHKOF%%\A?:S#M M9/0=9&FT;04WH=CCMGS_%12^UD`ARR+"4-:>J/#\CW3)*YPL7U=-11`_(*6ZO9K:.]_>ZM_=P^.D0G"*9&O MV]K:2]]`SU&;Z!2UO7VCP(YLZ%[6[[GC-^%NZUI,=:[`L M]::/0!RC5M?5&BC/;.2E>E1)?V9NM?IC4>*9#I$&<2D(?>`BP[&D93B>]#T" M&#SF7D\EOM6J3RE>:\Z.TVRSTI29K6;L9?/\)T9EGW!`):\:Y#]$JC%*23/6];[,4J`2^XQ!+)5U@E#:TM$3I2BR1T M7L3P!BW^F_1]<_-=]P!ECRW^ MBVZ3%*@LGK_$<`]$MSJR?9C6E8]-(L`#@S0@66/`2^2O-W1'JM"85T:LKL\M M9*_'=<3*K)N1!6>$K]FQ;.JP[J*TA\,,RKMF2L.*IN[.,ZM!"E186> ML!,8\6T]A(D=[CK,-I!D%G@(\!62$L^@E/B4>9S[@3.O$Q*0>7#VW^\,T2:6 M;9_&=.>?WL?;XPS1'B.E)CN:T9\M*0H$S<=5&G$MDH#-IJY-/`-Z4,4R6P$_X<]"(A18-KV>BK9^[4]IM.<^+ M6[Y4E;^R77$N9U5_V6,8Q3H>"-+L@_[.77G1><1Y-2#O-.$,K*+39K+E@+PO M1O3#[E=V(QZ(SR"2LGGFPMXY\-(D%+PDRK\^9"H<722SMN7=VZ^O34X8-9_T M!)XIM@K6NS1CS[J)T2DRZT%E)T2'/9)`8D+QH8XD(/-]MGT>2=!#7P6JN-+7 MV'`U0*Y[*["0)B7B5;T5!\S5T$Q:#C\V.W/^DG("3/P^QF;QSG+4JE6=\).,S8;._8MAB;W?LL:>_@REE2<#[$M'!]'N(-9DE[QZI;CRFMMQ-U M&"5]=1-G[[!*`PZJAR6JM0!M:MM\^TF?_AE3IK@8F4O[\=_/I,\J@_;79DB. M9M*G?S&`6(\1QNIG.G2<]('0KX#,'62EET-A^D8^7^'ZY,%6B'H;?.I9MLO! M)T(Y%N0%T>YA\*E_AUV>=6%B@6A]\Z_/N:?^(RP]]\28*>J2>M"YI_XA6MH* M6:L'6;S%W%/_)K>:>Z)<6K"J!YY[ZG\M]7X)D0BRQ=IJ]COWU#LH/?>$B#YQ MX^WGGOJ73]JV@MO-/7V7$4%9ZP&_*`1^5:UG3^=O]AL$B$Y!0-LG^,/_6M;.?Y`VJ>X#C+^\"+$ MO8X_D/V,/QQUE5,?265QW7K'FW[_``W^_8NK;F>7DG.3M)6U.T2J>VQ>[QTM M&%"AP?)ZR7I3\WJ?7=#]^PS=!8VYQ;7/V*$+^@TV>G`O&SV=FO+F`Q[K->*U M&ST7#_IWGR#"6M0=N_.'"/JZDX4#Y/F6ZWN&QYGNP&;,L*6'#-.R*>6NJZ0O8X//,Q7FRE/5GQ^31D)_0*3=-D-+_3`(E\RLGTZR M$4A+20+L8[K,H*F.'=_R8J*#+FF11EUB+81FR#)/#;>,*0\%L#QU'Q'.L56/ M2Y;)7HG#FGL"V^]QO!J?P[!)/.P:@OG,8+9+#0?,H"',@(,X,X8]"_!!C&DP M3DW>^%F!=0A6//90J5$>9.EXVARC]SY*$9B:M^3.'H*UV]*E'4II=:G7`.Q\ MZ<3FK4!UZ:@Z/N"R=$V8U8\`;J=]DV&>E7EVVL,YF'&FV@]14XCZR3R=P#2. MDIS6'F?YAVZ`&D+HXT7QI-BFA-$%>=>?->AJK"$#,?0YH[6#(5^&TXSYQF1?2O0PMX1["Z(LG@`5H/O=;2OPP4C)TN9X$A>(Q&NE?Y]UP? MMSJ/6H[9HI6++!"B\-(%].Z(.G'B8WE2Z)%S0B>DAOZ]'&LC'UKP-,V>OD&[ M@LH=SLZ:/3ZYE^7/>-2/\.53SW=56H/(7'-U-IT]OA66F^/-1:Z.YPN M=7DPCU$Z:KJ+XV-$M7-&A47,C17Z=DR-ICJ5@(&(M;$^*&UHG*"8O13Q=T'7-S7?9GSP8 M/TA9B9#@&5_DQZ:9TFW;OB!-K,*-/36_'2HQU`&SE%(T3UK=._05X9J]$=(O MG6A'R00<\S1229/<4;?P7=5]\+C*/T5)FD7%\\ROP1#<$E*V5)5G='?P6WH'8[ES MH[1R\U?MM"%S,)^FCZ=%C%@OUC2V0]G84(WC=*@W7=MK0X>W!8Y)A"G!72&+ M@_>BU#,L7_B&3SR;8\DLB_)IITJSO-4-2U-F*@.JYQB.;_VI_I%Y9#)47_X% MP!6 M1_H"A#6+877_:1A/P'96GG?\,"E*6;FX;1;.MOUQNRVXM3KRRHD`\;`V_ M09C.M2FLQSP=-]]V'GV^>"BCSG*>/(<,LBPD',I0F+YC.I8>LPP\JK>N;,-V M;61PB7S3LRR7^E/9-SGB]9+0?O$VM@5N;]40\AG0HWO].CT"?9&T%UZ.T(_H M'S4"!>&U8&H;1,W]SQR>NU31^&:2Y3J#[EU]6DRD[[J8(6E8`?*U]KN&90>! MX;IZ@]ZUN:1!M;W+5D:8UI#?;,Z&\"K6@TT?PBC11N0B6?1V'*,9Q-I4"!/^ MJ?=HOXBB/1@Z6FMHK0V'EI90-R^525%>E2?TSYE!Y/`:VYXJG\-NA7+(?/C\HQ44[XNP2-CUGTM@MBM#: M]!$(B\*XU@,[:W+][ABA!VFYY&SJ7M8CJ]"/5'1^E86Z#/'U>7R3;G%."1'L MA=.?$?7`Q[F6P80N"'`"@:Y`(-Q6P!TNB(4\H7^8K(QR3]Y_^?CEE[,58A8T M^DE1'OU[5^Z2)L7G<+S5VNR+5-"_+W^S+S_95W_S/_L_#3Y^=BNZVPAY3(-X2CN'XE!F^R4P7Q(,&#KDNN[UO0:I4 M1><2)4W^!E&L,A=,R5V:;3'>N#_V0A0)L:&*=95`C08E/77^+A&XH-Y+AV6? M>O63YU7P$\!G6]FQ/;`:R/^-5O2N)6D=U=5/@QR>YO+P=;T7_P))JS1?/3_L M3?\Z$EJ6#8W?E@G5=*Q25[';3T;;G3>Y%S*K`R8)N/+R@,FU9#5USU6Z>3O^ MF(S4TW^I-]$^?:B>?BWAV$)UM6O0MB!].E2S$)<]\WP;ZG4(`&\W**Y(7T?; M2RB@&5]$80M//ZMO@,AV'R4_5!S\-O@+`VY._W!4___B#?OIA]NPG M^_+#Q\_G`_TP>GCZ>;#5R_2K;O3_:-;\^(,Y,`9UMOTE'#_\_.]/`-GZ>5#Q M4#]Q=C-[]O_:>]?FMHVL?_"]JO0=4-YDRZDB%%P(D$CF<16O'L_C6%[;^6=G MWTQ!)"AA`@(<@)3,^?1[+MV-!@E2E"Q2E,-Y,;$DH-%]^O3I<_V=GV=//B48 MC+_:L?;X"1@LQG]BYQ036Z<8[U($NP?UT<`\1?IR_+*7^2X]/P.+JM4PYC>1 M@?92F"[U+2W@.^5F&^%LEF>WH)/@X_BB@=0QD#KG9U7R&*_QF7*LWJ_T/%%. M_;+_ZT_&W4T\NC%FG`=1&),LQ]'/SZY1@43TH6QBQ&KH,!T;:9::_UF`33.) M82HT02/C,$"#?SP_PYG*='(C)T3FAC&+M1EB01)F=$R5)M$2V07ZVL3MM!]:]Y)BD-2YO$(R(L?BZ: MSI)L&47%1=UK)6Y?LFR4&T"T#B605[%.NRW4(FINH,#YF3;/<0S$G&<\40/^ M$,,E"`;U6&0<%XMDCFZFBT,>SG3F0,YP#*>`O#>,N0F(18*SA-L`4 M;<"%:[!["RD](M>;H&),91=I1&EVYV=W\?Q&\A;0[RHRKME-"8P(1ZNZGPUD M^&1!V%NPL07LJ'P5IF/W4XZ)63SW,0MI-M(CU.6-2"T\Z@AE]C:>+J9%2P!_H.7V@V?$%E.B#AF$@"?XMNH_PZQX7/I)/=`-T"!YKCBRQ4<*A' M?Y[P2L6:<`,6<^"2>3PBFL/N1B%\80D:50-V`/8"(_'X>Z!(0,=DI)(!@8%N M\FQQ?6-@IX*&$8Y&6PD\ M^CF:S2-:I6LU\!,.[6P>`QH/35^*%3\V_%RD=&X-. M#9S-D*,`H#B"6C>-TZC`661P'#$/&+]%QX,96E2+X$`L,>'W)+;@;Y$`[8?# M@?[B6HI^UD5D^6N>>AU58(9`UYL0KR?%]CA17-L<>!2Y9&^RD12TW/AY16U1 M@0QJ7L#"/RQT%>T[T%U*"_![CD-K^4T6BU/$_.;A"9.1[L`0%"CH!(,9Q"_X>L_ M8#\65$5XR`L#CT(Y&Q([$79A@*=3XQ]AN@AS6%";3K97R[&'4(>?:SM_PP1A M3;"-PWZVLK_&MNUM^@VOW:SN[?E9[8VXV]YB MRU#<6W'9X,??#@P!L5S=:FV3U1I1&W><[W:/.TF1G9]E&K(HTFBGG;)!#VBU MVF*K8)#)VH[\@$U;RH/5$$K`RH&JT-INK4GEG\'JQI^VP2UO\!(\*0+(!@?* MDR9EN(0`TFR[024U_5X`D(^JJ[-*5\?$G$.N;Z>@.??M=FR_Z5OKU8>KLU^M MKR#T",S;N$Y)C?B8)?%H^>0^(V8$)FW:SVW1:OM/M M8X?0H_():6J&Q`;1Z'0(Y4)^?D5D[?.K?Z!=3<6**)$6.2B?O/1)GDV5EVQE M0O2[<3R91(0*-E_.Z)ZAJXY02L`P-\(RSZ7X!=BJF)NS!/AP$K$+F=!,&O2' M\[-;0M04KGUQ$J[(06!E^&&9/4YC@\WN$PW@1=KQ%H_FDT M(7\+)D'=1"$:`DKK&%Y.H[&TNDKJ'<3?L*]/B*-3 M&(304+OI=#_F?+3^RP1`$E.:]_E9A&X=:8B/2`"K[1B3TYNM67;>RPU"ZVC* MMRK:I60?@F`C?L*/@ZT"M*[E'%1?M-=96ZI]';3LTE@;&U=+6`6=@5$D)EQN MXB]UGXHG8E7\C&`!W(G_H1'D^".*W/(Y:<:R,B3 M18Z&.:RF&.7Q%5(F2K([8(8,?W\'RF2CXL?`3\IUJFTF1C%T1F'-5VV-G*C< M"V`9XQH.52IY`?9C08X:]!5E,X3:0,=BU>,YI0)$@^DJ>'0KAX5L`LU"_#-. M/@.E5S$,"J?LWRA=>"`Z\\P[DNJ"BNA-Q*$G.1>I*D+0>'(47*#QF5]9N6^6I508:&FA0?CE_.SU['F!:\L1;B(1C0+SI8[+FD>+7@=.^,5X;?]DQ'-<"=I#<&4N M2$%!RH!$B$G)P"4UU;)D%D<#>(#(^3QZ_), MD>PV9F`4IIAFII%4;C"QZT\T071COD%R5V8TC^!.&NN9\89V?:1Q2 M<=R7IX\O.2'-Y6ZI44X@FC+)=T1==YEH,YG6#7P*4D+!X*(9Q%V_F- MGY%RA1?!N!5,OWHI$1:5Q8AK+$"[:O@(3E0?_.XLSO=P;:HBV0*WI01(( MSGU%LNFBORBU(%`BKS)D:\D450V+531D!M%LWLPFIJ:O\8V(MYR(K)`P41Y$ M34$-N>0"^?=Z$?-S>/TE&,6>4Q1[N^WT99=Y:`3!2TIC0;))V4K(TI(Y9K_7'*08V,)(N53,,5\*^(#T):4D/8-3I M2OI*S\\6A9+Z]ZS:X'AP(3>+2]:7Y%V?AG]&NKCE1^F?4CG<3.T)THNCL*,X M'RVFR$RXH&FX%-=OC,CC<*/`"E'P``$Y((AZO!S?&&?H-D1Y&L,E.F(U.>0[ ML'P*K]5%"D2.V:`1=R*HY+.LH)]E^`M^O>3'03V^,`8\!,4`R@M%( MAI=,=F%TRKNY(>S'`@_,;0;,,:;OLI>"+^85S?*_N$(N+D9F$R_-,YC%`H[S M-.+(7?05)UVCF9+()SUQ@IJ7.M+G9U=A0H>PN$%])-2N##$$S);N!)`9*:L5 M#)B@_`/L2.`K."F1$BZ,/_CS^3@:K\0J?VCZ&%9?%&2"X-7T@W7AJ?!ES2SP M=_#M]4`KO]Z'W>)?V_1K6_J>XT)$\H45MC)W0TW]_$R;NSQ#J.[A$M0/04$)1,+:R27CO"SC1#!PJY3]]6*%A MP=?P;&ZF\89\'!A%:KBE9!>G@^<@W85C]D5$;-/3Q^2YJ;VU0LVP5\=-7QPF MUQ>"1>&.I7#(VB(-;8W"A0>:Y&9";$@5P<^SQD[R=;3DFZFB#)-LDI9>5F26U=V%(NBYA?08PM5D*>+/SF-?J54VG=5%:RV8\AEW=A5!=#:4-( M4'T-5>%/P<,=UV"7:Z`78%%-LD43^- M>.VQ"\!AHH$V0?)8+;^Y"\C@GGL`'";`B\B*CF,[S]`#X#`+Q(*8P/9A1%^' MB3A`#X!O7-].4(\N]P!HM_RV7UG?\_<`.%``'WL`N$Y0">!_2P^`#7B[^XGM M]YM!,[`[CCD<-H=FL^#KC+6,5W0_Y']&H'F3A[E6+_JC]/^25_DFOD;U M-8GA6ZB-EUBG[*R7*=TP]%P@?[%*I:E3Z*M"&YN#F"-:A#;W'6[YG?C_J=MF M'$96(+IZ,P@"O8?"+FTS$'JNN)Q\1"4JGQ`3 MEPLR;&O],!/9(HRE!1]EX>YA'Z@TQ-&M^Q$8<=K!/(*H@95D%^S\`;/X[B8# M\];,[E(1!XS'<9C'')#5:XURZ96"TX_NPIA\57H%DO81O0RI47GHKOJW:@W3 MHMC$DQ6_Z,A*[7T9T0-^.7SLWF)4,U.,N&/*0S* MLJ>*EP@+)E+:B9C]H6)KX*5:>7S)3IZM6WE^INUE^:T9XK#G]9ZITC]OI?*Q4D6TJXL'1 MLEF<"F=W62C1$*DY(T%1G,@B#1?C6*"&[LK/,G4@HALL5/C@G"R`^6.JRBP' MX8TV\"+/J>2E\K"X0.%FK43,9RPNC$D8YYB`!CND;<4L*T12`WNN2<)D"EC; M4+?W),GN-D80-I[?%=_SW%ASXP('%,0`Z#?(8ZJ00?>X1LA[Q$$H8Q?XS,88 M!S%_/-VT3*1:!F-(TL7D!*,@!@;5A-M%ODQ1#73H9Z,1TE,X-":+),%0'=:! M4T%*[6R,GJA&BE,*O,ZETV*29?.4*H#'9<-'WG2:3>GDIH_5T4(>HEJ7)W*^ M@8ROG;IRWV`-V32>T]G2TZ-B*O@>B2*??"%B]4"+ZT4BR(<$I.MEGPNZ&,E MOBJ](J$4,1(]C8NB*D7^P"DE(C.!HT8Z)0I9OSI6@ADS6\:8H3?G?`N,@;[#<6TA%&R0TRM&84T34G54A6EHYSX6B6'7I#[@VBJNQL M>P--2X8$Z5864V'I7D:;668TBJ&1!M7JD9FF%^V@I'^+1KK9`?`9='T<]`E: M!QW(^$?@LU;3VF#[W[.>/??&.Y#+$C&$?=O6(82?MS/>_>M^TLYXKNR,9^GX MMP_IC%?3J_?I[3=W:/?[PW;'[-A@Q"$BHMD=#FRSXWJM;G?@#/O-[I'9;RO( M'JYA&D@J@R'??@/.`DI-EEE$D?&8HYR8?X\W!^HDV)N)A+\(QQJA2D%8&J^I0C">\Y@_J0QE81#`'0,C M3-&[%(YO0\JLR1;2KZ2N4_6MRGJ+`6BUGH=)XY"S3*"OSR\E]9288DM+_ M?!/#]9V/;M#80VH39`$,+;,8XW2V@,]B<@VGJ])':(1M/KW:1ED^+.6VV,]A31TLM&+5DXQHD^Z&6"$86 MI_@6O[S?+E/\><9X$/1S MF(!R]#^O,$4MRC59.<_EA__/X-.7=[W.>[/S_MU;6.<\F^G/C>5S'SO]_KL/ M;\WNY9.2VL2-[/Q!XPE_E=+K#50 M3PE="E2E\"0L3L+B.Q46;E58_+ZN]Y9'J%C,T#1@ARH,-!-B\ZR2(L6 MB*J%+,FNI#ZR>#L30: MCU-0]/'P*BS1Z^I7J).O2I@:WJ0"306,6\C!\W!,]J\LFTF691T*-JQEM['+A$;U].(R(#T#@26$3C:I!RFWNDPA6P MT17W""7C4^$D>8`PLPC(BP&-'4]0Y?BL>!K*E/`5'B(LRYLJ+XU%%(52MXEO M")-@DUN(V"+-4-JGYL/I($_'-B?.R_6"D!NHK-<6VIFP1:FPHUA,IQC\QCQO M36MU53%%J7I=)>'H3\.&65'XE%[I4V!YIG*==E/B8(Q7-4A! M]2]OGX50!L5BA(*.M`2RI`BNSKE9E.90?B[40"VS"44!%'QD;C5&5:VR=FNE9;'HMOI_>_;3Y>_?^CCD;S\ M]`LJ"7,XC`\X+^)\>]Z/NQ-.RH0'O*+3,HDF\](T?.0@A`U>CN(<>BXG&OR5 M:;#S@%X#_OO3@\[FZ@3%[26[857TBQ)@X/Q,(G/6K/W1Q*%O M__"03:$W[$:[[3=\;UVFW?.IK9,\]"I>NTV[8=OMAWZI[NHZ_`YX3:_ANR%/"G"3"D MG*+@)IH:?1`XTJ(EX5.TTN,E#C!7=77ORS-8_0/U@#C92"_#1EK?IOW;2$WK MI!N?[(,3#4XT>+EV8E60:JAT1V0SMANN[S2"P'O1-J/OMQM^TWK1:WCM-ZP6 M&(_>@[?B&"Q?X"$/%M!^RCW8S?+=GRFVHIIO^%#=*BJZ^HN,TG7F]P!2C>M= M8PS9/)WE<8'6-;6':@"&1]46Q&7EZA5\VJDF#&]JD6RVZI8 MS\\JR3Q`Q*XJG]Y.\E-FGM$&9E M"(E_>E]V/V4YTKYP744^)O;#`M,$YGD))_$JE`L!$W'&YIO ME#X>;@`JJSP64]&34W?`TEQK)LFYDIQQ@REJNC M[?:OJL^AP/'45XTI*OUM!N#S%G.1\@0`Y5295;3(E&*_035LF;64UUP<)3RC#5.Y40;"?O M0V4^E-VV8>`2?[*N2ETK1,4QRKKPC=7D/U@7K@*<6RA3W[@FBJA^%VJ6E!#" M>7OJ\&Z8:MGSX?P,_8TF^1ME_X>:-`26K#&+I[+3C"J8K4P"B_,$9,)(B1!B M9=7+"TC\@WWA:&V^Z*QB#TE5O"]]EW3&!LK5^6LWD6H&YVHF^[-O<2<>=*2;K_??0@$,[5J8V7[UQW&;;MO4V]!OG7UWHAVB. M&$P?!6Y`=PGWV?A=JGJO'3,H&U7DVJU66P=2W'U!.Q'B72KZN!XS(1Q[K4!] M]^6LUJ=+/##&\WN'/E#,B3TZKD>8+==S*QB:]7/?#$7P*9JI+GSO$;?AZYGFU8P&)I-/^B:[<'0-H,6L/&P[_9M*V`8!NW.WCCMG9!# M28-;A>0XOC/KPE4%N@K\T+H7#+)V255BO&5;#%6<2M_&HP5"=E^]"2P+KFH- M1N2>1:R@8(YNHO$"$6<&7Y%)%G%Q@UQR.>E'5_.GAXX-/`(UD$*%!_LZN?\@7*\`U%,,?^NT;LGRS&J2Y]X MNG7]$]','I06\DP\\!@B[9$=A`0\@ECNU@.QI=KZQV<\IYNGY3]L6K6%$$]9 MD[X'*GU[1?K#)O6@F.BW"%8QO?;#IF<>,DGK!=YIWS87."#NB[CC#S.3`YV$ M!TPIL(*&%?C/=)$IEB9Z5VJ(=>H_WLMN'/*=^VVZTK?7RM[_R379(^A_1)?)H M@]ZY<#S@Y'&VN$JB`]%MFWVTRR2?:[^=AF=9##BX MERI_D&.X_!R\'A6_Q2E"<"]E]@9\L#H*A@CGR]\(.>^=UK[NZ&)]=&#=IF^W M=+(?D"2;(H=E+8U6/=J9J_RX+WA*GCR4V+7A[-IPD%O-=A-[RPV03X6=WRAQ!.0UJD\_D77'Y^`M%[`)IV`M%Y\8>R)!B<:/$]0_02D]8RK.`%I MG8"T3D!:)TOA.U!"3T!:)R"M(V;/$Y#6B]>-3S0XT>!$@R.U$ZN"]`2DM;]5 MG("TGGOV!P?2VI;(\+!87#6B]RDJ(FS#@RW'T9+,J.'\T=8^.J_>V,V6[_AZ MT?[6->P$T?`R:M6#5V]<+V@%[OU8%?=6IV.RRSL%ZB(J?+Y$^?0;%EY=5:_G M#`=>*S#M?K]K-@.G:W:=[M!T^\.^-1ST++\_A%5YK]Y\W%IA&8N(M9FER5*Y M-HQ)G!=S,/6%?T."PR!\U!7"7G^87Q>7%5R!YCC96IWL5)8DP6B.EDA(R5$AG9+?;M MG*,+=0I?)7\/O'&AHZQLVH>Z+(@OX=>/8!R-ED\>66_UG=%T3#F$+SI]K MFYV!/S2;+>`W8,M>V^\=662=!XOQGTP=@S(=2%K&RG7P(G']_D`P*$XZXHZR MO+XYKD_THU<-)BN=RI;<@"TC@N')HT MFL349*\*QZ<.Y726Y>B6',>3280Y/?#'JVA^%T7".2E;J.FM":D3'PY/R&9K M'0BKF(%#6BJ-"#V93@//>#'CHY0L?^6F MFNN'L79^$JA3^449LF[+JO@Y1Z`EXE%%;J:344JCBC":P]&@##;D@.LL&_/] M7!F88"6!J\=7R6.I MEXQ`_F0XF0F*;/GL^5EYUALT"?X*HVI2,V^@,JHJ!":X3A\:@.%6"9BT;@I& MV5MXO`;1>'Y6P6BL@*06)3)DD@G5I=K*>(7'UXV436K+2OZLA*L92`#*HS,\ M0$UUFO#5IJ=E3J_->P4G*XQ!%?_?&%,M#PZ!MFL*-&AT;=OQ'`W_:FW:ZZ;# MGK10M]MU>Y;5-+L^0L7X`\?L@!%A>MU6J^-UFLV@=6SYG9H6^BFZS9);/*H( MGH9202#!X<%&G9X,B^]!/^T4*'B+T:+`JWVRR$E(@+3XD($ZY)/.1A$;DCAP MI8?"GE,V%78%/C\3L$7&((&;)(]'1B^*UKH^\'6'>`!0 M'6*R1@WY&4=`K=9T?E<#X74'@^?7K+)A@!G71+!"\=B,4W/$'VD(R4_8IR3\ MQW#,5,=W0^A8U.(8=1I8``IJGD'U450XKR)2OH4=.F9#5!FL`JMY94N470'Z MJM*2E0;&;>9!1Y>>!3CS!5T1HT7.^XQ2((THQ1]H"1L,@\'=$U8,Z5UF!OKN M^JR,S9.Z_QZJD5D[%+#DP"2Z2TT4P"BQK_WM""6[SU![CG=/:ZBD8.5,*`'D-@ZO`NUZSDMK^VU3"OPFV;3=?MF,&@-S('3[_AVNQD$ M+EZ>Y$(-@L#6("]W6\OJB>%#B.K"\>VQZ^$R/=]KZ]Q?SGBEKJ5VV9E!QTP@F'`=\_RI=4;0]!H.(F>SE"N/FQ_B)C-IK.DFP9 MH>,.;*Z\Q#,G+X4DF#%#UMJ(A+^2^)%5LD0_BR2.NL+)U5C$<\QGS&_A,]*+MW5=&B5Y&MPW0RT) MVPVH-97J0*55AE%MMG%^MKG;QI>U=[FMANQ/@H;X%,U=LGRQ%\AHGN%O*VTT MDGBBFG8PP3@*Z+VER>2Q[,VC?>7B`!MT@$]\OF_KJW[3>Y*LJQO^RS,0YD6F4^^< MU?'<>:@/1&9\ANGMG-3Z%-OR^"RZM:E_XW=V'^UYTNE4OE]+)`#+7!84&*CX MJ'26P^9`/A!&M&TRV1K/]D%*N?>1[/CP)?7U6FR26 M=-@2=X85J/ECD'\JS6[M*OSVLH>CLLA#9)5F4:G7GY?;@/%0$?O]J[Z/SL)D3O!HI(;%FI?"L[^&%*A((% M@5>5OM@U7\3[?B.P]^0>.[F)CL?)83?L9KOA^0_S"+XP M.W?O-'3L9J,9M$ZNHK^FJ\B&S0]`7CZDU/K%':+]$*[=!N+9>W=3?X?NHIUJ MH"K>%LMJ!,WV^5F=NX7+JK+4E+\QQG$>45J1[DVBFJJ#N).TY>WH3?)\ZQYO MTGWKV^YH`K)K(VYWD-1@(3P\?W.E(W8VG<:,>(Y=I`E1_3I*1W%4].,"<^<6 M^=/#F7M]QPX"MVWV6LV^V73MP&SWO2;\G^]UATV_V^VWCBSW$X>ZPG]@IB7 MQ53(!97GG)_U;K"2)5]N3'[4)I$DT74TKF1H8I%)>ETT4'"'\L?Z<= M*#*Y#3P6,<0D)(9!_WL:76?S&+,,869Y- M81)9OL3`2#:;;M'"LXD"05AX)N(/U%! M#L,!BC"A'--O.&9<6)UP>`>^,UZ,Q/&V+8[(:("\,<)CA`FEQD5JLM1ODE@:"LQY$(NC,J&@$`E)N*3 MJG;%R-+(!%&9CV7N/U:`90S1$(*]FJ?1\O\.9UD!,FZBM#K*\Z5RS30J^`\R M*"8Q*5#XK`;8FB7`P`PDKJK8NX#+PO@M7`H%>HWEB6!P\)/SLW\OQM=TWB6+ M$[!!%-+%1-`#A=J3:,2%\8)EY"4#I%[,3P5V M@"SFI),7PAVK+DDQ?;FE5L.JFBX.AOH<1YODBE_`6+*+@B8IV4G(;'WWD"Q3V4M`9*'1+Z20/$(JF MXAME4YUH,EXK08ER':^E0F`%(7K71JGY$P':T!'#I2^CN83;H&MQ*62/,5Y$ MS/:T-7'*$U"2("[H.!^D&.4`2HDTO=3NO$6>2$EZ]<1E#QN^8I6\<./K_$S! MPPGI+HJH\.!A";J)%XP)%Y-2>`HJ-%=P*7B9$/9-CH?QZM\BC2-4?>>,Q0S/ MRP*A&JZ6X@:9D&(JR7I^UJ$_=]"L7=+)[78^]3MT+^"9%HI:0QM62`U$I./: M?@'"1!_B.2)SZV4]Q/&@R:/(CA5:%:X4O@&O2X0MA7?44(`Q>*FK]F\-N-N0 M]6^,"6@UZT`M+VG[U]G^4W0MPDE`F$]LJRFTOE7\MQ?._E2$6D72V+I\XT[: M6C'E0:$+[NX&S#*R_T;Q+"PAC(Q_+!+4Q*P`JP]OT60#*V\42=@D.$]XY\2@ M(1+LEW!D2B$O02YJ+8,_Z*PIM$3A4)C?D9-3FW\QA[$4^N,PRT&6FVZYBL_1 M:)$SP@)9+(.OW!*#O4Z%U/IX3%&&2C$346Z;+!6HA;8<8_-JI)*HS_+\3)LF MG5$JN8.K-@EQ8Q0R!>.PP<$6]I8PB1'[D:'*J$BV?ODEO`7<;'%2PGT@8!Q( ML"2I7YBQV[K.SUXS`-A2J*E%25FA?".J%*JB.!!M@(#X0@*CBR"2M$?UF"QX MGM!/&DT*L"<9E&1M6I@7#W-U&L=KKD&#*L):; M<&[09U%.=Y636$?6IHR*-5ZH*S18F3\*FXWG3+;2(>A+M.2-*&:[#28VQ>\! M7^J^S%E\?;TTK\+1GQ7<0U$@S36S+YBC7N[,?T>^$.G=TK%8*Q#+--X5^8,R MK4X`Q1,CG,CKQ$D)WP29F'C\"C$(T!DR#D&FO)9.:+`=QQQA"R7\)Z%?8OP- M1)5(!/X)!1+/IC2Z4+9+2ZP\*@*X56)]*@B_;/T>T4ZC1!J\BCCLMN):W7`L MX%RJ#2.F_PVOK"@EM\00S%PX*Q5_?D,WYV=#Y3FMI67)*.207.&6:?AGQ*'?3>Q"46J@UTR!A!^( M62)X9PD;"=M-(!P+5[RZ.2<\ M`F)W@"Q`<%]$R-V!&75@V#JNJ_`?^ M>/S#PNG54/P?HH*BPP44'Q9XH"XG%.*_+%6^+ER_(T3\A[G.HZ=`H.*MU\&G MWGT8/K9O>_O5FV8;OF_I`%2/6]HJ^B9CO"ID50'.U67(W>-#X@I>O;';;5^' M&[MG#6LM&\I.]<<'#$LP>Z[O6:[?JK1E*">]LIXLS22T'C]SM-TV;!?VSFVU M/$?;O(WSKRX33'G@]K2'X)#I:/D%++,B)&Q(%`GT([MJBSUAR3I^N^/T^VUS M"`?1;':&MMGI.:[9'_0'7M\/6FW[B('5!/D,23]#H]CWD'9"@M]_AI&&R'.K-8`!@"52.<*LRL*=<)#D](%!;HW0L=1'5&6$K M-)KH9R$#L"@[N,"(EM:@E8:@ M>4P7DOS";X6Y*'ET`T1A*%BBU&M0*0HP2D).DE;8_YHF6>B!,@-UT/F&E*-2 M5)V?4=83\PU\07"%CJ;.\6>9KR+Z:F`D"Y]_P8K]RYWYNY0 M[^7QDY\Q]*](*08R*5E@[@X[MQ^13I MB^@4>)8XN*1\$QO(J)%0=&OAKB04$]=-7ELS/\K&'*LM"0R](X'NV5@)<4D_ M/:RC$.&V2+/\4.;%V:)`3E"4VT:VBG33DI#HAJC9K!WLH$"^#M!_)T@_DX0?R>(OQ?L33Y!_)W<1"M@=`!+BMS(3^$\ MNDQ[87&#-0KP'VST?1LFE/]S=>+O%#6\LQ?\AZ5LY-#"=L$H^`&SJC$29, M@75.&4AQ]/3)04.[Y?5[_:;I>#W@]WYK:':]@6,ZW4%KT&OU?:\Y.++D(!R* M@`,8Y=`Q3./S8CH-<\I/ULAGE/0S)`%))+YPV('S,A.]RW6N$^,CY]E]-RGH M5.-7GW5HE$@;E=Z[?_`A"=]J!7Z<1HR&2DZ],8SS7I&I?42OQ&Q4'KJK_NV\4M.Y*#:_").M5#=G MHNVS_HP`7KG0'ZQ-MD>H`NV,$/C7B%\^/YMK29!$IZLP89"ELO8[2F(=F[#< M&BJ6K/GDY<8$TG(K-Z`XS'*L(N=47MS5?$QU?%0W?\U&+K8['XW0E8NV;GGB M1<$AEO&*3/!J?4`%$O/WB\\7YV=O.YV/E4+:#?G_-)I$_X/#!RP<\AW?$!6+ M(T%1@GA*"52&E[XK/V/]/3,TUA]74H:I%WHQ%_AD:9;#W85!D47.X;;*PP(- M#N%L(D2Z0BF)A<`L+JC%.U9RP`YI6W$/@`TQA@Y@4P\^N/'\"IX"VRJ*YE@F MH2!.79L#::IS-OK6/IIF4R"!"B9C+I M8B`5XCN.R)-25HWPRPI0B&HR5>!ALD@21`XHYSS MG&)2=#9/Z:(;J^),L>DTFVJQ0RTMY"$B3(?54X2<;R#C:Z>NW#>L`9G&<\9F MU(K5$6TV7XQ$LG>^2!2PR?5")$T3CXWR^`IW?,GG@CY618TQ:D!C-`K]@5-* MXHA`8V5%34F)0D+"C95@QM*4RD*0*%?J*:(.I`3V`\H.?]K^(S0I#CR+0\3R49Y<%J"*P?.2T,@MV[&XB; MPSGY"!;$!X0K`U(80"$N%)&`A)2L+#$H\6.Q3.N?(W)?5$)]X*PVT+1DR!S! M?&`RDY@O8:`P;J:J$)=#(PVJ@,`S32]ZX04_I-']7B`LRL08B'CY*J+6BUP= M718LI52MSP8E3VY]/%^NR"]4TZCNI]#N8R4!9'X!3@SQ, M%V(QPA&)\)(UY8/&ENK!#N,/RPML1+`$XQAHD0LXO/E-5FC$^X[`&D^%O*=" MWE,A[ZF0]_GO]9Y\7/)P?*G`QT>T@'09<\-=/`?FO/^ M>U`3<$VG4@+M1`N\UQ>@PCI+%U*)=.APHW=6<[/X*U%O;?ECXC]5@0R MER0$@Z].JX#`+#$QX7+*XVML-8!PR](^I0.BI9'#^4_0\&0(OA$M0IM[[3P. MH5T>4(']%-UFR2W*NO>8WPH4ZH&\C*EICO$%KDOC?19^%ZILIV"_SZ)`X359 MY"1@0:JAQ\3@QD@K6,Q)AF"/%?#E\S.9&C5`_WX>C^!`SV+,].AE^2P3]F?% M-_QV()^I^(;)^?T;)0'B%7AA@#!''&=F4[0IY9=I;@+&EY/[9PMX+4137L'B MPHS+#_$``B0WQJ8<_!G'83!==-L:=-C([)Q7\'7AWH+!\VN6JYC=*[3_61B/ MS3@U1_P1Z=TEU13=-:!A7+!B@C M7\)_RLMM94O0=20`H$N86MF.Q)A&8'Z.+PSA+(,G4?Z0=VR1"[4`A$H:"2U2 M.+5B#6*7Y-"-'UU1%@%`S@HKLX.8ZY+KJH]=K+C0O'(Y[&[S&!_1!^EE_ M90CI(/H0BO/]+BWF\7PQ%\"U?X\0JKLZE0_O_EX-<*'4PJAY?2F$="2?GY4. M9-0B09\;1Z)I%/%I8)5L4OFWJ.-.@/:*'$TZM%7A!O"N7L%$"NDO(VY)Z M+]AME0D0XHI>H7GO1/F@W"#I"5=J%YA! M"5P/R$_X<6PX%VWP\-U$^NM"Z:A['<%\I;.+@Z>4@!)AS%9%O,0J?ZG[5*R@ ME>D9P0*BN5-$&J7$9(3<; M:XCJ*]CS@E$,G5%0/0=^D%LC)RKW`A7C:SA4J>0%V`_6$$,,/I-SE_L8P=\I MQ(S[Q&JBH5S6]W)86#`90Y%GQ&6XJBP6/T7-D7@@.O/,.Y+J@HI"HP?AP4,FXB!-U_], M_GGNNXC$"Z6DS3?5AU7NJU4)%19J6G@P?CD_>QW_5!*JLI1"^.YO,#=B_*OQ M.M8?33-Y7*ILJ??B6.TB4Z54]!6NDU]Q!I6!96(<-H4KRBZ52^['AQ.A%;^. M;[67E$OSEDPJS&%`*[62D216PHRHIJ$7\O]67;IT)XGB MYS,N$WN`$WXQ7ML_(8@Z@J=C0]$46PK.(^$I$)U'4%O128@19\R:*'AUCJ9H57!>E M=?N1_3S*Z6S.?ET42NK?LVK83+#7QJH-#J=.+*GW"F4O:>*6'Z5_:FDY&Z@] M07IQQL`HSD>+*3+3B`(V2W']QAC<@1N%FP$B$W&/$@V3!5,PT(6#\E2DOY;9 MF'IF51X1;@SF?B0E\@:HY)AQ@#^#$*?@$?QZR8\7V$)%)+-1@V\RL]!@OL[) M9RIHA:V9+28VUA/8:+LR?*@<<;6@M/( MF=%(AI=,1BXR>3+GI8U;8HN"&A7!B?[!*/)^Z6>#O-KH8T>.YDOPM8\YQ-0]V=>Z& MFOKY627;*)7G\][<\Q?L`<%P6+W`WR#(=4-8.P`-)11E>F&XD@.AW+JRJH9D MM'3PEFD%&VA<+YQP^E+#+26[.!T\!^DN'+,O0B1STL?DN:F]M4+-L%?'35\< M)2,(%H4[EM)IUQ:YZMRFD.(60FQ(,,//L\9.\E5T)ZXJPR07-_FP:$F51=,: MI%-/Z,15QUX#1"5'ON;+&<8NX-C*3EVQFA*-[%JF;W&O/#FIT7*4'"C3.G2RB:3(IJK7!8EIZ2"4GI3,--6%MUS?=V6X-=KH%>@$4UR19-9'W23-;I-8P' MK!$)4K=(X[XUOMQSH8=Y"=6"*M$-O5K]>XCH4E-ND<.DX4H M5&'T5E&'4!Q$&@VX!L[6H`M+5PI`EH5SX::K0B9RAC)8-Z`O*X-G>Z;R:OZ) MG`;54Y1+0G&AUE2F5'01/L/\/+K)J,$JOX2+HU5.LW&4;/QL]5UZ5GF)"E+- MI4,)[&H*OQ7L[6'P2$JBG"BCC`DFH^CJD=L,_5EL?XDGA7^E6EDD,GEP6S9. MN.I!XP^2X02[@[X\(>74MT$882+.JPMC63C8[&U M)1M7Y[ZVXZI*Y,4>^_,SB6:R"URIKBVK:Q?9;RL^;04>T@#%:B32YN61%7N\ M?7-Q$%G?"E,9+T:<,EO&H.A'B8&*>5BAD8NH8?5ZM)T?RVL:<6;1%6W!W$G:B66,5F@)P['5?@51E9?J0'\B\!;N:RB MB:A"Z2J:WT71"JJ]S,FFZGM,W,/APT)AS&Y`7;XPAK14`ON7R8V%RCL67L%4 M(P;#RE,AU&LQ_Y_*A"I,'RYSM4(&9R^QHO!]RM=2J5\351X\1T0O]"8V)'XD M5UF4M=#X+`)KY=%&!W*)!3XB5C03.4.F&,)TP#!'1VJ1)>D4J`P*2K^4WU;!5#T`B;$J.]$/=%``O<8BPXF MHLI:AR*:9D"))/Z32I%OD*1I-M?!B`S`EU(;`ARUSP:W:28 MY'9^-H4-!O%K8..1&3;^6>*;%1^PPO.B>HPH#1/!DNB)KE\*E6A7RJDT?A%J MW0M.H/S"(.R2[=>$`Z8\KGKDG4HI&";G.RHY?R75CNZ:7:YGNDY54O^O&*ZI M.XRU\Y-5!%08A)]@ MO2L#4[,,+'H4\$+P1X53CU/"A.]R=/7M6&&AX#)$@Y>P>GR5/)9!CA'(GVPN M:S;DLW`QJ[/>$*TY&.6=`$VH:KV8(20"M[**RN<(6$\%8=8M8PUM,%B0=9L%%PD8]>_K"8 M8U7SF(P`#5?G/XLP![YJ8&6MP)I0,<95;?8%\QN!"`B-1H*B"T$DP96$:J(: M&AD(*&".D2<1#P,E';,G0AX!G7;913SJY:?.ST29U0[;5VZ7JKV(I[-PQ(68 MB"!2@H'(.:H=IS$:"G\-!JDKO:B@LNG5*4`YR0,U5AO5F5;P616JZN8J?S5% M7H141-6OR\54UJ!CK]*54YGFMJFLH8,QBMA2Y1P@6,`"]#]^7^*5?E<8BD/9 M`6^%\5&4-`S)SC4"J2S9*&+04\(\892%*Q+5*R]<1:-P(:K(RMVM<"B^KK9Z M@X`B2`/MP!GCA<1QPTFSX-P`XM`1>17KE1^V7G2?KJ+`V]9%H/Y<EGFF=IMA!04]^)9X+8$3B1;5V\1."H:6O^C/<&)0?] M/ALSXM)-GBVN;TJ<:F+$1S58*MOA7_R1(V# MNY[=[07-MMD9M`9FT[/Z9B=H^6;/=SO=;M#W_(%SA(V#3TW43DW4CJV)VOHQ MKQ[9ZG&^S*_#-/XO[7'95!);S:=CO0OTY40UF2Q[3/85J9^\D[C3[;MMO^V: M0Q`+9M/MNV8P&'9,VVUU^D._W_<]^P@%PA7^@SN)VX9IZ-0EQN@*U"G:J*N7 M+2+0E9NCS]>XBK,9MJP.1Q%H42.V3@A#<)*-%L*K*O*3D/_A^3$CT^/Y7*#S M=$IF1J3#T-;KL/Q5A++[MT(:S7`@1!Y&MVJ1`9/.!9J-@9/8/#T2-#=8$:_U M2>+3.Q;UTNC#VHA;LLF00T#1,$7M,LT8RY1!-?%SXAJG`5DUT$%"!*1NP1K! M%2YTA"[XR2)I\/OPQ'@QFA=J(K14!"F](C=SZ;(7[7.S7$1;;K%+!]DZ*%[3 MI=#R;QD/&`=57R4`TWS$7:-NXRV81!AX&,>JCY36SQ4!KM/;&%1+Z=_,PUD\ M9M=ZEF37[%X73>_H#D`?/H*9PT<9F8Y>3*OP>5+`@BPM6,8C2578D%M:@_14 M>.SL&IS?Q/F8(.!>NDOP[ZH"'PV<.]9T2WQ0`3&B8=1H(.;(P!I4?1Y2_P3N MK-<0_S63./U3(&519Q;1XH6\V015A\B1(JR;X"[E%`\1P13B\%([W>&">NI+ MJ'K%#80?ZF.4DY.4%-SED]]8W>&@;??<@6GWVQ;<6%;+;+D=U8)^_RR;M\\BZ?O,LG[_+)NWSR+A_`NWR_*G2/LE+5;+!]T.7DDX9% M.1`%9X_6:19IS&_%1=9T[-:_?O_`2;E13_\\KT5O4>?]#KV4VK;09# M"UUWS9X9=(9#L]=K-SVKUP$C?O@O%_4>V[;P?^5B-\Y_Q>68RORAMZ!>HDYR MF?;A,-U2+<$W^"#O6^R:CC>T^H.@-^B;?1^&;UK-IMEI]RW3"SJN[SO#IMUT M8*VV_>J-V[1MNZTY8;8OHKKB=R*?:._;^=@5!J_>.(X?V-IFKLR9%S2+9[]\ M7H#()UT]3/[@B^$=.<;?H;(O^BW^`<;Z^RR]QBZC?;(Y#K;DP+=[7N![9F]H M^V:S:_7,=K_MF4&[UQJZ;C<(/%3;(#-UQ,Q. MV8FBNRP?^8.NUPV&@>D,^Z[9]-V.V>EU+--O6P.O'P1@#`V!<'`8+$&S/2ZZ)"T2&IL7 MY@NR#W_CEK_+/EPVOZ&Y?>1"DTX,9;MF5;`M-AQEN6R.&JGQ6DJ,;L]&;7-8:?M]^P!6+&> M;3;M%IR-7KMONKUAX#GM5L_O')L;]A3H/`4ZI5;UX'-3E2)P!@?D$?N"(._< M`6V/,8^@YW4"R^Z;3M\9@CSM668GZ'1,SPWZ7<^SK&ZK?62';27FX6LYV>ZO M6JMEC8#?1>SC4G7KKA0"K;0,?T_]J5,T*48DW8V.:@O]FLZ7VR[;8?"\[JBU)-F11$YJ4`Y4N"8D;0H7XS3U56WNFKQB*"-^O:-6@U_2 M%U$V$ZI2A<'ZB2Q:+Q2])T=Q@XT):`VT$=D#=PA&SKPF[^2,XE+-J:4G4(]=&I9^(;;H?!=5JBW8W^#19/V`:7#XMKDEL* M^"@=P_?)OKX*TS^-2ZKU&!N?\*W7[]]U+S^!1!?M:B9)EN44%;4OO!\;W&O8 M^W$+&\D[)-].T"=8R]>7#J4)`*#U\,$Q/E6%H' MS[('L'`HKEQ>-(LI"KO/VC6X)OJI@F&B\2TJX+T8"T^.59'>.U^%#M'Y\?`VI3Z3XMGZKV0'(0%WY88]PK%L/1`U MZU603,]X3C=/RW_8M!X(3;>[D-@CE;YY4L[#)O5`U*]OGE[[8=,S'W^&'HX% M]@+OM&^;"[JU7L0=?YB9'.@D/&!*@14TK&`=[.@P%\GQ[/\SZ'CJA#2?G2]/ M)V2/)^3AU\1]RN;Q,,7*3._B=)S=86AG5P/B:>^:;:T1CM:6J"?:H?=X+[M] MR'/JM^U&VUH'#?TKWV2'I/\172*/-NB="\<#3AYGBZLD.A#='@QBN3+)Y]IO MI^%9!$ZX_<2]7&3+=Q/C3M;T+NO<^)2E+;)!MCCT9SE&;D745WFGC:E(8**$ M$@J&H_916XILSZ3.4 M*'/J2;4,K:*"HP/SNXR;;JQ1&7QF"(+ MHJL-#BB[$*N`JP:_6&()JB"/S+1_L9&ZRT6NB$\QG$UQ5V)#:E,QQ^0):B5S M17Q8R*0,194X-;0Z4(SC),D*%J1*33@_&X7%34.+'W,EQ"S'?"4$N$RYKHX+ M18T_;N(D$H6,_-TRL`7"#]Y.LSD5`$4SFDD23SD9*\Y'BRE.:L3%C;?61@#COF8X2)Z@I>._H+ MYA@*SJ[P!B9N82C>&"T*4(6X:':F51QB6)&3>^-(5$\B6=.0\`#*/!7:+)FD M!F)BQ!VQ>81Q7"C!AW[3)!%=+],T)2RTAJFA.//"^'TFHM[92)T*JCLN[V9& M\%B$XL!0X3J";1#[C*-)N$B`3\I,-V07YAN!['$'QV=.W='_LT!I*[FN[%LO MT]V*&Y#XC155"`NDXCF'Z-4M`[*3T]7D:1M'HP2O&I2WF.+&-P>M3+NE"`X7 M1,!T"LH4YQ)AA15='.$2;Q%.Y`#%!T:<4O5ZCC=#/*(ZK$4!>WF3W<'Z\P9] M:Y42W`:-:`'4$I$IBH`,77&.?]_3/?#&;CV@9 MHO*,OR)`"3@UET!1PP5*S3E6#H]&42+R="^,SC13H">XTDC/D()YO1V&?=)BI_@QKK`1V0BE;!7-HE_U&I>`%G[YW&^3-2KX= M*JB\=E,K"=12]#7HEHK2"`26(R'0!$%XN+& M?$)_L"]\NRRZ:^B"6UVTN'VJ-"Z3:5%TRE@?5C6DI,`EH'^)%,U"P!2(:W`2 MQCD!6BOTGO+-^4JV)LW.#QKMEL\I3GH:9$A2GRP+8=V,8""J5:T,3SF2R'N( MF,TWBJ7:57H#KJCK6$X9KN>OOQQF?+DS[R1%1F+06#U,BX+3N'%? M*8][T^EB-6ZUFM7XP;%]:G)`H%!#/H'5)/M44TQI_Z0&@E9S1/4L.F3)W4TI^,9& M)3L;NW,VVEZK83?=M?IH!`)#H39FUWNZ^M4Z15LEX:_R<;6(Z`'5 M0%H)D?KCY42#6NS1%0@TW5/-WM!J==RV@]6[@6LV>^V!V>X,`C/HMP=MIS?H M!,/^D941:35[&J$,12G:S8Y,V?^D7"ZT42^\@(\\68P"LA3J$:U8Z+W=.,.C MC:AEG?$M'K>Q46W\V-?@PSH+L!W(6U`I`^IV/O4[*Q5`.#@A-?81Y%'V(,#A M")F-"I0J+3;Z67^UB$BX*SZ$0HYA06L\7\PC/FY_C\($9$AE*A_>_;TRRN;$ M=$8C@KT6[:5MV9$(O5-@W8^CU7H/5=VA_5[X6`N$ZR%/X!1HC;)?N"3HEBY= M>-(CAD7W10"^9/VX:N*_>.)Y`M7CP>DHR7&+`@9M#(3+$,,LC8*0> M.T3T^P;>II\8[.13)*]31DSL*!OJD\":0/?*YS")+O/WI9%_?'`2-J*#.$[+ M]P2ZPF$)4FY$#PXRZ-[$L!])<7HDK?[5#%HMU_KJ^#MLM!TAH`3\"&2\0=:1V+56, MD4X"T@BMDWI4AF^$'H'UMUN>\]6S_%8K>`3G=#VGY8$V;EJ!CP"P;M\,$!MZ MX/0[OMUN!H'K\Z*!=US/=IM.B46RV]J>A1ZVY3J/.4D[T<-!>MB(M--L>W[[ M<00AW@F+&U1V;^&H:.@4WX8O`C0('*_YU7.;K7;[7Y[5#+P64*1I>>X:MHB# MZ^UTS4Z_&YA-S^F9W=50Y M8.7ACRHMX=N6W&[:3HMXW'&>?,ETP%U:LB;NMJ[DD(OVK:!I/?FB77',>9^/ MDR_:$_?7@W?ZH18(@MON3`)8.!J>EB\O,:_5VJK8;0?, M&SC-;KOM66;+Z;:`$G[+#'PP-8+`'X*X;S=!:6;9YKUZX[7OM2XVKK`DS5MT MG>W'W'PVXH#@]W73Z\%KU#@GRC&1.[R&9X%N,,@D9N"QZ`'*CJ2$O/HL)[#7 M*7'O0;$"9^`/.VUSX+M``=MVS&ZKZ9A!U[-Z\"1O;%E#N5+U MET\1X6QF*5(*#:*B&TW`RNK'B+1V13$YL+JZH$",;I""G$_QU-38Q!?^XZD" M,K-I61IC?.N:-:TX6^22IL/H(4KBMU%C[93L3@UT4#0U8JPNH5SM\M*U_\MIV78%V'+)Y5'SDQ(N.#`2IXO1/\I[I M<+[I`Q>NKDS;:=M@`[@MVVH_9K>]81>L_!8V/^E:9K/3`ZO(\P*SWVT.AEZ[ MY[:[-N^VC2"#&N<_9'GUXG#]-7[Z4S2.N%W/4Y-E54"NFX8[DX-U1KM&0MZ_ MK&=DDAW<)3479Z?I#-IMWVP'PRZZ0]/IMADF^P7'H^J1A@Y1[+L>ARXY#I[75^^T("1[O']Q4$ MHYO65Y+AWFO3GIU2=-9'MW`6N/;B)<.&OOEY$OX]7"K MZS9MS^G;/;/5'#11IW#A_'DML^4-_9X7-)MV/X#5@>.`78<3VQX8BSP0 M`SM(,-!FT9?JKL/V89H;:$O.!A,0_ND6V7[UQ`]_6P?OK9UY=GP"@11J, MIW&*9C-%$HY5V(+QZSIMUVGZY4KO64/-Y5)SP!\2DRYCT$C![5C9#Y9"B_RV2R8SW5J,2WVTW0JDO2;5W!!E5X M().PCVV!WJLW;3![@Y9=HP?+6>\W>>%;5^K[PP"L[*'9Z5L=LSGL^&"<.1TS M&/8'0]!_N[[=Y:WT05L,[&]+W?A#='+K<".W#]3'[7)"(UR6)>1/KG#MU"5E M5X'01K:V@Z;E:F+X<2NK4@>$[Q%;?;:_+@@K,UY9S,NQ]-#U'H"@TC,R=C3S M'MTH1_@"J#=.\?!^0-_$Z#W+[K=ZEF\Z3?3:]X8ML],;=$P[Z'H>$`=^.V0+ MT?%\WPU*JCSM:1+=*(,L_=(>U09P-]T&TX''YPZ`YI!UIA\.I- M$+C.+NW1CJ(3V"%./FRZ5\8=#M,,[-%?44DGG:)8L+>_Z*3I(DS`_)E$U!W^ M89DTFTA\;T9`3X[&IQ+LIYR+8T+1;OIZ,]1AR M/$'T8<\E"#9%'^Q68+FMUK-%'_:^2)NRA&W7=IXG_+#W!<+Y]?W`MQW_&<(/ MCU_=3GXZF\,/3=<-])30YXH_;%WMD\8?[".*/^R=@V&/6T[3&'Y[")_W("C%VO!ZC3$")KDKGCHE2>PT=[9U%*734\N"E%QTZVCO[ M`9U:?K":S?#7#1SM7X4C)2"PVW[S>XL<[9UV("L]VVW[CO,\D:.]+Q`C1\VV M[^D&V[-$CAZ_TMUL=0H"NH%C>2\A+'-DB,K(40?D"`.T MW4:BA7$<%8.O"*,9C5G43&<+!N*\G*SJY`_-B-Z=6#4N=J<%MU+0-9O=%K"- MY3IF!W-`?:_9#9R^U>_80[8/;=M;<;(_R3*?,.:V_SL$G1V.[0;N@8-N^U\9 MZ",V'`00\R\LZ/9(&;&3ZYV3W`\3;U,JAJ!Q5T#]'AVGP%WI.%;+6=6BUJ:^ MIWCBSBM\9#S1/IYXXOXWDT)+[4K&S"'#B7M?8(#WEN,YP0L+*.Y7JMDDU?[" MP<1U\CY-,-%^EF#B,2-A'4J0'0,0UD%,PX,%=<4]B$`TQQC4?2I\J%V#NB0U M7?B&Y7\;.0;369(M(["8\MMX%-6_":HW>H[`#$5Q4'S)YE23K?Z.^LB';/[/ M"!8[RJY3Y$R6NL#IXE?XG/U8LFZM,]_MFA%E]!_M?]KV;T%?BT$=E`),?4$& M6LBCR4!#P6"(AC!?BI_@9VY_,8D1(7AT`Y+]?U[=S.>S7W[^^>[N[J*(1A?7 MV>W/O7?_"Y<#?LCQ;73]EJ^50Q71-4J;-W_[>I4GX_B7Z.LLB4?Q_#?&^!S' M4W0.9^G_O%*..+Q,.E_CXM4;^:O?PJ_Q=#'E=_[V<^U0;_[VL_R66-7/E67] M;59>XCRS>9C/^WCI('U,JV5:H#66OU4/1NE8>RPP70N''FL/@8C6-(2?Q=Y\ MTT95Q4II0@(!)(2__[E#OZ]_/^B M//N,R:3[.Q]6&[;_?@Z`Q^!"Q4K8O7#`%L2>H^*`<13_\CZZ#I,!S:;<0:UO MT!YEF;737L%C^]RK+2!2I[VJ2-9=]LJFO=J39-T"<7946R5U!/0\YK8_VG.YNCLR!XJ0[85?YJ"@^\R2+9Y#>NS#+7O7B+5"^1\D>I\W; M#:W\*#=/[EFG["C_#-OF[[9M_KZV;6L3@J/:-]DL$COAY0M\B;TPY:;],PKS M+W?9?F_47535?IC'=6>*9L1U`\P#ZF5]C`<88MFS4)$I&GL.?X7V[7- M+=Z.<@]5&F9WJ?[Y=Q@3XS[+]QCUJ5J/*PV7Z`GWJ6Q);,J6CN(P*:5!]>NB M/\]?BJ6V=48\2I;"3HN==+S2<+$4#)Q4BK*B#+P43\5"SY4J=G1,<\IO.(+\ MAN-EC%."P_,FBQT=6YR"@B]DKXXK&^4HR.-6W>XG%?Q%J^`[A^$/QE(G;>HH MM*GC98R3-O6\Z:)'QQ8G;>J%[-5Q:5-'0!Y+Y@K:)UWJ1>I2<8H`3O,R4Q'8 M2?YN3WSR[(?HD&NV3F?C>S@;UH'XY)C.QK[7?*H(.5Q%2+FM9:''OEA913=] MI^EZF/C1]EK'MZT2]@AA8_IQ,4JR8@%;!P;+)$),%,*3T33>LI_W;92_CZ^R M)\XPT$Z>\G_M?8M.)^]P)^^`VPK_;05<07!D)T^%?1%5Z'(B[NW+_!."C*X6 M##QUM/]ZC4#WSK2$(MV=-_'X17M``G:?Y<\\!+ZU\OYJ\UORQJKAQO$M+*R< M-+[V`2RF/)QGY5'7OBN&^P6&JWZ<%U3_/@W;C])L"I;9AH'I].'<-@V[_O[? M?M:F?]_BURBX<24[D7%E6XZ'CG6,\6U$I-8=J]3#7^Y`-@'ILOXZ27WZVX91 M6-S"/_Y_4$L#!!0````(`*6*9D&^Q*[9%`T``&&P```4`!P`<&EP+3(P,3(P M.3,P7V-A;"YX;6Q55`D``U:-F5!6C9E0=7@+``$$)0X```0Y`0``[5W=<^.V M$7_/3/X'5GEI9R++LIM+SW-.QI;M&TWMDT?6I=>^9&`2DM%0A`I0MI6_O@M^ MBA)!@A)I$+I[.1\I?.QOL5CL+A;@AU]?YZ[UC!DGU#OO](^..Q;V;.H0;W;> M^?S0O7@8#(>=7W_Y_KL/?^EVK>NKCQ=C:^2YQ,/6L'N'?49>K2\V=C%#/K8F MZ)5Z=+ZR!LBUER[RH5GKEGA_/"*.?[3$OXX%K[Y3G"S@RQ+@T:/[+IO&=UNW''OX4DGEGOCDZ.H5[ZRY@N/0?>K[T:,!SV[`!- M9];):8/6/G*&K)C4!:P%"/GW?6<+T^,O>(LED/VC[MQ04[ MWW]GA87/7CG)5'@YC8OW>U_N;A_L)SQ'7>)Q'WEVIJ)H+*]J__W[][W@U[`T M)V<\:.66V@%K%`BTI"7$4S6@$-9_YJ M@<\[G,P7+NY$[YX8GIYW%F0AN'UR_/[T6%3_X8K:RSGV_/@O\IQKSR?^:NA- M*9L'Q'/Y+%GBC<4VJWMR?Q8ZCX^X,/4B>Z&$UO MB`?V';L-KXL#C>4Y?8 M!/,+QPED%KG[ZJ=:.JX1/E"+@_5:"`9(1=#!]:OX[T[RIMIT`R,X>$+>#(.0 MW"#"?D/N$H/,+]DM?L;NZ2U!C\0%7F)>T[@I=U38!O<,W!TPFL7CFL665DZ)G^!7_](% M&=N%!V](7-*$/JG%;04/=8=>0BMX&&8W3 MIAA.#>@`2H!OF=Y=$4JG+"LR4>=!O'R*^&,0-%_R[@RA14_(4@^[/H_?!-+5 M/>Y'L?,?HM>_1VLVOTXM48<7HF6VQ$X4 MF1%:-HP4ACUD`B<9RJK5K49H;0Q>SH5884<6_+REG-]0AL&2"HFVPSD5RN*% M\]\E#Q:?3QCD9X)>Y:-3>T]:.);XT?>(.$-O@!;$1ZY8A*D7K$(R!I17U(*' M<^QO"N[&C_KH*IGQF3(ZJ+PDKHL#FXO!&C/&-B;/T8J62[&\O`[JQ;:!,!GA MCU@LGY$;&)'^`#&V`B,R,*HE2-3J:D&5SJA"`)O%=-!ZA1FP3NR1K:T$GZAG M%\I]62T=2#Y2ZKR`=$M(3G[609M\A`$6 M9^2!Q`Z(BGVE4E,/(KK`S%_=NR*N&WKZB\@SD$(IJ*(#PQASGQ$;W*%]K+"J MK>A!ZB/B@0N,F`>$\#5/\`I/B4UD8Z9040>>AR?*?*%1+REC]$50)@&05U(+ MQ:KV1$LLB,_>8\9/XJFC)"&\J$:"8"V$=L&R8!"SXY;AOUOQLVS:9U2BQT6B MBVBM2WP\C^M/&9UO>=!Q9U3FO%J4`=.#S.-WQ\<=ZP6+]-K@&9X6C%`&HW'> M.>E82P[$T4482V@KNF(5G8+]^1#`2NR:%.4_#@%EZN&EP-Z;!FS#X%G'I[@. MI^#[!P2^()"5`CXY(,"%:TP*^?2`("LY`BGTOQ\0],K6=LJ&G\QA0TZ<:YT) M>8&9!&??H.$NP5GDL*=X#VA<)>&@%*M!)F4)UM*`>0K:(--2-?PKF'`KEBHD7*`8/,<+5!S]V02/$:9(6K MXX,Z!6N00ZT&5B5?)E7@!FDS1?A-)%BE_#)(]ZGQ2V6S M((6_BRIL:WYE]HRW?E*W3W%KR>5)HC//V"O(Y=DHIB>7!V8VC&UT&"LZMQ:= MY\LENZB&EAP>$`J&7$&*,R<>X=<%&6U="!9TZR@A,(S$4O0)Z.% MN)]%G(>\Q%/0N6$Y4*J8WQ$O4!Q##R0><[%ID6TE5%IWV'^B\,LS#K6R;._O M+2G0QV&@.QKF2Y""J70K5U9:#^4A>XNE>K.4'DKC,0[Y%],D)5E27`?M8*VD MPBLA.%M&"Y6P]H43TIN%I!1+A;R\ELRDF)38898E)&V5TTIMJ5SDE:SA&$=@ M@!?;W.%!(5"\:Q;X&-N1D69O6.1CC%QQ,OWS`EP9Y.(1NR6@HIV\-5\#`=J2 MY:K.JI)*FM*S,'@W8JOH2MQ70H/DA6(8Q77T)-*P2$(^@EF_0"8CW'Z#?)*+GBHZC&MQ!T8<2L0EI`GN6G?`M+0YV9RK<= M+>;046^6RWN3IE5]*RB/3#`H.U.-7+$J0FZ%C)AI^VK@=&$6UD[&LU8[8_M[ M`:VY?>@>O'(1S+3!8>?X"H=_919'E2;TY`1-,8B64RU;HJS6M^RF71!<3Z<@ MZ:/I]:L=?)A@#--AY.6+D`12I2:T9'`ET:U`ZT\SQ["3,]BR1"ZURIJRC3*3 M>>AMG(R0YQV5U&L7FM*+#I2JM@:3.,R1/>43+,:)UUY^,=?>S;:#%]'1VUBQ MYQ[!5>:`4F/MP!V?LBZ_&5&MKJ8P@E#MH`V?"5A?EZO/7"S-R5?"Z2 MX0H-M`A?N.&X![Z\!EJ$+]$6N^++:^`0PUS?D%1B5H%!JH8?I!XS;&3I`$-.1\ M*;Z'"FY]>J@..OP78B#W6^RO7+TQY"KZR^IBL)$PIC40"=%&@I=4NA M:BNZD8[!$(TG\2WQ,/P9@$4J#6RHU6T3JNS%,;N-9+7V=*//\?U5U%^%%NI1 M*,^$AZL[+.GT&;,53)0KNGSTITLW]HGS58E233TW2R*&+S<_""KAN*3PMS3S M>O88=@A.;^QH*3L=1MY)U!"#B+^*Y*@:O'\E$4&G=&H M'GJ*4X@K6MQ&7D"R&WD?KSDXI&VY]TW(B<*GL%^%Y48Q:WJ M00DC;VVK3Y24@@0ICPQ*5*Z^GY"G?%0"<9(++LU41ZK\J>*J&WD99O7]FD-+ M)=R-`WI/CIV8/P,5^*L<=S+R9,U^,T_]C-VQ4:=T]V**XCDD@]SV_?BAFJ`F MN5+AH&5%%OXU\X#WGM.F)&_6R&^K[,>3O'0`,T]N[\4&M>1)R7GN@]8?BNEW MDH/>7QEKU#(R)5?1?&6\VLJU-O5ZF;JY4BF_>;]/K;S]>:$KPFV7\B7##X*[ M;#6:/H`S&3B)GA_)!("\IRZQ!?KDIN^A-Z4L'`]=%QFO$2^LJL=-JRJ^`D$_ M>3%O!\$F%A]Z-XBPX%[XT72T9+?BQHK3=4'23G)"X!U,!'@.XG4M'7T1?2;A MK5AB5S"X=6N&O3;+Z]8]Z2TE-(E8KX65VLK4FZ7KKB+G&SMB"_26(D_'J@3Y`KZ-X??WZS>K_6DZ.:9-\EVHUI M1N[&U,B6M?ECY,T+];,B5*%&[I;4SHQP%=WO(20``,^,`@`4`!P`<&EP M+3(P,3(P.3,P7V1E9BYX;6Q55`D``U:-F5!6C9E0=7@+``$$)0X```0Y`0`` M[3W9$ MMN.M/YU\>SJ=/LWN[D[^\N??_^Z7_S@]G7R^^3)=3.:>ZWA@9_\ M8PE<@*P`3)ZM=^C!S7YR`U:.YP1XU,F]X_W[Q?+!'R?D?WN"/_K']>)^W#\!>6^@41F-_6,+-V>3T-)WW;S&$'R<_?;@\Q_WR;Q8P M]&S\>>&C&0)6-+.-0?HXN3R_N#R]N#@]_^GYXD\?+W_Z>'7YKV)KN-TC9_T: M3/YS^5^X\?F/I[C'10G5/T[NO.6'R=1U)PO2U)\L@`_0#M@?DI'&P@ZQY$:P?S^(OX]:^\]&/YKR'RXB0 M`NA,F"W(7Z=ILU/RT2E>CZN+#^^^??)G,N$O"+I@`5:3".*/P7X+/IWXSF;K M@I/DLU<$5I].MLZ6K,WE^<]7YZ3['V[@,MP`+TA_6I[]V0N<8'_GK2#:1,"? M3,CPWQ9W)2RVKQ;Y_A4D>RU(-NX9:7PF-.Y92^`7N..O3P'>HV2*^>K6\?#Z M.I;["/WHY,Q=E0/L)C@(CGQ$+!XM!!HMA\3P>(C`65JN@)2*'XZF&>(ZA0#.XV2*`P?'Q%/&<+0%G#JL:_IGEO]ZZ\,V_\VP' M@670$O##\=I"?./X2Q?Z(0)/X69CH?U\]>2L/;P;EY873)=+S)L"S$D?H>LL M'>!/;3O:LY;;]GY2,K%"]#&T(.+N9&/@71%-\/F=_-IHOXD.W<$*SEXM;PWP M)KFU'/0WRPT!WO,AN@<[X%[=.]:+XV):`E_1N@E/IP[5;*:OP")_D^/1Q=Z4 MF$<=R8Z!UBD[>;X2<^F<,,&WB$!XV_N8T=C1'_@8/"*L'&&AF?Q9D-CRSCGP MS^`]N';Q'FM"@R-"US$UN>72RRR(0=X\P1ECKG"))S=WW6#\0JTK9S(HA/VS'^-^`E MP,L0PU`0P#JG@,S$YM"@B_M`?OJ$'A9:BI*$81-.KCA>BIBVH'=J@Y45NH$<=(?=CP,KW%B.UQC4N'>7 MD$8SG&[`Y@4@23!+73N$\14/@9;A"SC-*",'*6V`!%X[\XD1EU@)9GS4@&<3 M0W_\*1E*M;\B`@*#@8]T:6Z7>'D@HA(L0M,'RP]KN#NS@7-&;CCR2W35G9Y? M)(Z68B(1^`6WVB6^T]@H<^> M?8/O/PIHS*;=0YFN63SW(T`.M&_Q9SX%3';;8\-):"0&9=[R>#`6MCT^:N`. M\SP>H-3FQX,V7D?VYJ2W.QY\SWA8#EC1U]U#$UUH1"$ET@@%G/+W1X)G/\,$ M0,1<:(/WOX(]"ZZ#=D>##^L]T(L$_\B3XL_#@,01D``/-K"\3L>"_":19A@P MWA3%E>ZAN75<@&;XW*TA8J]RN=6Q8%N`M>/CW>4%#]:&>32JS;J'[AZL+3>> M>_KNT"[@:HON8<*:#MG%3_O-"W0I$)6_S^#)1;DCXK M!#<"S"B=$M+NN@E$6*/_=')Q?O[A'/_#K2.I]B-1Y(#]Z21`(<@_A%Z`QAC/.`V=H9T18>*0M"&(F5>E1+DP_D% M(4>O,:M(U3EJE[U'C2$`Y2A>#0;%`ZDY1_*'@2%94F%R-'_L/9H5WI&C]E/O M4:,+$CF&?QH(A@?B>H[B?_<>1;:](\?RY]YC297',P0OS@>"(%]QR_'5).!0 M[:15K*DJ>XKF@7:0;U)=:WA@2:\BQ-!HRBN7*JZR^/QR5C80=VTT%@P0;ZR2 MK2S_):)SZ)^N+6L;ZV7`#?STDZJ"EGS\:Q*%X#]:>[)SDGNMHJW5-)93)0^< M=_@#,C)6G.PDUI3XC>/8YWB&4BAH"3*YOLUUWE8$#C>AB]??9H5SWT/?OX4( M.&LO!GH9>PG=.([*_M_0C]SI#P#OGV?KG;TZRF?20K$L,O#1"S#]!;;`F1UD(SA/C:.0P/K`>;WLU$7&K8GW!WS;CQ10Y*0S/@ M%:>^"1+(/?36)).&!$G6$)S24C?$M:R.T5@'W)%2&(N>M6#3VVJ#6D:XX'30 M`?\C`ENLC2;6B=0X(:+3B/34@Q'<`A3L'UV2Q1+'-6\3JP$3%4X7'3@L`+[R MG&4`[#8ZA.PH>C`-L!`+[,\6\C`@?L%*1`K'+!W6F@ETU('/TRM$`;E1KR%" M\(U`QD"`UE(+Q*GQ]\`-407XL*%6>&GA?XQ&>N`4E*$-D9JEY63#).-OWDO) M^N/GYA\&`KP>QW<.\NV>Q+%48\LSV4Z7K1M8;)J1CK61MZ\7EX]F"<^YJ M7C"["MQY=L(<=_.BW)6L.\,BG>-M7N"["KQKO<\Y`1H]D+YBRRFI30B1Q+31SX(`&XWBU39CIE9\@`\W_E"%*U MY^5\QUSM7PPSF1M2A#?EV=P7I#(8LH(3H?!M"9G=3?#421APN1$ M[X98=Y%88W*J>#,RB<1_F)PYW@QKKH8DF$1N9I)@^>D5O>D)&)8YBL"VH\OU M$:`H@981#B#24W/"19S_.PT#++&3&N_UF!ST,`*#.]\/Q:%/6AL!.;MHEE"7 MH:2.=`#-KY=CNLCW&)+7F4LNK=?;G;R&%?R2!D5;%X/'1BDAIB4=5Q;OK/$@-TX;A@P=;:Z7D9I M&GI2YO%A0Y9+EMC>X)-+C$/D1&5/8U+I6M=+!R8%XR6^!N,'=$*\^/,M>?D; M[UO_&JP@2HR>45I+!144(Q\HW^T9OSJ&&7/!";H`R\2UM*PX11?`#WV.C#Y.[Z!7K%V/-WAH[<&#R$QJ,U7 MD0)=,(6):>`-!^N#U\(`GX6`S5-8."N:0-E:2!^2IQNB7%$1^Y!8+86I#GFG M#_ESC;9+[77?A^RY1IC7B7-]2)]KA+@0SN:&`M9JBI6$;IZLVX>D.2E\:\W@ M?4B5D\*8ZQ+J0UJ<%+84HTX?4C":X5@TIFA/NAC#:E1')U3=SL.)H>%L]^%$ MT`C('L.)I3FJ4U9[:(YBLE$\K28_Z2=Y#,J.N3Y4"11#K#92I0_%`L50;6HI MU%Y1<(RA6[&R_S0E1U7!J'FUB]=C*$%=8R"&)E^E1$XLS5@J_/1<1Y/UE6X- MC M/*B*S]&!+T7WW=0+`Y+AB\"OBJ')9#6:7H]DLNB[E4[9X1J.!8ZKDFJWPHWV MBQ6I,'[KPC?_SK,=!/#NTR"8Y=>^_PPQ(X;>TG%!Z9YXA@321P1W#L;[>O\- MWY5W7N;IF&)FLHNKI]6\?MS%5%IJEPSS^6$J9(\`GR#BOD#`\L$-B']*(<<8 M0D\6Z0I@.A$J>PZ*06O!SIJR.DM7RYU7*2'-0*F^GUG8U+Z[)M35 M&)Q(^>MR[=5(BL^X??W;WJV'-8,6&6A)`<\:.4IB`#/P2UX32MDH]54A85R% M!C,#[_2]J-*+6()HTOKJS#LG%6:9P!>:C,["S-)"4V62`I]%58;M210=P&S\ MZE*HY0JO%>M(&,!N_9NO)&\@@?"FF!CD\:0.8C5^S]33-)M-U<`8U M]_X!1LIF]:YBO>\LU&4L"="+D@!QQ?V_.B2TEUO?AM)0#[S[R/*:U1C'R@+T MF7(WL[E.V)_A=(E7'0'F4]8UV`@,H.#XX<&7`-A1I#>I+8G)!^:K0DU&/.'? M+83W_0'YI;MW!F[QA:8F\++Z:]D_!0C3K8#OI.B6$A?(94?1C>D"Z\GI(2:. M0OQCAA5FII5;K*])6)7?[&VVDG+CZ<:>8GH5N?XD1E!SH>PBF)DGZ52+44TL$6Y()09[_WA";$\_7PF@\1@H.IUK.4[C=QJ%! MEIMZ\N^\%22^?[*#^5J5:&\%Q[$X5<*&XXK7=]X,>AZ(!/&_.\%KD653#F>S M<098R.CXS[AW&*.AO:R*P=FPQZ"[,+/L0ZQ>UP03/N!]B.([%K'$RF08G(U[ M+$*)AD?T(='W6#1C2<5]R!`^W@&L"3K3GDQL$+%H=M4^5.P[%GUDHD?Z4/]/ M/AJ&3PU:K%0?:INII@,U]J0/1<]4$T(L^*@/Q=&Z.BI9D&0?:J9U0`2I.$3] M-=>^O_35YK%&!2U;QL>EO>1!N3G&W6X*`7]; M3B1SS7I=72-N9*Y&M+(Q`/G5#%73&\>+TJ[;44B M>WI1B%T-560\_KVHTJZ$+#(AV+THX=XX1%>DI,.EN8JL&L2[L;CE]#-7!U:V M<80CX'.JF&>AE@G$3@6XAC$1&1FN-)%AK(>CO!Y.\QOBRESC0"OLN6PYQ]Y< M2T`K[+ER?8Z]N3*H8(UGJ>H+.=[F"IF"59&DJISD>)LK1K;!^Z!F38ZPN0JY M(*\3C<_,43978N:C+"8!Y7AJDFQ-*?FE90'EHH5IS_K%&?BRE2Z/7=_LQO&) M]!@B\!1N-A;:SU=/SMJ+`D2]('$YXOWY"%UG27BK;3LQP`5R:"F$AL&R27E_ M9P>>P#)$$>O'[-$-,37BMS\VVS"(`,1\L_)&PG1#$&.$%JL9VYRB8)2Z"P(= M%,2R5X;]:@6$EON8?5<@JF^OA:#0#X@GQ=F\A,@G]QO_^65V>YWUT[*7FZ@P M5UMIJ2ZVV;IP#_!Q0SMG">AQBIAI$E4'V-,W"]G^,R2W<^%[0OP'&/P3!,2^ MA&^QWYBO!'.'N% M#$C,A>M(EO._ED2^`N/AM=:QM%^M=V<3;JCPTMMH*>*1/+^4V=^>8ALCLZ`' ML_U81:,75306Y&QPI,G\>VW0<8],L846"$L1.8=R-_U3/DIMAAQI@'Z]5)*T M2Q5V"LSD>I\W2:(H(@GHUG)09,N;^GZXB6P!_M3S0LO%]\<*.%@!BFR]E/NF M^SG-R=L7P&H>(_(EBN*Z\Z@Z9D>3Z-Q`^=Z/(MF^8?$X!H\X1YB*=J?3J2`' MSP9U8%0M(B;6L6L0:<40!#MU'X<.5E;H9FI"V?!9;T`JVCK;W>7Z#<'^-:QK0 M'HEX$#,DSP^SL"D!%C7`F*)F!!,P:IC\;%WS73*6DE%!Q1I7E\GE8-J=EP,? MD\G%7-JARG$&FER8I04#Z=ZL87)UEG:[1;4EP^0:+1JVF)#AP^12+>UV5X<. M7>0F0K.7XOU6L^%=UUQ*ZZT>!8S])=2"["%*,HQH`:I=3S92+=&DTD''`PQ=/$+OK.1 MY9+ZMO8&,P"23D'DJN3VXD9[B/7M?UBCLG`;@`4#(JW<@!UP852'0H3.(CVU M1(@L7X$=DC(;:@[H]3X_HIS8MLZG'0(MN8]`=#+7L3/W.Y)Q2H;#;A9E@)Z^ M(RZ*J,QNLJ/G.%)4)1JFGON8[%8]/LD$12/]7M3AQ@GQ`N2.)7U(FZT;;#Z3 M:,Z)S1H.R8T(\!//Z^]2..RQV?AH]#G>`9"U61M0IF`6U<'Q[[PLUF"^FH?H MGH@95\4:X%KRKM/'C9("'Z1<`F;D811(5@`N@SU'D*$]M1IR-#AE5+FV7%+^ M]^D5@.`+@N'6\=891;-*)C,KCL&HLT6W'E8O+?8TL'DZO%!7S3AEO_Z/@P5I MK'SLHSN!8]H1[*P5KSMO&^)S'MUN7+,=KX=6#+X"BUQ&<97I`S)S+?%R8VC! M\O!2YFTX1FL%:4EWA`%;;H%=I&2JP%+3>+2?QTL513RO`"+OC,12%[[GLM<& M2DSX&L.4VQ[8_JQ)DBOJ%F$`P8/MQ%T1M MIP/TP8RLDFIUK,ODI((N=Y'$T[F:$@^$S24R:L<`K$.RZ,IJ,N:'&;:F!$NF ME@T]U&2WEM-)J7M`3&?2?BAD+D<9-9!*$YHFK-^%*+8C^%IB$5VU>H?^'3(T M;V']CN]"X<+9SU:S#'-TY@>39> M08966-M-13E=3#^2D$[RW1Z1LZ29=`[;*)@XES@+>@NSF"*O]>B)&+RE^GJ? M+OL^.A1BZ%#ZC/;V5AB4#E]TT=IS4K4A1`A?$->6[_C?//CB8]9$)/`(_/1= M+B>Z?JNK(F:C[VS>D9H*YVV5AC!Z@PS#4DT52^J4+!>X0(>N0&)5U^,T_EY\ M@B8ZXJ@+^TB4A6FD+#`%R<,VHP?03`]@SVBDB?F-?M)CVF%8RF#V*OSA#:2_ M&)%8$/IW9%DVR=)N1/BV_!9AJ^-42G2GZ9A$.['=9`CIS-AX$DZ>KK7E]`[G M&B9[%4/1L5M,4W``M9BMF)J9+C%/`QQ@2)(<@<2=%OE6,+,4F3S.$J$QYN65 MRI\#BO-'>PZH4*6I>A-.CZ-]Q!$<7GQ/`]R-C>CI=J%I8F2"\@\F",-<16*, M63$QIL<,E6",ZCE:5(]8W+.^J)X9W&R<(([E\>P9C`I*`D_1H^%4'\(U%@"7 MK_,5F8P\QQY&A7H3**+JO5YCH6Y*P`M1?):!?0L._"O4)GV.3Z,2(8JRO\5H M,KVLU1:J)IUS/+N5!JJF?,8-:B8M-NF_:UW-?4=L)Z5C>+U_(._7@)@_QA_3 M$&@P@'[\$M"X]SFO1^\QT.3][OI-<^JU\`""1P173K``6,XEI?*O M`99%2=)E@)R7,/H*HJI<2+E&6@^I`BT8`/_1VA-./EVO$;Y$`O"(''SXMI:[ M`-ODH93DS8%#'*3ZJPCW`6B)![36^$HXG#">9P%L$+\51(L%DAM`,R M0@V`!\V_JX"I\97X(T*HZ3)/'D7DLJ!RFUY`J8N::4[X=>AC#?6H MN7T47#B),OOY?>N@R&)S0W^'GMY.K]&ZUH)2ZSPUQR8I]DBU(H3-,"O7FV$% M3#2IX[2JC&I_E$O(UR1H\.FYZU0"2\&[LA]NTP9XRRCI_7"G-B`"YYK3[D_M M"N?#-[=^U(8C-9Y+Q@R<1;/4T6&@H5U-:,571$V/<=Z81`*.?:$S"O3%X"#@@2L9'$JN:),?Q6Z*8#&F0/N;UH+G^,`S M<:!G'<;=&7TL11'JRRFCN#Z*&%5WNJ%9I-CIW&IW5(:M$K=#&\/GG5'DMP1A?E&R-B]6+P^1UK<(X/ MHFRT[$L_^59J:>J&,@;GAY!9M74"RXT>'O/)ZYYH!^Q;B&Y#(B[>^7Y(ZCNS<)<>9YCAN#HB8]]@35QL MUJ#_4;%4,N2/Z#%>S2,';1WS^GW>Y#&QP$1&9]?R'JP-+;:IBQG,0IIZ1+J9 MXWM%7%?T45/H,[85W>+3,'C%HNUO!]&1W(>;.!&/(D2+NAH->0:#6'E#XG7GE M.I3FTR7N0'PTB:J47=)'HIKNU>A4$7Z:&)$O=H;0"JILA#H>R*&AM0SY.E!+`3SY,Q/$%*`-=.-!;9S"F-KRC& M9>6\=521#DL[1/(Q)F`C#9>9+O'B^?'>(;\BP"];4M]/A\V_,VPT>7QH<+&# M:5BMC0G*&`-1C`]$8=:/2S36B-Y$,04DM2NZJ2E.@)H.FF-C8ITAAJD^`J;4 M6@4Q$E=%0"_&*H/`*C%$:ZH>7'\%':]I#F#5QJ!OP$N3UE- M2!YXH9;=E>RL'Z]$2R`F1-:]Q.F@X$JOC![1A1%[QFS:$1C,H"A.8W-`45.3 MMSR^_Y5D3)%[$^_DK]`+7J>>_4]@T5BP:$\]9V`%$&8$L7X)9M`/_"\(^NPC MP&H_N.#=REM+!&,W.?,49B320\<"5V!Z1&F6,8>A\ONH"5+V\;!P"8#MDW(' MJ9.*Y)=F,C,^%ZD>0H]CEAQ#`>`E_I499Z[W"W(L`)ZPFDF$.8 M@N,"D*U#[H$66'(&,05/6II"?7L]KQ!X:V+<(.HK"^!B$]TPYLSC&FO3>.UO MG7=@%Z5N`2P$!E%;;'X'T+WS`MD/MK#;]J3,/'UB"<7M`=`>-9`=00'0"["# M[@YOBN)!9=*-UUI%7@_P'(@BUQVP*W<&WLSWT/+87B&)SGJR[B`*F$H+ M'.T&`RE8FI2$3/)7&JB8\A5C,%UA/-B35IN8D\_5'`!B..4EV)>_5S0A_^&I M:@M5DW)R^LO?ZTNK$HZ<$2F)=&EV2:2:J)IB?)X`6;3')(HE0:I$VHQ\'L$7 M)I@6J5(<)M7Y;A*.O/S6QBB:L9`"29^*UG_WJW-U6R/INF'5,S?G^)9$?ORTZFK4K)*Q&C)YE=F MINQ)(D:MDGME9I:>.&J'NE>.FZ[\NOJ;4]J5G:++]>;JOV)J[](N$._#[2K@ MA:<4ZZ_:)_.K5E?RV_=5_D+4,UXJP%[KUS,):UX=>H5(FWY$99VR&?>I&!OS M`VI>BFY3'+F&]YS9:BK('AUOUHCF92IY)D\M:*-T)[#``DRM> M*"4!)<+-Y%H6TKAW$'AF<@F+X]&'%Z=F'%V-C]V+ M+HC0Q)FNO7I8%X00SC+L0P7+EMBSL_CTU[=4S"^$$[=Z\6Y7NV4O)SGJ?\BK M`X1K$IYRG`48#T``S'R=RBJ970Q(Z&M9S^QB0*(?/_$^1WD`@IY( M(;>+0XD%)"2Z*D3O7GQ5/U%;-2D7GU^)V_"XU5])2=Y MOB(G^X!U5[*L^'W&BAW]S*>]WJ>FTNF+'[VP(``UI9-N/!*`'/(V1F(*].W&Z@7644"N*K3CP?J!]QM4AC4>RG"<8[>O32RC MMYC_62ZE3IVR8;6D"V=UX6FD"5;'Y?3' M0@PMQEG`9"0D>;!6L=D-V(O(P2[I4N"&O0@A/`(M8HFH%T&%W5,CEHI[$4'8 MBA@&Q``*&VHDA!UEUN5CFVD>8`#\9Y@\>F.Y3X$5@'B+HK7E.;]%+LX9]'SH M.G;\]H]G/R+@D]@V\B>YZ`\ZY]:?9PS@-99(_ST4@\^P3"7*5YDN_2N?1HOR MDT)49Z6C--0*+UQV*B5[CY3TR,K*#%AE%".(^FM(N\8A+F90C^D` M)8HG9^TY*V=I>4&2'$*"H?%2+[%L/,H)1LL)@FO'X#%BG4>>/O+TD:+ M7ADCI^XIITX_T/(.+LDI(U:T7#;$HF(K+M5J2!V\8&;Y)*6*_"!/.>\LEZQ= M!-N^#EFQOKK>BA/#@=92Q?-CF3HQ7Q56?Q;Z`=P`5$/@)B-HB3ZR$,E/]M.0 M;S&2U_7J\]-DBEX!@PC@)9^%B`0H[DN/B'MV]*<;W2V"![7Y>#JPO_,PFP'/ MUKL8[&&7M24IX@8\@S(Y#;QESW?J+1:Z_C@VP`#O@A0`#"M>QU"*V M$^K[Z:F.C^\X4NC"GL'-%HN&L1%JF\@&>/MBNCL[\.A:Z?ECJ60-1AKUX8[U MX2/"^@M[=3K;1K\\KH4#VR?8C;$<.LA8S: MAW`=,2((:L]]",D10YBJ6&N/QFF-7B.577_$>@">`=LX2T-G,U(U@B:*0$G;[6U0RQ8%V5!FG-@RBL_E&2]$8.3%: M8`9C@>GP8M)NGAD%B:H@D965S+78X45#MG"HS\2VODPOWBPJ,6;S`7RX3E&RSQ[BQB_[UWK)?D6>%ID*ULM(KB2KKD<",' M'SGXR,$'P\&;7RLC.N9,2QTX0_4I<_C"RU0./6.J55BIH$/O+TD:=W$O(E>8XDK7KA"ND%KODU/X):8 MK7P=RO8>->A1R!@UZ)$-#YX-2U^K(Q/N,Q,>_=T&P!D#T\` M``3N`P`4`!P`<&EP+3(P,3(P.3,P7VQA8BYX;6Q55`D``U:-F5!6C9E0=7@+ M``$$)0X```0Y`0``W%U;;^,XEGX?8/X#-[O`=@-Q8LG7U'3UP*E*-0*DVH4D MW=.[A45!ENB8.[+D)>54/+]^>$C)NE@7RI9$SSYTQV63Y\;S'1[>?_KKV]I% MKY@RXGOO+XRK_@7"GNT[Q'MY?_';4V_V].'^_N*O/__Y3S_]6Z^'[C[^,GM$ M<\\E'D;WO<\XH.0-_6%C%U,KP.C9>O,]?[U##]8"NPP]$._O"XOA2P3_=Y#O MH3]N'Q^0>64@M`J"S;OKZ^_?OU]AY\6B/5_0O;+]]37J]2*>OTOIWJ'QE=GG M]>)?'OVMY_#O$U]]H-@*>&GD<''>(;-OF#W#Z/7'S\;DG3E^-S#^.UG:W^PH M>5D%Z`?[1UZX/^KQ&D9*S4MT[]E7:.:ZZ!&*,O2(&::OV+D**;FADHC;TF/O M+Q)ZO2VH>^73EVM.>W`=%;SX\Y^0+/SNC9%4A>^#J+AQ_[&LC23B@A-&I"ZNI7CB2_#+E(#X M+<">`Y3EMU"_Q%"2/-A8$`6ROITBZ(*U?9JKLJ"UM-A"$(Q$!E^]QFZP5Z(G MO+=O1,J'7W^;V39W_(!]L7;6PL4?MI1B+X@X"?W>7U04OM[+#<53DE/,_"VU M<2U3`)5:$GQS%U!A[?+B$&NPU_OMZ0(1Y_T%<;X-S>G4&'T;]<>&:7XSOAD7 M/T=D4$@'A81^DLR;U2?@,0<_M*J4F5)J(^GD*3.C:<^RJ!T)Q3]6:!.6N+9] M'CXV02_54$OJKRL])>+M*RE_70L/&R*=O'\SZ`L7YU\`=;K%SMW;!GL,LYGG MS(,5IB&7!V(MB$L"@EFF:>K5;1@`CF]OUYR%B+"G"*;F0F;?O!E^&X`+?;`H MW?'N&KU:[A8CBR%_B3AMWN.ZT&<@ML(X$/TA_.(O7/(BI&2(>#;P=Y#E.9$' M7J(-IH%%/"`9^,CV&7?/8&4%R**<&-=PR]MQQRLCCW^FO`;\L*?%^U[N;`&U M[&!KN4E^E\BGR+*YH;:ND(;G'2@@:RSX+_F/WU?$7G%2KSZQ,4,KZQ4CSP_0 MCBNPP-A#%-N8O`(77ICP+AE^76#^/0_>%+KDNS<+NAJAG+MU,`JL-\Q9$X]C M&K/@$LH&@N,V"&U^A7Z#Y(1KR[W2Q78@[&?+MD$;GXJ,(C2K&[<5^L'A%O]. M@A4WAL\SHAVVJ!1-?`7%/9^NP0P;2)#`IO;.YL&++)'K>R^8_@BI!?,C<9FH M9+V\4-%K(3MJ76L-D+LL;=_+__\-+"AQ+9.M`$48WEB0@;H[Y!!FNSXT:-@$ M*4-I;NM[#UF.0X#)9:;-10,#9PH]QZXLF MMBAAP,K94M&@"64H%NKP;[E`Q.?@^)BE3#B!O9:[\N!!,32J,)VU)["AOK.U MA8-R@5Z!2-S.4:&5Q0Y:.53H"OV"/6XNU]UQ-_/0G1<`#2A`'79HBN\K7IT$ MD9\P<$5&'&%PWF[0HW'I["T+_#5WO@7FTG#;VBN"7T6+2-]'-B4\'A!+.OZ: MEP$YFZYQFVG9T>E1)"MU3=8O>2ML<%, MV%V$HOGK#<4(02Z`O,SYW\Y>B'W^A4' M\^6S]5:+19Q[[X.U(8'E!XZ]0"B6 M"'V-9/H?73%$KWG-K'G%K$=D7H^;%_(*^!8^VV#;;3AO$L]A6'L1WND-4^VA M.AW86FHS+:'0%<2Q\[2R*+Z%)5A(I7@>);*D<%A8Y+UJE;L,5TH2J2'$,#A( MP@`4D46"+A*$49)R-"&B*8PTKK8(#,\^9%H,:/;DZKR=5!D7J]P9YFNY;PK% MZB8['I<,VU&%;@%.G*^@EO[#"XA#W"WOT/`3MK=4=&MW M;V+9POG$50%4;>6JYWQY9U%856)?,!6XFXDEC:*HU@CM+GN?)@16C-+F^.8F M1%J"*XK9HH@O`L8HP1DFTR+>B#,/.S7)7E,'UK7ES,ARO;WI6&PZ')E.K!;9 M"=/Y2X0CT_%T3G:.6GO`)@&8ZB`;:Q(M<8DQ'&3W?V1^[#(R"(Z*([/)>!!! M6U1K!Y*0VY5"LK;(XSAGM`H%[PP7*0=(.7:LF#[/K)HV2A?JW%-KS24,;Z;# M\33IL?KG58[60G8,3T]WST_ZW;=T&N)017WN7+'#-%6FNM?72&/1OTK[< MZBY2M2A\A`:)8!SM]CF7H%RV;_1`7>T^K12ILV5U^7B].6!C,#*,/%\_D_A] M@E(BC'](.;[>R>DRERI$@/;H?FLQPN;++[R1HZW+,\]Y(B\>61+;XA+*C=X\ M\__BN\3F(X1G_!;1[!!7I\BIN@1C&F,)/\$,QN5)=F)O78(ABCFB MB"7Z"DR1X*H)JUT9RHP-Y:<-I1/832`DB?^3K:DE3!#7A?ESN>?[4>R\A9WD M10/PXO)=`KQ("%6G'`_#N6Y)"46D4(*6)D@VH5KZ^!'=$T$_+`3Y'[7"KLKC M4I@J-4<#!Y)N*;;LU7SY(3[U`/MMJAT?1U*52\FC MQOW!9'(C3R-)PA#"DV=$[#UM9`'Q\$`"ZB%ONUY@"N7A/`5#2]]U_>_0!Q*/ M!"2LBZD-'YGEBC-,3\\]K=;[EO0V\1 M>Y[N?YFA1:Z[Q$>*TNY2Z1RZ]N?7C1#1]OQ:QM72]6\9\3!C,_O_MH2)'7_B M(\7XH[^V2#:VJ-?K,A6H$D:QWQQ,C2@E""FB!$D4T41?)55="7N3VII%VEZJ MJ=M9PJ#JIZG$04U@PQ+H+J%NG19%("K*]`ZHS05%.Q0@R5 M**83-PE'JT)+9`D=&($]F'SL#'_NN$2OO/OG(YE9$)V'_QV.PQ>TJEK=#O&C M))#B#&F_/PXW-HK=TC#-)#XD"*-9@/;W!@C:K:!+IFUWGE.&L,95'^Y5AS.< M8E>3;'%\$;IUHEKITE=C^L41P"6U&)LO_\9'Q)87S*FXI;EL#%I8OLONM4@( MQ9[E9A"M'PM*L'PBIM;HYGHS[E?C1NH[;D(Y5&#J#Q5L%-ZS$D>8%VUR9[MY@:PK# M7RBQ\?Y'%OY:JWNJ(J4;>Q7RJ>[M'P\K.[6($Q*L$D78OHRF;9EM&T8B65Z, MQN"&+5C,L>"BCM`B&^#1BNZOF"Y\O=H;0OW(':IUUAJ\%)%?&=54['Y7 ML95SOHR/DW^P8&?N[>Z4R%>#JNX@J"ZJZJ+F<&Q4Q4/)%'Y*7`XA^<+]:&<= M'-LQ6#)0,$08V\I+RS=C>5"FZ^GPK`!J_C&ZF0XFX12XI""O!I:#@&XGO4_1 MP.A2@_*Y[5/4,)-JR*&(R,,O]5Z:5(J"_1QVKN)-X"\^N.&)TVB<"_;$"4XX MC9;7!A4UNL9FN3AJ#C(=3Z;A4;#D$29/GI_<4T1?!D2ZS(=K2:9ZSY\Y M&&=AR'(\-.9P#GM+6K.$F;6$E;6$UKSY*`=/9='U+==HGW[`]8%X^#[`Z[Q7 M*)6J:>O=BV52<[CA:#(89+OX'(=#7Q_$*]%`65='WXRN"F&F=5T5^_QF%*Z. M)I4*=]O]5\/S,`>H,)6N1"!\/B5\4$7?T*8"G"<31K>A"Y6K?**RI![I%XJ@FK5,C#ZR< M*DQN2[KR9&I\A[EV>#:A\P$@+]&&*_U:=`A7`R2K?+0`A*76:2@9CUC!Q-V] M6-DK`)!"!0T)>+$TBM,R_,,P3KUCV(B],))BRW@IR[F;42\G*G2G7F6:W8R. MYH&.X3JUMOTLZ@A+9M(5UM#$&E/+97=H@TT6'$@*-9-6Q!((Z@T`"1,<1;@ M5]A\559%9Q@X8B.2,>H7QP+]VZT:TK`8.WZYBMH`5+7+JLHPFJ%4>AM9MI@> MR-2Y;LDA?(G`F4>HCML-O M#?$M_S^GL\'POC!V=V<"S^*KJ_):1!,,-Q2OL,>XW>0SSK_B8+Y\MMZ*G:FP M1K?@+!)#]0**P21>OHQI1<^JPPOK\R7B]#3=C].,@N-#!>%A<\T`J?*Y#%9* M#:$'-O)2:O:(7[%7TGMEBG4*D#1O9:?A?T)4A`102$%7YW6\'J+S*I&^.X_/ M=Y>TF^?HJ<>W&4?7(R;KQ98RV/R7>4S\H(&*RG?J[05"*.8Z0_-FOW.5B<"? MI*7WC?M&=#/WNM&0D#SYY2^7#`=BY9L[M+R'R>$>Z/H;L:\U?.I>.DGMTCGZVEI_JH/4(PF^\UKG(!\8`+>@N8DNGU1 MY!0%C%B!D`("$CJ6Q(Y70CY!%(IO7`\07-_G>R(860%W5`_O_I.)EA&0!9AR MA;^30-RD#M]?HHV[Y4,KCPN)69#;@-VLG.7C)5XKRS%3$SBEV"'!)\LFKCC. M^5D,&//:*;]@UYC-E4(MQ'.UIZ,0N8(,BNF@KY)2Q]M,3];&T*!-.9Q/5LG, M54D;+DOQL4=GL=9:DM.D.+NRF\P."W:9CAYP5QRV&*.)F>?Z.[TWEIVD3H[; MEZG36599Z$JI=#)?=?V^7WX765Y1;?Y?ZV:NX30_^.]TWSEVHDKY*#B'*\9* MW*H8"8U<*L:P??7BOUX[F$@8\`]9[^=??0L?A?Y$F&VY_\4'JG>>\]$*LC,2 MI44[\/XR_HJ/"TRF@RC^AT]X2TH(2*$[6/G@Q+I%0%-JF<>HU38*5-P+4%!I MA`9&+!_Q`D[?PC6RP>Z96AZS;!@M5!]TK5N[X[%-#=$4[PZ>CD:F'/`\KS#B MK`G%R(G/LXH+C!C<<>39T&IRKFL1\)@%%SR*]4;D<+$N40`$EDL,,]V\&F\> MXEF>3;P7/H1>XV#EBP>1K+5/`_(/6)9T\!(+FON2(3.Q?DG)"__:C7APF>`= MX4OY[@!<>"*>LP;U!3\0`OF>$&-AN7`8`[$5QL$5NO>0Y3CAFX*Y.KY0GTFV M'@[0AOHVQ@X?_G/7%@1)>+PC>Z&3J`(%EF*"GY.C7$BQYIJLUNVD3TM>(J(I MT!9'$R5UE"!_'L>@6S2`B+N?]JZ:(*QM['E$I(L&I'6-I"-3!QGO/190$17% MP_9/&XHM9^[];E$"LWB/A^E+W=H=YO.*(JF^H#0>3A.PC`DC01E)TFCNH8@X M>NP\ZVE1]1"0;W"F`3H5'H-X?(;`^QKI2S6E0T=Z<'*<4,=@^L$9/18W6T,O MK>0#F2K:8)B60]4!^_UA/O;VCUY*>N>`MN,UE!"S2+A##=9,*%EL`P$NG@H" MV+[+:^?.!V;YOEB,K1SSZ`?4?;C>!!C_N*5:A84::8'37E.5XR@`VLT-*^6X"`0F;-T6%I4PXQ9GARJ!ZD- M,[P3]L#]Y2.@+:XFEDWOG*I2/J);5ZERUN94O M^57`]?[=1%A6^^Q[`3RE"BMME>U47%,KX@O%4GTCTYR.<^&?>`,42"-!6RSK M`'6-P:`1C?,B0[[&LS8UKA$G&E$[D])#:Z;'R)?QVZB.IAGB(T";'TW*+:9K ML*SV)'E>R8Z'QT>]NFWTS6$_@:ZS>5G\1(VB@U[AQ-)#")IPNQ7@2*#J@:-* M]\!8X0GQ(F/HP83D],*GHBGEX M*K.)3E25'[3/EM*`FEK'TPW3.$")UE/V)VB1A@#5?]J^P&7RO%WW6?N/>$.Q M3<1<`A_]S.0>T[RI!94:G7I]H1B*>^$RW9R()0)$."7^'=#66E.U_X*11%\7VIFW&_'RWV[*-0,MYHN`;#Z:04.C%%72.EQM3,@HC$7<]Y=+*EGIC?CQ8;I8FN[+$BC=S#4:?1F@V:TUR1Y!<4)0;,^.7U!L[:L:CYO&OWA8=#LH?SK/O@/ M9QLW6S700=S,-\]YA\U6+90-FTV[4,>1\^A(DQ,YC[-[LY%SZ[J[4ZL M.E+WCJ.2$HIS(E"UY1J--O/E$WGQQ#5U7O!ARP)_S9NX_&3$,12TQ1XE\52O MZY_<'(8@?XD2'-">1<<7ZK6G<#;XS`L4UG_"I&5#B%B4KSKLA)K9XO9'>$/) MQN05KA_2'X=JX?LP'*G;L-&H)-ZNO+48=N!%,,Q3,\ZO,GE;:7'3W75I:4OAM435-&%^T;.)%>2572M[[G. M;K5HEH,(=S9F48UU[=GF(.HU99N.X]]QD20G$AYAZF9CXG:]MNANOORPXHV' MV;VW7Y>8+^=;^@`O#PX2FV;4HN/15/7%R6-%5I\G.=RJTD,A6W$V7C)&Q$LN MD?$?.'I.F]B#:A^LJ:ED5Z7/K#G]L)=BTX[.*))'DI/R_/K#BRA1%BE1-T+IAUY=599``,(' M@B0(Y!J[+VCL`4QCIO[5AMK*6W+#F9IEY]O592G<<*N->N!BN<]S@UV-2%VU%C M*6P>6(U`#KV[RZMP[1V_5!]./O5SXO]NL/M$N$C.ACZ\R>NV770#WLQ3<(4' M3HDBB3KBY$?A7`>2?3HBV:O=XD`*F;]JJL+A6SP*5GAS/5YI M]#/YM\LZ8]7/6FKRJ&7`M!WB:K&X`%S:#S&M$,N(V>_RV(M<3ANY;+1YK#4Q MT>>Q6@VVL4!+8IHA(7\2!`?9\,9-02>.&@6L*^@H,-!*)B4"JF6R;_\ELU); M?U$!]FQ?FHF^>`&^3W"I94GMXY91H.+!V'%F-^2%V12B#4H/,8*6`ZX^Y7-: MRV<3'56&=PD1K4;LX>11%(;1],-6/V<9&87!C3WI]')1D@81<%VP.\OC-)7' MIN4K3>G2Y,NBV[/U)T*VXJNPGRU;-AW3W``NPQWZ-IP5-^7=,>+=IL7*!G%I MJ)ET$-5+/KD1K1$5$[2(["-O>TU`X_FG!.MZ(=:]9;%Z20TKAC4"G87HV23H M49^7)Y]Y6W:S/24*4\"D1TD90+A8=-MHQRFPUNP^[=-^)++'=`S(XM0)2UZX`PVVSF6I2!Y]\/(.L%SE(S1%\)SKY0G&72CPEG M!GT?3%0$@K/]'F^3A_VG'UN6L$"[FSX$MVY,.[;0_]%]#@"AI7M6%_D$:!`B<`ZG!R=40TX0?+/1` MFP''M!OPEA`'A6D+VRY@MJGF0`#\>O3#,\;?"^I6<#;&9P/O3 MP&T8CD"CCEZCOSR7-'HEJS1LKU)K#FL8+!=\V@#?[N.ZO6_X&$8)E4;9;W;@ MP3Z<$[R4P'`!/=_,9L/X0LX0[PD'TU5V/`H>Q#5>&:OX8_E('?#[=Y7*3SI: MC_DU#-YP3%;N-8?@D$Y8`[^'XB=9H4F1-%'^WE&92&-0XU\X1NXKIV^@/]CY` MZF!K_AU3_FVDFRA-0^2;E$6T9*OG6QPD$;U"ML,__H;/.O67GK-INY>#&^<; M.0O)AL\H)8,8'40(`=ER%WF&LEH$ MCX%M7B"I3D>V8*4\T2C];!4J#3:UJ:5LBJ"`V>#OPKUCR+T]>R[O=BOELV6C MGST?1[=DP78((WV04WS*JL46AC;^]+-IP7`9$22H0)EO:U&<1J+8LV6E\11- MNBRS+O60=)%_=5^V:\_(QJ[9='-O8(J:S@G'G5!`E`V7=[85QF@EC MS[[5)E0T<(78()OF/V@)E),7O]#K&0_[._R]9J!P)76>VXM"']]Q>,D]^B M\'0DS&9]W+\G9(:C;-^Z1[JM6IO-V9FL171VY=4PNW`ZF:8`ELH8ID,B-B82 M@Z)L5)0-B\2X(P"Z38TY18U=:51VU4UGMKQ&7W"3'4LO7P/6]YQ5K*O.4AJ] M"N)#]/P86KVSG"W*?N*LV#N=Y^U8"MT1HP*+,__K>' M(Z*7ES.K+7O]PZN?]BM?A@%F!4>&-CJ9SAT5-*6_9;33TL1_4/+PZ.Q)]A(^ MC6?J7"7$42, MXEC`UDU.AC%SR0#0I3="#:@T"@'%4EYU-ZZ[\U_]#@265(R8IB(OQ7U_"4L2 MO1%<]N]-S(OIJM#"?118JC)")9:T&NFAY',VR'UP/"4Q73GZC^Z9:NM;N3R8 MR1N6"SO7L&/:F'&Q7/):SNRZO9N@]Q=O^X+\T`UB%$;(97]$]-+-/O2]$-'\ M73GU\^B>Z>7T/1T?'2./K+^/Y$_//-:/K]"))I>ZM,*IA$?B M:;S3*U2)9T,XBZK.)IH!G;`Y7[R[R=_QZS..ZJ8/Q1L0DW69#=.SD-FR/%6G M8!*-;_[@%*%GZFXREI:5G-R5D'(4<[7>_I0SM48C(X#08X2/VFG=[!TX&!49 M,32RY5*T=RD#*2<(,"7U+J1B4CKF`@+.2(ULL0)0"M6`0DKJLY6N+G8/P3>\ M/44D[CO0,F/Q[T'X'..(M>]F0M#[*20F]#T6R%XNCROK1`P_+@2TAQ+&M+C! MYHYQ@BM;>RMAB)2AC)#/&?0HJLJ;>_=S!<:T8#P:R:,&6)E.IV5%]8R??4AU$@<3=^**"T8 MY`&NFJO"NA=I8O9*CV"LT3XW!N5!2RDIJET6]0M0VX)*;@R//]>;>=H268>_ MP=.R:G?N.LM7Z5_@TL[Z%;+J4``\3\P<;J5].[UBAG(!J@2MFH?'`/T&64GS MZ68QJ8']@/E7C1#?6*QJM$.DE?4G6S7(X5+'S+!4B6W@]#"13WH?Q$G$P%>5 MA:)YVF8PKF;!,-IGDV2Q6%E\>;3P]+*QHR-%KB!,'Q7178!10WTF=$'[A-[(FIRU&'H+OKH\? M]H]1>,11`D0ITQN. M@C9BQ%%&O1N2F<"G[+M)(O\:X(.K[[75O^CK3/1PSTK%[;SX&,9D5F9'>*GT MM&$-KI+=%I*;F;(,VP:J`\$H#G#D^L2#7.]>O8!=?4Z\-_R)5__3V4/-6S91 M6@9^YB1@)!?2J8N;)`X!B&NW?/UWYI M\;--4*5CFMZ6F8CR7>)%(%"T8-NI8]N:=5^80<&`9<%Z.$3X+2)Q'XGWMACO MXL^$C?LX/M&4^(>]5-..X.4?;D0+SJB.%IO3L'SDT)A!,W?I+#<3AY]$L!'H MFH`-@>CW1%XZ"%TM;'F]PYB5=J0^]3T=R>Z%@D$5,;1&OC@)::>_?GS6Z?B9&(,R/E4]8=_?R,.; MV%BH>@$!=-KKY]U[*H'L(!E[/ M56*N%?=3B]S7(ZZ5"&EQN:,7\?1L8GH+4&R5K+P`K:*,?2'KB3Q0@RWY$0AT M2>.;?]XUQ]<][?[A^NC5_>&]GEX1S89,<,!B(>%7PV??.W`3X'M^.]8Q1'I+ M>@*G#CIY(2[:\\_(W1/S1%XV3HF^]6"[M<8D3#,*T*AN*88C?_B_IY_P[]*' M^9Q^^(?LLX+"7@'!`O`OU=`;]-_#&N!G#X#`7HQN_NU7\J1*W@><5%MQ/[7( MO0'\VHB@F%17L.BZM/(BM@HR0FR_W@?;\!73@U"ZFKT-2<@?G+S@\'#$7(7Q M#=Z'$>;//;D_*>^;J/D;AFQ=3YT7^2B([IMF$ ML@2Y/P_@)^0C`-L?$,X59_5QKY_I0=U6EX>E>]JZBRNQ8(B`C3.?%-Q17B[Y M#T$*Z'BY!\&<%H+9Q;+6T,JX4VL"#B,$W^GA]0T.\-ZKQDCY:>L8*;%@FDJ[ MG*T+&"&$LA2,E!0D1#K)Q6N$-)KMS.5JG5+9@V#KYH+9A;X6/V7HJQ4!"GVS MRPK:QR'`WRJ1?K)>;#8E](_F&D$?PCE%X4:"#8.D_TKA@=`183?&=YC__SZX MWF[#$XEG']US10.#^O?LXJ6:&H,E#)N.#U#6^Q]]8*8=*KHP!9SH]QDZS9R@1G.6&XH*Y7 MF=<%N$65XL$CKFRB9J"[T,UH=\$ZJ1'4=[!Z2%QRE>T'!0?JMB3TT(0N- MUP:\FJ;!KYT:+-,Q"^7HZ,XO&Q9EX\J_CVA:'4A=8M9EFL%\F12S4_R0J<6O M5@:H9V@!HEJOT53-X_`H&7NW[M%+7+]^X]64`*B7T'%E.,_-)NNJ&#I'?$I^ M#)NV`VB`0?SVA3Q'D$UOQ69RNW&,$XYV">?_-2Z@U]EV-:0K%3@.\+(ZO-[N M#N]Q%.%=NES/A]N-"%] MW[I)MW&Y&A2S^Y95?$A21S`NW#>!1;4/,-;J./S![P'QQ#[>Y6L7<_BKW@5% MNX(AT[9#\\FZ`MR"L+0R'P^..TK-8)L)Z(Y]D5YAL-7`U*FIA_S,-'OU#D>$ M,+TJG!6`4R3K53QL.6]3SXEI/YVE,R\F;F_=*#K3:(]U0J+WUW89=1(.BC)? M,;OB1LQM=V(EV6GA%.(WPXA%BB2*\L*=W43L?G0QE761TY(*&]M/#NU',H>G M7KT7-C0\EC`ZA4H8K8>=2!ZMT0',5,S3K*H+U%P^975Z+0QMN,\S7R\6`@9I MPF,OY68ZS)>MQ5@7Q,#P)2TT-E.<]\KB0IKW(XF%:[X,>P3`L.FXIDW.I]/U MA573MZ$V;MKQS[=FW/@%L14:3[/AI,9@U+*EJ"PZ$[>7@(W3I+V(\M:<-^=O M=-6&".<=;91(@B)"W'W%?&HC<"ZNV!%K/`T=MCHNMJ^BI%V MA?SMP1'C[5\/X=NO.^QQ7)`_7,*!_-/_?B'K>/]3D'C)61%ZJYZP8/2*80WS M3%>K67I?B[V/.`&00+&C$$X#(8:VZPI#H::LDQ3"M=>GU0%ER#7.WIHL)TX: MY`R>KU9W-;DE\^SJ\!,E/I8LLYJ$L3'D?A5STUBIOI?0WQ$WP^\"UW\B]6LP MMJ[DQ?3VS4JT.;A,Z)1)IM?XP8'165(U6E@N1RP1_@MK:J`6&`!&E3:JP99> M56,$7$VJI?'K(P)@PR3#Z4(31V?WUS_^7^Z?[3=W3]]0Y] M?WJX_=M_/WRY^_3M^U_0I__Y_?[IGV-&955>92.E`:.4=S$RP*-X$`9YZ>BF MC6VR+I,RQE(:X)-;"UFDZ4PD(8XO"+PP)0TB9.G'8?OF<]+E"Z!8:.9ZIY.I MJ"RAP,28YID.XO$#XC)`0'/TZPVN&BDCF"T"6NT\PCLO^>QN*7?GZU>:9/EP M2N*$Q-1><-!^5Y-WK>+(@"'3_=+Y-(-4P`O_,[I($$:<,I)(0\&K9ZF=3.JP M)/65H=CV`-C`?HM8--7::&"I[XBL?1P:?.:M@U=341Y%AS?(MLA]")=N5`=D MK8"^NJ^0B0FF9E8+F![3#U3T;$H"M$$&_<&#]B\E6#Q#V0QS[YWL%[]O$- M2YJOK=[0/WW+*0Z],F_:\GXVG?&D",U<@#(.$&4!Y3S0AP47B+/1?_V(ALD4 M8"JL=&IZ%3[`J;`R;0-,C[S"7,'&WKWD91>Y[V3IS%H31?@M]-^H-OW0#="_ M3Z[O[3VB.7ZY!BH+9!#7)O)&^O\>4,Y?7,BRBVL_!1_0N=>[ND[NO>:KC&5%RQ=#RA1CX]>` M5[@R+Z9[+*M-C?=(%XDPJ;E#2%N]HV0@+N2"6&6E=0OCDJ)&`SGR;_<)?FVR MDY2_`PTVP8CI/*-+0&)(!QI^/+=/=S-:F9\$1CM3QL%D.,!Y1]**&`T2U7PCZ; M!T6'P.=,"]L*+4!"ML[6ZQ!!8?MDOK="ZX343+Q_ M,'(C"GT;BU<=]NK%@T38T^5&CYE&>MF7__?)V]&3VRBB55!9N2MMX]:JIZWO MEVM9,>PH.E^MUV+O.Z6%9&(P_5U[DFL*)5?-CG(OPCD%X>#V>6NAD^_95LL- M,@&&P>$)1Z]W^%F;#"L_8G.:D\8U[! M%T8HQML3+PC2,*GM/^53$A(JX MT\SU$!"INAJET0,T&%*$>CC^AH^IQWG89U[H/O@G=J//Q"X,OJ\Y+2!`&3-H M6JYR/5\J(9&@.HAD&7F*#B['@L[&QZQ#<3%T? M`N-/9'3M%F@[8F-&.>/0-#J;944U6L._A1(-Y,+P+@LX\%\-S.N\$[5=;(PMA_]N*MZU/>NQN,FNPX0:_DU70F6V2G)XT=0#8N_6<^,O,(H_<&G14F M/(/S03Q#)4A:>@F]$J$]QE>B.^/=+NEA('3G')CN$2W6Z@5X3@D>@NVD\"H*Y_<%>]>Q'0B7"KDQ$A`&9T@;UJ"KK!0)&Z=49 M9J%-F6BAL1OGD#M@XS MLXH`/)X57!FWU%NM#'"<#3#6F;FC!O0S\T^GF.V3_DS^$SH8-:8K3-P`RSH] MCAO#[>;H*D*CQ'3C9C9KDZA;A>VQSM$]*<7)FZ-^1#RWF*/K%#1V MF:-5!.#QK.#*=(::&,W1V0!CG:,[:J`X1Z?3,@HSJ4>-X@JC-D"O3G/C1FV[ M6;F*T"A1W'`"6BPVBY9H'NNLW)-2V*S\\&'QW&)6KE,<$+YY[13B7K?L"J1<] M*&;07DA:+G[4E5\C:UM.9HOEAE=(HM9V9".B2`Q),]QB,B2]B/W]Z1=GOD3/ M;'"TDT9'Y%_0,QN?%<)+.?BKU:)*-O65.4<^(LJ&1'1,Q`9%?%0D#XO(N(@/ M+'*OZ-#VBS395!8O>'/_VS4*,@N+>7W_F"G*W**@RD#UY8Y$K:A>U-^'FPT# M&F5=GD?HBL\8O6+;3=;P8S;IKB?3C9.Z06)];)%1.HH;O`*-UK7U*.,46,9J MM]2CH$XJ*-O\**4+@%64,X5<(0\+ME/F-/Z&70I4F=QA65) MI3I&!9BZ;;_:]\8`H(;[5_/E'68ES0A M:H+C1_=,"R)?'PX1/K@)EN[CII=T>1=G94C1Y'WKP6L#YLQL;;&! MEWC$DXL6$S2%G2PW2!R!T=[U?)J@'S[[WH&QA]Q@A]S=SJ-_D=Z2GL!O.#JC MV21Y03OR_AFY^X19LQBG1-_R%L!0ZDP=%:&.4O(HHU^H#9".D/9+APB@!](` M+]-Q0X&+K%KXB#[2;J@XDB#C1_/V'?780\AT?6)$"W0RF M?=YFT*!CPO2P:[5."_9P2G3O+#_V$L2`0H0^9',DV2B2,MEB3@PT/*BSN$)8 M4*D-",!DG*3QB0XHY>?6;RX`IY;&%` M:T2R[:M%'X7-UZPP]<]#8J#A&FLSFZUU6`!?2/8BW$6ZAP`&Z.*QUM0J$0*^ MB?E07,-69'"HGH1`1\-T@OEFO5[.+G$Q>$Z'\3313IQE=NF<'2.FDT48C&.2 MJ,Z7T(D.8O[1P0V\_S#=W1+UA;ZW8W^Y#G:/Y,.+K0M:[8R=/[C^=_(OO+?- MG1=O_3`FJ_PG_".Y(6S^2_>U^Q[&)O!ZYMUT-W[CI#E8,@.HP`$B+""9!UZ2 M,.4"Y6R@G`_T!^4$,5:@YD)`C3HEC=)=KYM3[`48-L]J*"@67,\0F@?Q6W07 M_3J.<1+7UCU4/VO3@Z@8,"V\Z61N@!T<<#+@-0\[BR2=A>3]/5PN'$7D#N]Q M1%M);<,8MB].I:D5P*75"1A";L/78X1?2*CMO>$\W/@<1M@[!+PWR?;\%+E! M3-,BF!]@?_.Y5]C]OU.<4/!_Q2>]D7"_X1%8"EBJ.'"$DRH#1Q_$-[:YO?C_EV M3M857>.VI]<3Y81\Q3^GD^_+5_4])?3RX<'(^315X"A]= M&NG7';'T1'TD;KP!RZ9E)N;KE9DGSH-9E`Z/Y/'14X@X!_"G/O8U*"VLMP4- MTGN$L"=%_>++U&\UU7,/*8N,'6N>4Y$%9ID!RTF3=J4SN^GF3&E;YS3KDKFJ M6&R<(N_U2/BA00EA'$67H6$>DK!+;W*T2\-&T\T;*24^+U, MCG,?)^S/\8G8LAO0=$S_G/_B2]$EX<,-TMISVK/F!T^JE^P MO9)3,LLK-PR@-)/Z<*OG*JM+K28DBO#S#8-+TO7/.2 M;?ATO%X[(2,M90A9OS]LA*->I*RXZ`@.HT9WB`U4`@&G1]?;W0=_\X*L)YOF MDRH>M`B;\NBFRMXH$-0^&*<^;J3,5>,A;4N>E6VYU.5(# MKMSZ%(VML^Y$QE=>J@4\]ZO.U(H(J5`$)$Z>PNLM63E%^#&B\UAR?B1?)"'K ML$_D7X^O^K5+`P(`6*KGRO0(>>VL+]#U%**4.!+4$2//-O>R`8`AUZ\&&`@? M";YII38N.DW(Q%5"V\:CN4FK$&JHMQX.@O)&N@_[\I5R?I/\&][A MUZ/FJ*,A`-?$J/GO\&K$Y#A'V^ MMDI"=EKB[O=X2T"%XA>7*,/N"<=PFII>:(H$!JK*%'P(E(]A_V!A.!TX7:R% ME7V`VK1MYR#$IFL+C?;LU+(ZEM?O;K13;N]7/@[HL"YY,:UH.EL[*O(:_L3ML$T!UUT8/"^4A%<5."L)ZFBWAYX=IR)=H3 MK5$@U4[BU*_046<58W`Q.KBJ'(I2Z3_T<1LJVQM7/PCF.(B-FT]1R MLEZL2EZ#DD*,UK#-CPV\0'NA2B[`DE"F#J"]9)=112[9"*"LAHX"QPKY^P`Q MB:%?K\GD%F`]>$O/V`;M)0.&7W^^GJ4%]"0*0!#M(L(T$P'9D*$:D5T$<2Z^ M!1C^=%:?X4XI)OD:='?/W&8+VWJ&^NIC MVHO"+<:[F#9KN(_C$ZUT2ILRO+Z&P?C8"\TQB#(!)>R`-.&6;T-J#_/W!YOT6L,]"@J8ZM.RFR#*_XY>G M%$;LK`A[A@6"-LM5L1-64_L8 MS9:<2Y%D\CF,V#KTLF^7IRU`WI2*U4V81JR9YHHO-BL5JK,T+-HLD^_+E-K4 M:6YDV-B=&4P5>=H\["Y,*V,N[L@TUQ$T;K/^'C'Q+[08*(F#(KSS]-ND)N\" M853+D'&[JME:A@'X4Y3U]@GW]#;^6^B_L21E M-@)R#Q'&X/F130Q:A]AJ+8X)I]\P;9)+D_I4'3+-9MIF]$:`YUHF39-^)QOE M0K^(\7PT3;_844S$@^F'.8/;%_(L;;[$#3NC0%BX@O, M%`OM']A=\7WCJPX-*`#Y@!JV#*W:<:;*F9V7'MD/>-VA#YSWJ`/%0CJOJ3/* MNP_-C5R':A,U`N%8S5'YD,+H%;M(U?)AN.$\GTRG&32U(+2_Q=ZWB$Y!Q`*^ MKFC"+##(:BWP`E75.NEGM_S-BWGIE&]X&](>K&0U?1>>GI/]R;_>;FF>OV:? MW.A-^SOD)FR9V92SG"[24[OK['X']>0BKX5\'R_,,E]8?D'Z2Y2.C;8O;G0@ M,9U+ZZW%B=1.Z(J1"O?[F"P(WU^\[0OR8G3``7F`%E@3=XM\/WSG;6\)_5TJ M"')327A=-_+<\10=PYA-,&1%=6)Q-.$">V^T'"$9S0NV_FE'_UE<8A(_7M&Q MW$!<8DE>7++F/))IZH?WZM)'"7TO8@GGO%(<*X7YYOHGC'YB//(7J1Y8`$O( M/1,MA;[/_OZS]H$(3+[1!>#U#T^WH9#_;C'DR`8UW=W:B'1]]B;Z@[X+5!BW M%>^.">^V(H622;]7SA%.P6)(F](_^R[=Z% MKR3.@+?><@Z[3L@>HECBUDG,E7IR$N`0EQ^0/V[YYMECZ'O;LZZ-8//W+4>T MC9@SB05!VM&KPY M%E0UN>`X6:Y6&S-L00>^_8I"%J<@*0DD:"))*(HI0H%XCZE95"59=OI9;.' M35.S+"+02"\P.'O#P0G3D\M#X-$]XNK];//WK**LAAG3BMZS?+.(44022?B= MVD'$=33BPJ+,T"B+(#/12B_'0>G]B2\$T^*"@;:46-73UH]ZM*P8EJQ=3J8K M<;`C+I%08OE-&IA:8SU)-H63K.9XIA?QG"KQX`YA:M&4'[E4JP%B_OR^?<&[ M$\U)OL,1B9UI=SVI@=5U\MGU(K;^?F)M>VNFU=;D+,ZV;7DTC?V6RS3-7PQ$ MC30?JM#`[3I!=#2^:878>".8H&UHB!?X/;V^NM&9)F7RFSXQO>HC:8065Z!; MNF@FJPUR;N\*&'G*[Z1G6&_QZ?7HAV>,O^/HS=OB[[2P_XT;DS5Z^$KWW7E+ M29_Q0OY$KS"QN.8_>/?(LH)9@Y:;\S=\#*.$.L2*'+_!AP7Q/L/(8IH9M1*9 M7;*7$BRAE"?$F$*,*R2SA7*^^%5%P1GBK/&^2.CFC#AW?+*&3'L2[I_4I6?*A5_!5Z-M6\?;\YK.M0^]V(A_BDP![P!\TS_ODQ2]TDYWN M.3PGAH&?]DT8KZ1CQ_1&VT0DEQ7\2X$JW[-[3D836_4A611^?9X$-EP5WBYV"P:H')$DW=?PC-X?C[1X@;7KV&4L)B% ME=7]$KJ@!]H-3;S7@T\&U3DP7^$^:"Y.H>=$894IZTYH;E.AYT5`*]J#.HA!Y@9I$\'LG+' M!\J2H#24&D7PZ(LFK9_U!Q'<:B0\V+S?&N5T<>\ MW#;PS1*_K^/X]'ID!9&O@^#D^I_#:(^]A$#\FYM<'MW:&=-V%#"T0&:F/Y\L M9DX:/#`\*](EY&7@LU@&/I>7@5?R'0>)NRO$^4,Y@XAR:#?V&).^*_VG^;); MK6Z;VJZ.=\:D\FKOOL_HQBC2*,M*F&3+M6;1E95O-)Z@S$"RKR<:3*;[._'U M*7D)(WIHW2CPZ#(.>"C8@7G#@&LV$Q=[NWM!SDJVD4G\7\;-F$)12TK-_5S, MVSF\$871=A&BJ^_X(M@>,%D?_'95_T=V86^NY],D,>*9?Z.-C0>VV])P']"A M7A%NXVR&\VN"*=9]A+'UL1U<%R47_%RF&-Z#AKHZM?/_:(Y.A]PA_)WR M:WPHM_?`PU#&?7P?\(SUOFU8/8?E@ MSJRS.KD+2\+MOU"8JN1`B7U0UU6)OEX25']BU_#[R$LXAW&A\T M^'`?92_30!;#UF7KQ6(F;V/6^*?G*O\DE6SEZ&1\H90Q6LME0'_5^_YESSKN M:0ZHT3'0G#`F15_6QHZ9F@`G"%M.LO/6I.F'&$]LRR>VZX#P1_O7>&^8YHBE M_6H:Q2W5E,"CU$KV#&,G9[JLCH'08),9!8B"`HWX[&F'( MS,3UA+A0A_7=K5V)WV:JZV/7PSL$WM[;NH6NB73N]'#\Q0OP?8)?E1>&S5ZT MO1-AQ)5A4+5>.9-T3R$G6VB8F1)&?U#2B-&VG%'=N[S348]((H/ M]2^KF=.`*SK4#(M&O@*XU%`E:W65ALQ>MKF",.+(]$!Q/9F;H@^\R%#O@E^6 MW:_1`>B"H9$1%Q8)YFH#02>92?FV_"DF(44-C_][(?O\?5SG$3N5INX7/4*!!X4 M?!B&,V0MO;A$!NT&1EOB,GK$R:84H5'24<@+O(0-A+2.G0I35*)(IQI@/'WV M`C?8>J[_&,:L%Z,YKO2OPN!+RX^ARUYL5HX"9QE9).B."6^]"%W&76.A`?!7 M:[H:'%:K#!B/]\$V?,6TRW?X>HSP"PYB[PVG_VH,32,J,"@U8<%1&ST``+J)[6NP;:Q04)A7-B,H/@0!TB;E M]C>+S:RT;`/M)-!:BLO5V@AZ`R@-1FGZP-OP-*GV)?1WY.M\^O?)2[09JN4' MK5KXY>BF.USK/#3,22!.8Q@[#Q/7K[;S+K(LJ2Q/=`R>1)X2^@O"6I'L&;W. MEHJ&KQ1_',9?&ZAI7P`%0Z.(@]ZYS9*NRZ`80935AWC.I7@"(?\U+HA4AT>5 MFN@CO:,T@FZ3NNYIVPD=>E8,RR>O%TM1:%,%@J$WL+4I'/T(IDH8QZ3X-4SPG1=O_3`^1>5V\;7N6_<^Z)2I8H63&SG]ED.I<#@:R*E$2-V9-]W]!=K"F06/7P[RX;@[R0RF7%7Q*- M/-9P7HV@`K8K%`"RU#X=CSX[!')]D6-T'^S#Z-4U2>@Q?-OF,MN,)=-%YG(N M%MD2W3RS#$FDX7>M^Q?=*8F^R_<4PCW:4D7LJ2*\?"#0M7RZLO!NHKX^I M5QKN'RZM0I3TD'_X24O-+(1=[E5;K45'=O3=1LF#:M;39RL MXX1LJ.]\F+1X*ZVRMLU&0N]D*.23L7ZI+,LQW#P_M#[*/BL=!O%Q:$6T?"1$ MAY)"Z+NA]%$=(`RME+3F`^UO07Q7:B"QL)`D1#X.R&)=;2N`2XDNGB(+/EHK MMP=?)QIK:7`!>2=AG$;"V(JO MM48D1])JN?N81UYPA*_W1/'ZF>3R$=MSR<7XILYLY:1!+".`&`6@^:2#!%.K M$E3/*1W$<"[$`)M7-/:>S2PJ&=O/+3'>_O40OOVZPQZ?5L@?+F<3\D__^Q2Y M.R\X?#^_/H>7JB__;F'V*`UJZ&A7JTFZ69J^C?CK=JVU$_>.&?=#6ZO6+*BI MJ@4$B8'(NB?>DP]Q'>R^X^C-VQ*>I%M=]P&9L)A_CY$+['ZI\H6][T.83/R MZI%OTWN[\\DF@Q\?G-V\RH8O7J&4AD&,!?W/54WN+<1]0*KDOH!I)FRC&6M! MY``H+,2??>L?PE7]'CQ[OD]K4_.3HO@;WF+OK>+V5]4;%AU)!1N&MTS6SBQ- M'Q:TLN/+&.748,#=DWA.03R7%V"*450IG2V`&MB>C+$*YI8H:M_4_>651A5LF(X+\QGJY6`DJ"'*$%$*:*'`$DT!P'4 MD5V4?ZO!5&^RSIP+80^$(ID/`Y2\8'3[0IM]T`W^5S?Z%T[0FS@-V&7#D5^S M.0#*Q?2F#J:-7.H][?`-(?,;CIY#:U)/+XW@)THR_ID9?5<[9]*=,@*_G2VFFD^)#-6:,P MLFG-RXW8NB.OTT551@#(_[46PA%"A#5"6+-\I;D4#+TL;`\[Y>D1[Z=19E*HEB1I'(3 MO;,XCBP.SL79`?79J,6&V%K72PXQZZ3<*$^]U,]8G',*`YN6N-PL+FP=YJ2H MLPRR@8/.-$H3D2>:LH@@EHR]PPN)D:_)BL`]X$+/\(=3$B=N0,$;MS8VUX' MNSO//^DCZI;$;&*C%8>F7?KFTS0[60R#TG$0'XC&`JS-XRC^;CD@+0QN9G'+R6:>=G>B;R/R.DSZ M1FO>I_9XKXPY6PO@R`)`!9=*NQ9!95FTGI#T1'ZOQI+\!`":I.'-/^EHEOQ/;?)?BZJ60CA%(2"1I;!S&5N7`O:%KO>P&EO9[Q#($H.;?]*%C*OW M$!!5;7B?VN.]'E%M!'!D`4#1=&G7!2P51..&G3+[A3Q+_D[^1OY``F9,_O+_ M`5!+`P04````"`"EBF9!_DNGS^PD``"*Y0(`%``<`'!I<"TR,#$R,#DS,%]P M&UL550)``-6C9E05HV94'5X"P`!!"4.```$.0$``.U=67/CN+5^3U7^ M@Z[SVERE:A&3<4*0&)-76_/H+@*2X"``! M+@(%(0^9&0O+P4:`U0"`/_\\GYAX\G(^#/`A?ZB\\GWYY/ MQ\_7]_0_\8+D9/2$0`C]R(MSNZ`'Z_WEU0O#[$?E_=X3_],^KZ9CW_/9'QT^B'#Q^%/ MUP@D/;M8J$^CBX_G%Z?GYZ_0\N M_/&/I[C&>6FPOQ_=^[,/H['GC::D:#B:X@&B-7`_I"UYZ2!'&%$__'Q2&-?[ M*_(^!&AQAMN^/,L*GOSV-Z.D\*?W$)8J?+_,BI^?_?/KP_/L#2R=4^B'D>// M2A5)8ZRJYS_^^.,9_34I'<)/(6WE(9A1:"0$''%+D/\ZS8J=DC^=8H0OSS^\ MA^[)7TB'/Z'``U,P'U$9/D6;%?A\$L+ER@,GZ=_>$)A_/EG!%4'[XN./EQ]) M]=_=!+-XB:=.]D_'=V_]"$:;>W\>H"45_F1$FO\VO2^-8O7FD-_?0#I[HG0R MGI'"9U+MGK44?HHK_OR,IST@74SF=]#'7PPZWE,00M+#M>>$(9Q#X#89@V3+ M>QS%DX-`H\^AT#QN(H(SQ^M\7'A)!TLP]B*`?/S]UZ#E0';;ZUKB"98"70?+ M%0)8G!!WD?394G!NLUW+?^V$;W=>\#V\]UV(P"QJ*?AN>VTEOH'AS`O"&('G M>+ETT&8R?X8+'\_&F>-'X]D,GS81/AV?`@_.(`C'KDOGK..UW9\ZZ;C#X6-I M`3VOR<3`LX)V/WF^`N`)\F=`]'?'2\&>,['Z`&L@7?Y M`)U7Z&$L0=C1=Y/NKKNA;GOZ"ASRWV1Y]#$W%?KI;G!XEBQAE'3EXSE#UP%6 M4_M9?LJ]=3AAHV#VG[?`<[&R>_M+C)63/K87R4XZG)S)`>\O7I"#%_N,--_+ MY)3OI\/!Q9ZW&2\#%,%?@?L"T/(A<-H.A-UF)Z?Q8Q"!\"78*EW;TS2E_X&50M.<*&EM>.1?^!;Q'5QZ>8TTPV*-T/:,I/+Q[PDBR MST&,//N##@2V?0\"B1?GU=.#0]ISSRAL=89\%?:U`,1=Z1QG'Q]9IL.>QRQ0 MEGH_$13[[GNM[ZA5I&SO(,AWV_/X;\!KA#]#(D-!`>L=`96.AX-!'_N!>O[:)=W?> MY;F.$?%LWN$OXWC_`@ZZ]=T;_!T9HG&+JDFY,Y?Q'WZ6^3CCUS!"#G'5E413 MKMX_J)D8"51/`,'`O<-_"QFH\LON6T[R2>6DS$ON3\;"E\0[`[C'6XU(4&;Q M_4F;?$?^6F*7VY]\+[A9@5CTY_ZEH6N4V`'D$&"(4_Y]3_)LKC$`B'AI7/#^ M-[#AR;53;F_R874S\*F^11W8X22.2$"6Q,KYPHHJ[4ORFV#I0)\K8_KSOJ2Y M@QY`UWC=+0+$_\KE4ON2;0H6D!Q7?O3H++E+HUJL?^D>P,+QDK['[Y"U`5=+ M]"\35C#)+'[>+%\#CR%1^?>M/$5=C\R>+SJ[-E%&8_:7JWTG__'/*'0F?G`V9O^FI6''VU!3N($R%6T8Q<%.&,(GV)XSUI(<2 M@723\AR`,[P($X,)/A)XEL5TO6:GN_\4A)4$\ M`CQ_7IQW_M?IO""E-R?GD=TI/+ M0808AO]!*#%KQZ-4L>C:06B#57!*G>.,1*ZNEE'E^Y5P`-5B.F2]`0A#1V[" M%<[9Q\"?"5=K72U3PJ;-X_$6IK#>",DKHEKCWJ M.(5UR$V-PD3UK!6;75:;U"K*A:""#OF?$%AA:S3U3F3."1F;1J:FGA$%*X"B MS9-'[AXE;/15ZC7@#D501<<8I@!O>7`6`;>-#:':BIZ11EB)!>ZM@WPL2%CP M$MV`.9Q!WC>3J*AC/,]O`8K(CGH5(!1\)Y)Q!L`JJ47BS/F[$TRJ"KQ;4*N\ M#&=UC6XA557KF%B,:$XA/7)*V@4#L024=?^!:?O?_->21RO,75J<`8AJZ(BT MB;VY)-A6XZ$TE2\C#XQ8H3&5,"./#\=P,)4G(P],[J4SE1:CNKNT);T$D>,= M`A(<5TL1$$G#8HO7A5ED3F6\!*&H'".3CR@)C(3J2HZ2R0>5!$I2+I<<+9-/ M+PFTE%TA6^0N33[K))#CS:A+LTZ^`7/Y]$P0U?!7<D< M-S,-GHXF&(=(DZ/7Q!`ZJ%DGHZ5R&/ZY`636[20UE!0O'^2@&:^B24PM)G.5+9A8Q&'#M%"-/>RLCR9I13?V[FF8VI&J&;X MR%SC-#5)5$/$^K@J;&J:J680R[!A3U\N,D:R@\7ZKTF MBF69("JV2X^B)X!H.AH.A5&FIN:+KTDVG7$<8?.9O)!4/Y*=&H,8P7T8QO+2 MIZ4'(3D_][%4%5.N\)IU3=9>13CPJPB6]C$`LUGHG9(ZELVW%!6AVCWOS3<- M&T&4*12MS+HU0*^!H0"Q,S`::\I9![!U`!OH`-9L]R?.MK&'9?8I$4R/@;\E M^:^!+\@#52FF)P\4_C)X]Z&3V'?3EXW3%Y^98HMJZ!A!YA',E+0K)X0S+-@- M].*(:\+7U3+%#&Z1R0HO-N1XY!.[2^C35.UD1:5L&PZN=;5TC*3@@<>[:?(: M:8P__F0%$)VWX168!RCUU+\X[R#\"GVZS]W[>"*]YUGE^Y1`'\+;?;C&PN>5UB M5E]/2RZN3*2,*LN1?K?<(*2MP9Q?7JOTM6N45;*#E.R4@B!F'22/3V.5HL!! MF()9&B.=53@)4^!XQ+?W;17XSXX')N@!8N7#95D)&@30EMQ.=8>KJ:0IG1IP MT(S<'K[!5J@7T/0IXF&(Z]CHF#E)K;[Y*%UY7[`52M;RQ,_OV/%`KJNE8R3_ MP#O0&[;KQVN\]!;@,5Z^`C294]._X'B6\QTT;$RGX[#&0#M&%[,-DU;FB+3* M6YPM?-O.],Q*#>&J&.UR69>HC/%VETLPHKO2F8^G,-VJ3(!)A_K:*GG#001D M&\W4VK/?].0-C5"KLPM,S][0"#0IO,R\3ECKZJ@D?!(9:^UR-@Q_;BEA51N] M,CU3@Q):PBAPNZP,AB'%\*2VN]QKV![%]'ZVN\X[?(1D&6]56HAED];,+\LE ME52JS+\L*`/47HD>[2BJIFQJ7/Z$W%7#`W9L2*[=)@J+0J825M"% ME;>$3WWIOK-#Q:UAL"JQ7OI%N;5H0_LFV61Y(CY-/)XH0O`UCLA9^1(DR4#J M^(4=M6ZI44J)`]*[7+[+@%X^AX!4*P='`K,\&8W^\&XWFYWPL>X-W'BW],`_ MH#@9W%$[PGG.M&-V>GM,](Z(YLX M(\DC?7=>\#V\]UV(`%Y$&FR/7,4(7P*L,`;^#'J@=+R^!$32)Q2L(1[WU>9; M"-Q[?QNK'V/%99VD;8KUTI271HMPCBVP?KE1=(T?U\\6`QO4$\.Y``OP( M."&X`_ED?OL^>W/\!9CB#7_B MLZ<09TA*39@2^6F1GV9[+8'Z,N;X_,`G1K1Y\AP_(E!1=C0':\G*FC*2E+:6 M>[_R$!AG2/7UAC6:X@O8B@,J5!W,F,A#9.4';JAAOM5B2J^1R8]7I=EA8+$5 M+7TWHCX9D&P#PQC?4_)(>7:,,A\KEQZK5&/#&'?VA'V^^.2'R:JK,V<2>=B$ M*WRAB&4T;!VO+!,M35U:--'X=`?9!H8]OKKT/^H-#6B\";^YQ?=D-3#L\37[ MGJ*&!C1>A@M%;9RL!H8]OF;?]7.(T.%3$^U56PZ MJX-(9Y4\]/8W2"Z_"',S,@KJD7=#/A2)O&&#XP&1>R-Z/._R'@_"\WX%?N7IOXA;? MNVXB+Z^^EOE3D#";"GA/HKN4O$*NVHKND4ZQG9PM8A(XQ/^XQ@8SU\LM5W=( MHYKBS13!601H;K56;[4VBAFPUE#`TCL`UF`$L19.84MG5J(S;P/_\MSEW2H'1U3> MIYSQ:N51&1PO0^[>GP>$EP'KGYV3K-W!EE+L*E4EDM>A[OWKP/XL`\8\CT+"3[VS=J>(JF)RS9%]`L M-[[I:;CWA:T*T4DNJ??A8JY.^A(CR:($RF7^/>#3K6L0F?PLN9S`%D5%=I]< M\F`+*Y_";'I2X1X`5&(8MTM*/%Q\;3:*:L;]QM3%@L=*)63>+IFSZ8`JQJYS M,,W4%#L"DTOWR?$3I2HYX(.XW]DHP3G($38S\TA?^R>/(97C::;;O_L)*T5R MRF$U,WE)-["JW./($34SUTGS.P*LHTF&S2GWTIAYAY4JI"H4,>-?(>L$4I7[ M/NV>*#O8=:_H#N:E(KLP\S6I;D#KQU>?8V^F*ZFS"2M]12Q'U*P7K51N.67: M?4.RWA;"2[/\;_5$W&:3CK&<+\WT+[5"3GCNY\B9Z4QJA9S04LJ1,S/CK>2S M/$HYC'+,S-2\)=.%*N49RS$S4[=N@]E.SKD%!T-9#]?%$%K MX+5)0+OU71,@D[X.DD-FINTFADM.)\XQ,M/&DKFG9;,<5^^`V2S'@\URK`D7 MM2MX9X^7209O)_!DN?'ICRX]2KA3>AY\" M#\Z(H>*Z,!&Z`*:6O-%8+)<\,PG7X!G,8D3M*&PO>#%&(WET=[F*$]2P(5%Y MYW.\)`/+!*LFBNZD[>'D&F:DGMSR.M,R;Y]Y9\I<+=7!A^]D6Q%D>^JV?2U9FI?57XHF5296VYR?YXT2")#"ZKZAE\! M>:B;L8&*2NOXM%^==[B,ETQYV66T)$-,WSW?1HV>P6()^'GT^>5M-L*#R$8X M)6M#H#[GOVN33KADBB6T2%AB]>X:&NR_BH?4ILDN4N8PC_G"-GJUR8NDG#QZ M]M\Y$%'G^#@,XR4U_<.Q[\>.AU?.'$!LZ]`X%V.E]=_G<#)_28QJD@SD"^4Q MW_M,<[*G3G1.H'SF4R[W-ZP8)N*1H#+7INZUNR[@$-EM.W&"XL#D*O8M(BL5 MF60EG?[1>D]1T27:;A\WU0??FZ=CR_B2F'BF@FNO5U96[(XN6EJ@157P*)`H M*XE%+"JVI%SZA@-&HP,=.]MPA$Z$=G3\X0*IKH642'Y\GX"IK]22/ MZ0O4A.1,3079;HWOQ-%,?:"^'4R"8&F[Y^I-`VQ/?B2YM(S'`GI?;B=3=<'1Z9:,.6BV[A8KAZ,W3L9%+:^O9YP4$S;Y]LS*]5Q2,SO'4P\SW: M.-;AF2J1F#\M6;E;BK*H*SD2LE0+@R7*IJ#3([^JA]+LAKPP?%^]'"Y24[`* M$+UIQ:31]MR9I0A_P=LE/GVX,VH?P*<\ M4>MNP!IX`4V#)H.S3$TM?+39&W!CDN6MF^5YMWHG.5[0W5_2\U83_W>OU7GJN81^;NS:Q;7 M-#-D>.]O"5&3^21&#T3+NRR^0*4E\4;VZG.:R8Q<]\"Z4$R9P07AMK+G`^18 MN:V:U)-\9%`8_'S14V(3V7FHELY$N57K^]TB=>5XY.6;YS<`HB\HB%?07VPG MS#8=VK63\/GJ@ANMF]6+Q88EMLB=)E55\YBV__J_$)N;V+S?T(4A\+)*5M8Z MKGM_%>-MC"YQH0==5$/K"+X"A^QBR2-).S`+0V)J;6@9Y>Z9(YIPG-(='$+W MA!3H>(73,(.)<;8("MM05O*IZ$TCK"V3ATP3C1SO<]L7_DHZQ@N6)63_))S= MG7:A`Z-O/DJO6GW!(I#+6Q,_GU.\15!72\=(TJ]NRC7=1\U_IT#-J<5$ M5\[I]P;S29H"E[*"6'XS0]>0WQ.$^..BD\H:/@X M]B!=M=6O(A?;[:U?&_66W/"9'>YX+@M;>DV%OD3BI=46%#X63L`0`_',#_M$ M=-@QU6&Y^LUN&>TI]APMBA3$V::1W._0') M-VJ8^/6G?1\-YGT;,-D&(736F'Y+>U\A%?-20LM96:4,>;6>TAPO\Q*`JN.E M0%-J$+%;!2&DB]X`Q#C.;E.OX,MY%&KI0\81#N1Q:+U(R^_L1,*,L)<524LRDI/1]&T$O)>4Z6"YAE#@H??9A%.B4F MJ6XG4O2DQHT>,DF)"33EX]_A+\@-T59+=-7I1!`6KA3HJLL77*"FTV*1PX_+ M=[.1$_=::8U<;1[)PY$@.3:3/[,&T*`!_>-+11,>5*(:.D90>?.8*7.Y3`=+ MZA%$3RB8PV@*L.I(MDGR@A!YAC6\`GCK)%<8(P1?8_I3@*JJ%F,)MFZRBV$% M$0B?G`TYX,>+!<(+,`)/".*)NW*\*5BE+]:ECR'MCD&I?A<\&X!F1*U?X.6T MVV'2SQ2X('DLDD7"46N@8Y&WWSQ5(6H$W"E^5$REG5?@*XL\_UV;=.+D_X42 M6A+3)Z]S"S?WY-XZU- MS1.=P_=GX^#K+AZ\J]=QU$!3C7;+`ZLXO=3#FWSKO!(\/"[HF)'3DK^P%(#/ M/89FV0!-P2FR,')LS-+RN7&L'4_$+FW2S"7$B)D5L:A$]O-Y828:S/B/6.X/8=VZ8P M!/0VY/;',/U5Z=/4-368,3_&9,^?.6[!B+1.'9Y$6>4D<7C8-XCO_H M+%DDN#YZ&-:@F4NDGSZT\-Z:RKX]A.B>/(ZC-ZRL_KK#)>VOGT-&:^U`C[@\ M\1'VA1S8/8.VTUT72VSG2-MQJA<7BZ!T+\+PKI?Q2G8EQ+U/XB]P#*I4TN"-H^%6N/9.\K[GQ*8*%S&,_+ZE`1$O=B(1E\&E055M*'M M\]:>YG="D\R5_H(FO<3V`;$5!D.1RLAMXQG^0B&5B?XK`N(T3/7U=,3E6%+Q MZ5Z\TH.A#5FJU."I4MS$DJD_A>)-W":`7".E1PSD%M8!7%$64GH]14+^\8HXIJZ@.F6_`:Y0G@Z8/#SWC M$]UQ)_[?'02)1C+=#2.KUM8_LFN\06VP^L#,>B=51?\8[GVLL($P(I#>Q.2A M*&96:,7*^L>5&@#$WD)93?F!4>RN$XW3/`0-QO,`'!# MDJHD"V>2V\9;_14O\\PF8)/%%=OH0/#2";A=+5>;*5GE`'=.?N!L^_)UNQ2T MV#CW(!"5/GP6?D<)LJ%/IE;93*!J7>F)0N:"DJL[F%$)DICSBGGKZLVF+%P2/IR=88RBO2*_G9R73LK_$NT41@4MXFAC'$*R,0A M*Z?%*`6-#&67U/%J!+11LP1.#D2=PL8AN&?/M]@K;K_C;W\%WX!85 M0XE12#32[>L$:X`>X&O`?QV'7_9`WB5@=ZQ@6SP"ECVMVD('0D_!.O#6>%(4 M%RH7-U'I+JXV`1\&B$9Z@%O9,_!D?@@BB??GWCCH4O_)5+=%5 MIX*[_>7?=5[RDB9:R*1:^-.]2G2(HS&RUE^;=HY.'9=>0R7$Q[P9<%QR#4JYHOL?1Y/U9.7*$TDNVX/*L<4CQ$M5E1U>^95_(7Y MLC+K"FU3?(1^]UP],"LWD%)8N_Q>1#%N9VH&B^;P*`7834UNT2E\#*:6J6DK ME''K@7QE:K:*_6$KXGF9FK^BTQ4O8NN8^LA:)P>R#$G%U`07C0%L0@]9 M8Q"E+Q*:GH>T)7+\2WZF9BEM="Y+7U`S_I&V=M.M?/?2]%?;E,&JN8&5XV7- MD/H[=SE:1VY8=):Z(T?4&A,M$L#D,%J30B)W0@[7D1L0,ED$SZU]4'?W/H]' M6(M`G#4H1\J:`+7YH7*PCESS;WAK/\?OR(V!1A>*Y\H@^D/%J9Z=>*(4C7' MGD1,:-U7&VRL!IG94E6TCV.5"!(GN)*PS?A9/Z$H#^#*W+W M@40*[X*X>O6Y75L',6IZ0ZBK82>-'<:XOP>=C1HW-?`Q)W0JET25[O!!Z'B, MW*V=-:LEH)-G6;;L?%7*?K$M'"L&W^G8@\X)FJA\;"'@0?=Y'OZ[E-!(J*$[%3.38\7+.`5-MW^T_Q=O6%Y1LWR*7;^E=EF%0S01]ZF_Z<&%NWLRH=F[YW982NTS7/AP#F>.'Z67Z\D%2;P7S;`9 M;E750:NJDM^.H^;(5;9JI54KK5HYB'--3JV4W12LLFB51:LL6F6Q>V4Q^T-S MI;'Y$4?3I)"846$B^6XK1:E5DSJ.^6LG)-DZR#]N?XGAVO'(MZ.R;>H&*U=7 MUPOGST>>G)O/#UK^,P"I9X38N%:]*"%K*R@TB:L#"[]2D'>5TM2P*_ M"Q#`G_PZ1N1JS*:4--QWZ7]Z=&^17*C-V],Q^GL?'S/@Q7F7&QRW^.%;_IQW MZDB&M,(Y@O!Q'/NSY-2MWUC4ZNN8`%.P!GX,L*`!WO?(O)2;"?7U]#QWA_`%PR\M3$*C(][;<<='S_B.G) MO>7PJ?5*FI[*NWYW5_0AF9[%VX9_;?C7AG]UA'\I2"V"O\.*^`PE;M!Y6H?E MR@LV`#P#M(8SP-;=QAZ5A9+04_WW5YH0%@8NS3=<2S+LK3_K!+=.<,M+',09 M*FD=]K?U'(WGV>JR5I>UNFPGNNSV;9W<*VK>=9<6="4A/.SC65S'JN!6B;1* MI%4BV\61Q=N2502M(F@50:L(=J8(6E_F@!6IK4/A!B"X=DAH^0$ZK^2=``C" M<;3]LO0KRKLJ%9NS2J15(JT2.8B#3]43J;IQ6/W2ZI=6O[3ZI8I^25XTA!'] M5T+@#6C0'/@D9-YI3L@6]X75)&2?B(J-F'(AU#"5VJJ55JVT:F7#*QJ*VZA5 M)JTR:95)JTPJ,3#)P]AO@8=''Y)[8-&&E+6YQ:U^==3ZE?RRX`U!MK[5'JWV MV(]34GX*6\71*HY6<;2*HXKB2*[$8ZLTV5D*Z1=:JX[L5'D*O97/,M7:UH]H M]=SCT7.M)GC0)Y9$B@Z5C=/J@58/M'J@U0-[T@,M]W'`"I;X:4_Y6]G"VE9U MM*JC51T'<<@IW[$6;PM6=;2JHU4=#U)U_.F,2/CJA`#_Q_\#4$L#!!0````( M`*6*9D&6>YI'V0P``!1]```0`!P`<&EP+3(P,3(P.3,P+GAS9%54"0`#5HV9 M4%:-F5!U>`L``00E#@``!#D!``#M'5USVS;RO3/]#SB]7#I369;=I!>/W8YL MQQG-.)%'=MI<7S(0N9)PI0`5!&VKO_X6("F!'X))6;;I.[TD)+"[V"\N%@M` M/O[U?A:06Y`A$_RDU=W;;Q'@GO`9GYRTOERW>]=G_7[KUU^^_^[X'^TV^7#^ ML3%&;T1S*B(?A$?W?3_?GHX-W18?4#I?PH]I.#+024?':'2_VS[L9K'48@YA*9KI*<>; MLWF&L_F4RAE54TB\0"/MOS_`C>WD3<=I+.:?M"I!+AE+6?-AS#@S(G3W,121%-U^ M1%(DID4L8L>=/(4\\0@CY(#_8IX]&GA18!`O\3U!3B!44E@DQ!,=1/;:L:[`=, M^],FIB5O,HS]L#-U15-CBB1FT`L42(YBW$*Y38M@;B.^K6;$)4A(Q)@,YCH% M10*[+[6J^08((\_$#"5!X!`-$UNJW(IKH=W&?%?;F(,QR0Q#+D6X,VI5HY[1 M<'H1B+NPSWTFP5/EUBR"N,9!W:[U+YU%+['P MQ1[?I-6G48A+\ET0V-2+KMF$8PKE4:YZGEF0,CZY0K-Z##%J^49%4FZ+O\]; M_#J:S:A'<_;W!-C!AJ MY!-0W6C&V%EW,^MBOC1CRCQBC,:8K;\9X/J#V702J$G2;?]NWOX6=1/A,_1W M7K!AF%=HB:D(?)#AA[\BIA8:=E,'J$[-;?N#0K"W"/^3Q*1W)M_,Y.<4-'P59](R'H]HRWC_&,>(2=7SS%*J"&.U2AX_:"=Q57!#N3 M/U^&4,,!ZE-UN\//U;*%G3=4VP]?:C*)K8.Q,X#W?-^P2H/BAOE62+F-7R@` MUI@1VF0UHKWO3MZ<@Z)LMYE7V5,0#LQQ+;WY`OC):98^W.M'*/B"$]AM[6+Q M3Q-KQR?%;'(DH;>#$$8MU,`O:$;26(&(H?$&FKG#36]86DZ.ZVJ%/%K8+KM7RC_ MK4OV=M%\2T9W5&\KF;XVOML!"C5`9_UWYP9;FPD*-=QJJ5Y%-+?1"Q7`LL+O MSM9;B_/IBLE>,%6+\]4QW18O%/W6K.)V-M^6S:,@6/1F0BKV-_@W(&>7@A;M M6P[EMF6A3&>HD"49HND03>C_R6KZ'[U2&<*8F$L41_H&P4DK9+-Y@,NDN(U* M3^.[KU]TYE+,0>JJ[_[[C$L6)?@ M:K(A^.?-.'%=%WR$871+7;L\=/?.R4X97OKR*$9RU_DJ,9'BZ(='#5Z\%EAI M?`LM>5[#17)/T+!QTNIYGHS`3VJWNGH07QR(I+YB4R@Z8@S_5@,EGI#,#=JC MF>"8=\I%7\%,IVHM0D>ADKC(.&F-:6`F'`.($Q$3_HU!C:.M2KM&\46@DY8G M`5OHH131/1V1/D;8BJ3[?KY?QMS30E9Q/5$42U_1Y M\1X`:YA,N.#!!:NI55QA+`1+CF)7S#O&6\V0VN0R/FY%I$C&X0O\"X",=?(]CP[L*V,\760_,Z0NJ)?, M1Y]@-@)IB;6F/[&)^0V#(U_,*"L-<,_B9[5/C&K!:B%EI%5I^\O%1/A#Z;Z6N/\1187:!SXU5ND5*8IKGCBL]E;G!.%7S" MH#U%K_LW4+E.,`>";;J);C+=+^F&$C,@??W9RFCS$<0)U"B[;;Q5V$L8M83> M`JT&S>2;;*"[E+()E6:JH_(^DU,=&U!IICI*MV6>RJ9/KBB"PTQQ/Q^)>&# M@)DJB(?-+S;U5R1T073R/HB(H3AE10>@!]>2#'3E35= M0M)U^67-#9R3+]H;"XE1( M*>Y0VWII>!7G-72"8!\"-F$XWBF."WZ2\(9#\`#=-S,K;YGLX]*L;>XU;238 M%SYZ&HVY"#=)9[BX]O7R6FQ[.=-K0A07EPY`- M6IR82^NX&-1D>I.)A`F&^"MDR6-S&@QA'J\3>S/]9=HRUD)[#?F[.445_TBK M_@E5]%1@$QX?J_+L;5QYHH^E?L5D/P83;/*K,N7H,J'S;KRYB:G/HH M%[`(U4QQ;@$]<"0*"V,'2).FRBM]O:AGKA<5)"AV-8KSC>HS_WNEF3H2X4>U MF2H,XNO5QJ7@$[U'FAQ>JNH6:]%>B29N61A/K3B?"HQ""YQ_ST4T4N,H2-@Q?AMY&M]Z0G;0K%D3HXC9)U4P,NZ^`]G"_C)4?80XEH@)/&&)`+ M"=FMVF<8JD%KA(VE'8(.(9X"WV1A7SA3X4>=>(#?Y_D+-4\[2B:N:3+A"^K3 M=8ZC9!.]*GR#ZE7NGU;-%J.KP#9R<[UXI*O,>"Z@)EFLP&?>3.L`FFN;/M>! MD]V"GJ)O[O!Y\0=(<0VWP`NS7E6$1DUYFNE!/(U8]RSU-)V3;!V0;;R7OZ=X M'`L``00E#@``!#D!``!02P$"'@,4````"`"EBF9!OL2NV10-``!A ML```%``8```````!````I(&[=P``<&EP+3(P,3(P.3,P7V-A;"YX;6Q55`4` M`U:-F5!U>`L``00E#@``!#D!``!02P$"'@,4````"`"EBF9!2>ZBGB$D``#/ MC`(`%``8```````!````I($=A0``<&EP+3(P,3(P.3,P7V1E9BYX;6Q55`4` M`U:-F5!U>`L``00E#@``!#D!``!02P$"'@,4````"`"EBF9!@GL`9`]/```$ M[@,`%``8```````!````I(&,J0``<&EP+3(P,3(P.3,P7VQA8BYX;6Q55`4` M`U:-F5!U>`L``00E#@``!#D!``!02P$"'@,4````"`"EBF9!_DNGS^PD``"* MY0(`%``8```````!````I('I^```<&EP+3(P,3(P.3,P7W!R92YX;6Q55`4` M`U:-F5!U>`L``00E#@``!#D!``!02P$"'@,4````"`"EBF9!EGN:1]D,```4 M?0``$``8```````!````I($C'@$`<&EP+3(P,3(P.3,P+GAS9%54!0`#5HV9 F4'5X"P`!!"4.```$.0$``%!+!08`````!@`&`!0"``!&*P$````` ` end XML 40 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measurements - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Derivative Liabilities

Sep. 30, 2011

Derivative Liabilities

Sep. 30, 2012

Fair Value, Inputs, Level 3

Warrants

Sep. 30, 2011

Fair Value, Inputs, Level 3

Warrants

Sep. 30, 2012

PharmAthene

Sep. 30, 2011

PharmAthene

Dec. 30, 2011

PharmAthene

Dec. 31, 2010

PharmAthene

Fair Value Measurements [Line Items]

Warrants to purchase common stock 2,899,991 2,899,991

Unrealized gains on the Change in market value of derivative instruments $ 508,971 $ 2,898,869 $ 341,118 $ 6,075,555 $ (341,118) $ (6,075,555)

Closing stock price, per share $ 1.18 $ 1.76 $ 1.27 $ 4.23